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CHEMICAL APPROACHES TO DYNEIN INHIBITION 
Jonathan Baruch Steinman, Ph.D. 
The Rockefeller University 2018 
 Cells utilize energy to maintain order within the cytoplasm. Motor proteins are the 
enzymes that convert the chemical energy contained in adenosine triphosphate (ATP) 
into directed movement along polarized filaments of actin and tubulin within cells. 
Dyneins are the primary enzymes that drive motion toward the stable “minus ends” of 
tubulin-containing filaments known as microtubules. This protein family is divided into 
two sub-families. Axonemal dyneins drive flagellar beating while cytoplasmic dyneins 
(hereafter, dyneins) are required a wide array of cellular processes including moving 
RNAs, proteins, and whole organelles and for the formation, maintenance, and 
positioning of the mitotic spindle, the protein apparatus that ensures proper cell division. 
Dyneins move their cargos at velocities > 1µm/sec in cells and contribute to processes 
that occur on timescales of minutes and seconds. Perturbations that act on a comparable 
timescale to dynein are best suited to study this dynamic motor protein. Small molecules 
(molecular weight <1000 Daltons) can generally engage their target within minutes. 
However the first cell-permeable small molecule antagonists of dynein, the ciliobrevins, 
have only recently been identified. As these compounds have suboptimal chemical 
properties and low potency, their use as probes for studying dynein has been limited. The 
work presented here describes a chemistry-based approach to develop new antagonists of 
dyneins and the resulting identification of three new classes of dynein inhibitors. 
 The first chapter “Chemical probes for dynein” motivates the need for cell-
permeable dynein antagonists. It summarizes the available antagonists for dynein and 
describes their discovery and utility. Where possible, the features of these dynein 
inhibitors are considered in light of the concepts of selectivity and principles of protein-
ligand binding. In the outlook, prospects for future development of dynein inhibitors are 
presented in the context of recent advances in design and development of potent and 
selective inhibitors for other members of the ATPases Associated with diverse cellular 
Activities (AAA+) protein family, to which dynein belongs. 
 
In the second chapter, “Chemical structure-guided design of dynapyrazoles, cell-
permeable dynein inhibitors with a unique mode of action,” I present a rational approach 
to the development of derivatives of ciliobrevins that have improved potency and several 
improved chemical properties relative to the ciliobrevins. Structural analysis of the 
ciliobrevins suggested the hypothesis that replacing the isomerizable core of these 
compounds with a rigid tricyclic heterocycle and synthesis of such compounds led to the 
identification of two compounds that had 6-8 fold improved potency compared to 
ciliobrevin D (named the dynapyrazoles). An analysis of the mechanism of inhibition of 
dynein 1 by dynapyrazole A revealed that it inhibited the microtubule-stimulated ATPase 
activity of dynein, but did not potently inhibit the basal ATPase activity. This finding and 
further biochemical analyses revealed that dynapyrazole A likely inhibits the ATPase 
activity of dynein 1 that arises at just one of its four ATP-binding sites, AAA1. Taken 
together, these findings suggest that dynapyrazole A is likely to be a useful probe for 
studying dynein. 
Subsequent chapters extend this chemical structure-guided approach to the 
identification and characterization of two other compound scaffolds that inhibit dynein—
pyrazolopyrimidinone-based derivatives of dynapyrazoles and structurally-unrelated 
diaminoquinazolines. The mechanisms and sites of inhibition of these compound classes 
were analyzed using biochemical and structural techniques. 
Finally, I present an outlook chapter in which I discuss the trends emerging from 
the dynein inhibitors I discovered during the course of my PhD. Most dynein inhibitors 
do not act in a substrate-competitive mechanism and I posit that this may be a 
consequence of the complex chemomechanical cycle of dynein, which involves allosteric 
communication between distinct ATPase sites. All compounds with identified sites of 
inhibition act at the AAA1 ATPase site. I propose that this may be due to the low 
apparent affinity of this site for ATP. In conclusion, I suggest experiments that are likely 
to be valuable to more clearly understand the dynein inhibitors presently available and to 
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Chapter 1: Chemical probes for dynein 
1.1 Introduction 
Eukaryotic cells must perform multiple complex processes within a confined 
space to live and divide. To accomplish this, cells utilize energy to maintain spatial 
order(1). Cytoskeletal filaments, such as microtubules and actin fibers, are polarized 
polymeric arrays of proteins on which directional motion over micron-scale distances is 
possible. Motor proteins provide the force necessary for directed intracellular motion 
along these cytoskeletal filaments by converting the chemical energy in adenosine 
triphosphate (ATP) into kinetic energy. Repeated cycles of ATP hydrolysis by motor 
proteins power the motion of cargos ranging in size from single proteins to whole 
organelles(2). Several microtubule-based motor proteins have evolved to play specialized 
roles within eukaryotic cells(1).  
Dynein, the first microtubule-based motor protein discovered, is responsible for 
most of the microtubule minus-end directed transport in eukaryotic cells. It is now clear 
that dynein dependent transport is important for a wide range of cellular processes, 
including organelle positioning, mRNA transport, and cell division(2). Dynein is a fast 
motor, driving cargo transport at speeds of 1-10 µm/sec(3). Therefore, properly 
dissecting the function of this motor protein requires controlled perturbations of its 
activity on timescales of seconds to minutes. Such acute inhibition of protein function is 




FIGURE 1.1 Dynein, a motor protein in the AAA+ superfamily. (A) Schematic of dynein 
heavy chain structure. ATP hydrolyzing domains are indicated with an asterisk. Grey: AAA 
domains. Blue: linker. Red: stalk and microtubule binding domain (MTBD). (B) Alignment 
nucleotide binding motifs in dynein 1 (AAA1), dynein 2 (AAA1), p97 (D2) and NSF (D1). 
Alignment of ATP-binding motifs for AAA1 (C) or AAA3 (D) in dynein 1, dynein 2, and 
axonemal dynein 5. In (B-D) Identical residues across a given comparison are shown with 
bold capitals, similar residues are capitals, variable residues are lowercase. Key residues 
defining a motif are red. Uniprot accession numbers: human cytoplasmic dynein 1 
(Q14204), human cytoplasmic dynein 2 (Q8NCM8), human axonemal dynein 5 (Q8TE73), 
human p97 (P55072), human N-ethylmaleimide sensitive factor (P46459). 
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Dyneins can be divided into nine families comprised of seven axonemal dyneins 
and two classes of cytoplasmic dyneins(4). Axonemal dyneins are localized to axoneme-
containing organelles and drive ciliary and flagellar beating. Cytoplasmic dynein 2 is 
restricted to cilia and flagella, including the primary cilium, a signaling organelle 
required for Hedgehog pathway activity, but this dynein isoform does not participate in 
ciliary beating. Rather it drives motion of cargos along the axoneme toward the base of 
the cilium, a process termed retrograde intraflagellar transport. By contrast, cytoplasmic 
dynein 1 is located in the cytoplasm and participates in transport of many types of cargo. 
In this chapter ‘dynein’ refers to cytoplasmic dynein, unless indicated otherwise.  
The ATP-hydrolyzing heavy chains of dynein belong to the of the AAA+ protein 
family (ATPases associated with diverse cellular activities), which is characterized by the 
AAA domain, a common structural motif for ATP binding(5).   These proteins typically 
function as oligomers (often hexamers), with ATP bound at the interface of two AAA 
domains. AAA+ enzymes couple nucleotide hydrolysis with conformational changes that 
lead to substrate remodeling or motion. In the case of dynein, all six AAA domains are in 
one single large polypeptide and ATP hydrolysis leads to successive steps of the motor 
protein along microtubule tracks. 
The heavy chain of cytoplasmic dynein is a 500 kDa polypeptide that in cells 
functions as a homodimer bound to multiple accessory proteins. In order to move 
processively, the dynein complex (mass ~1.5 MDa) must bind dynactin, another 
megadalton-size multiprotein complex(6, 7). At the N-terminus of the dynein heavy chain 
is a ~50-60 nm long 'tail' that mediates dimerization and interacts with adaptors necessary 
for cargo binding(8). The C-terminus features the six AAA domains and the microtubule 
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binding domain (MTBD), which caps a ~15 nm coiled-coil stalk that extends from AAA4. 
A coiled-coil "buttress" emerging from AAA5 supports the stalk. In the dynein complex, 
ATP hydrolysis occurs mainly at two sites, AAA1 and AAA3, although AAA3 is active 
only in a subset of cytoplasmic dyneins(8) (ATP-binding sites are numbered such that 
AAA1 refers to the site between AAA+ domains 1 and 2).  Of these sites, AAA1 is the 
major ATPase, whose activity is controlled by other AAA sites and accessory proteins(8).  
In this chapter, we review the recent advances in developing chemical inhibitors 
to probe dynein function. We highlight the ciliobrevins, the first selective cell-permeable 
small molecule inhibitors of dynein. We discuss the discovery of these compounds, their 
use and how these chemical probes may be improved. We also discuss other strategies 
that have been developed to probe dynein function with fast temporal control. 
1.2 General approach to inhibiting dynein 
One simple approach to inhibiting dynein is to block its enzymatic activity using 
inhibitors that target its ATP-binding sites. The challenge of inhibiting the ATP-binding 
site is one of selectivity—how can a small molecule bind this site in dynein but not inhibit 
other nucleotide-binding enzymes? The structures of several AAA+ proteins have been 
solved and it is clear that their ATP binding sites are remarkably similar. Root mean 
squared deviations between Cα atoms are in the range of 1.5 to 2.5 Å for residues that 
constitute the nucleotide-binding core(5). ATP binds in a pocket containing a series of 
loops emanating from the top of several parallel β-sheets(5). Polar residues such as the 
Walker A lysine coordinate negatively charged phosphate groups. The Walker B 
glutamate and aspartate orient the hydrolytic water molecule, while the "arginine finger", 
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which extends from the adjacent AAA domain, stabilizes the terminal phosphate for 
nucleophilic attack by water. The adenine base forms hydrogen bonds with the peptide 
backbone of the "N-loop", and hydrophobic side chains of this motif contribute to the 
binding of adenine(9).  
Although this general mode of interaction with ATP is conserved across AAA+ 
proteins, at the level of primary sequence these proteins have diverged to a greater degree. 
Variability in residue composition is tolerated adjacent to invariant residues, such as the 
Walker A lysine, the Walker B aspartate/glutamate, and the arginine finger (see Figure 
1.1). Comparison of the ATP binding pockets between dynein and other AAA+ enzymes 
or among human dynein isoforms (Figure 1.1B, 1.1C-D) shows a high degree of 
similarity among residues that contact phosphate groups in ATP. By contrast, the residues 
positioned near the two hydrogen bonds that anchor the adenine base to the peptide 
backbone are more variable (N loop, Figure 1.1B-D). These comparisons suggest that it 
may be possible to identify small molecules that selectively target the ATP-binding site 
of one dynein isoform. In principle, inhibitor’s potency can be established via contacts 
with conserved residues and specificity can be achieved through interactions with non-





















































FIGURE 1.2 Nucleotide mimetic inhibitors of dynein. (A) Structure of the vanadate ion 




1.3 Nucleotide-mimetic inhibitors of dynein 
Compounds that mimic ATP and the other nucleic acids are well-established 
enzyme inhibitors(10). In the case of nucleotide ATPase mimetics, these compounds bind 
to enzymes in a manner similar to the endogenous nucleotide substrate but either lack a 
hydrolyzable phosphate moiety or have a slowly-hydrolyzable phosphate-like group.  
Vanadate  
Less than a decade after the discovery of dynein, researchers identified a “trace 
nucleotide contaminant” present in some batches of commercial ATP as an inhibitor of 
purified dynein(11, 12). Careful analysis of the batch composition of ATP led to the 
identification of this inhibitory contaminant as vanadate, an inorganic anion sometimes 
present in the animal muscle from which ATP was purified(13). 
In general, vanadate exists as a tetra-coordinate (VO4)3- anion but can also form a 
pentacoordinate complex. The relevant species for its inhibitory activity is ADP-vanadate, 
in which a terminal oxygen atom of ADP is bound to vanadium. This molecule has a 
trigonal-bipyramidal geometry at vanadium, which mimics the transition state formed 
during nucleophilic attack by water on the gamma phosphate of ATP(14). The stable 
substrate-vanadate complex is bound more tightly than the substrate or product, leading 
to potent inhibition of enzymatic activity by vanadate(15). Because this transition state is 
common to many enzymatic phosphate hydrolysis reactions, ADP-vanadate binds many 
ATP-binding enzymes and is generally accepted as a promiscuous antagonist of 




The principles of inhibition by vanadate hold true in the case of dynein: the ion-
ADP adduct potently (IC50s usually 1-10µM) inhibits many isoforms of dynein from 
different species in a nucleotide-dependent fashion. X-ray crystallography confirmed that 
dynein binds ADP-vanadate using the same Walker-A and B residues that ordinarily 
interact with the gamma phosphate of ATP(17). 
Interestingly, although dynein has multiple sites capable of binding ATP, the 
ADP-vanadate complex is bound only in AAA1 in a crystal structure(17). This may 
reflect a selective binding of ADP-vanadate to AAA1 or simply the fact that ATP 
turnover—and thus ADP-vanadate binding—occurs most rapidly at site 1. Though it 
stands to reason that vanadate could inhibit any enzyme that hydrolyzes ATP, it does not 
bind to all nucleotide hydrolyzing proteins. Indeed, vanadate exhibits selective inhibition 
of dynein relative to other cytoskeletal motors such as myosin and kinesin, a property that 
made it a useful early probe for dynein(11, 18). A serendipitous discovery that irradiation 
of dynein-ADP-vanadate complexes with UV light leads to specific photocleavage in one 
site within the enzyme enabled annotation of dynein’s structure and the commonalities 
between different dynein isoforms before this could be done by other approaches now 
commonly used(19). The fact that dynein is cleaved at only one site, later identified as 
AAA1, helped establish this site as the primary site of ATP hydrolysis in this large and 
complex enzyme(20). Vanadate's hydrophilicity restricts its membrane permeability, 






EHNA was identified as a dynein inhibitor by researchers studying sperm 
motility(21). It had previously been shown to inhibit protein carboxymethlyase activity 
under certain conditions, which was thought to account for the observation that EHNA 
blocks sperm motility. However, even under conditions where carboxymethylase activity 
was only minimally inhibited, EHNA rapidly inhibited sperm motility. Further, it blocked 
motion of demembranated spermatozoa, and this inhibition could be reversed by addition 
of excess ATP, suggesting a direct effect on axonemal dynein, the ATPase that generated 
flagellar beating. Experiments on purified axonemal dynein confirmed direct inhibition of 
its ATPase activity(21). 
EHNA is composed of an adenine base linked via N-9 (the site of linkage to 
ribose in adenosine/ATP) to an aliphatic alcohol. This compound is more hydrophobic 
than other nucleotide mimetics and is likely cell permeable, as it inhibits the motility of 
intact sperm. 
The IC50 for EHNA inhibition of dynein varies from ~200µM for dynein from sea 
urchin sperm to ~1mM for dynein from rat sperm(21). EHNA was shown to be a mixed-
type inhibitor of dynein as it raises dynein’s Km and simultaneously lowers its Vmax(22). 
These data raise the possibility that EHNA may bind a site on dynein other than its ATP-
binding pocket.  However, additional biochemical or structural studies are needed to 
support this hypothesis.  Based on its chemical structure and crystal structures of it bound 
to adenosine deaminase, we posit that EHNA interacts with the ATP-binding pocket but 
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can make additional contacts with proximal residues to achieve this complex mode of 
inhibition(23). 
In vitro, EHNA inhibits dynein selectively in comparison to a number of motor 
proteins and other ATPases(22). As a result, EHNA has seen use as an in vitro probe for 
dynein function. For example, inhibition of MAP1C-driven microtubule gliding by 
EHNA contributed to the assignment of this minus-end directed motor as a cytoplasmic 
isoform of dynein(24).  
As many cellular proteins bind adenosine-containing compounds, nucleotide 
analogs such as EHNA are unselective in cells. Indeed, this compound potently inhibits 
adenosine deaminase (IC50 ~20nM), and cyclic-GMP-stimulated phosphodiesterase II 
(PDE2, IC50 ~800nM)(23, 25, 26). As a result, the utility of this compound to probe 









Figure 1.3 Effect of ciliobrevin on the primary cilium and the Hedgehog pathway.  (A) 
Transport of intraflagellar transport cargos (purple) along the cilium is required for proper 
localization and activation of the Gli transcription factors. (B) Inhibition of dynein leads to 
shorter cilia, accumulation of IFT cargo and Gli proteins at the ciliary tip, and inhibition of 












Figure 1.4. Chemical structure of 
ciliobrevin A, highlighting the 






1.4 The ciliobrevins: cell permeable small-molecule dynein inhibitors 
The first dynein inhibitors not based on nucleotides or adenine were discovered in 
a cell-based screen for Hedgehog (Hh) pathway inhibitors. This screening approach is 
referred to as ‘chemical genetics’ as small molecule inhibitors, rather than genetic 
mutations, are identified that disrupt a cellular process of interest(27). Hh signaling 
controls development in multicellular organisms and was initially discovered as a 
regulator of polarity and segmentation in drosophila(28, 29). A vast body of research has 
led to advanced models for this signaling pathway. Briefly, the binding of a soluble 
Hedgehog ligand to its receptor Patched leads to the relief of inhibition of the seven-
transmembrane protein Smoothened (Smo). Smoothened activity leads to the 
accumulation of activated Gli transcription factors by altering the balance of proteolytic 
Gli degradation. Gli then enters the nucleus and activates Hh responsive genes(30). It has 
been established that Hh activity in vertebrates is dependent on the primary cilium(30, 
31). 
The primary cilium is an antenna-shaped organelle that protrudes from the cell 
membrane of vertebrate cells(32). Transport of cargos along its axoneme, termed 
intraflagellar transport, is required for building and maintaining the cilium, and carries 
Hh signaling-related cargos. Accumulation of Hh pathway components including Smo, 
Suppressor of Fused [Su(Fu)], and Gli within the cilium is required for the transcription 
of Hh responsive genes(33). Dynein 2 is required for assembly of functional cilia and 
active transport within them(34). In line with these roles, mutations in dynein 2 lead to 
both Hh pathway disruption and ciliary defects, such as ciliary shortening and 
accumulation the intraflagellar transport component IFT88(35, 36). 
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Improper Hh pathway activation can cause cancer in humans. In particular, basal 
cell carcinoma, one of the most common human cancers, has been shown to be driven by 
activating mutations in the Hh pathway(37, 38), and considerable effort has focused on 
discovering chemical inhibitors that block this pathway. With few exceptions, the 
compounds developed to disrupt the Hh pathway are inhibitors of Smo, and many bind to 
a common site on this G-protein coupled receptor-like protein(39). These efforts have 
recently led to approved therapeutics(40). One limitation of these clinical agents is the 
acquisition of resistance via mutations in Smo itself(41-43). Furthermore, cancer-causing 
mutations can arise in other Hh pathway proteins, including Patched, Smo, Su(Fu) and 
Gli. As some of these proteins function downstream of Smo in the signaling cascade 
these cancers are unlikely to be responsive to drugs that inhibit Smo.   
The chemical genetic screen in which ciliobrevin A was discovered was designed 
to uncover Hh inhibitors that act downstream of Smo(44). For this screen, the Hh 
pathway was activated using the Smo agonist SAG, a small molecule that competes with 
other known Smo antagonists at a common binding site(45). This innovation in the screen 
reduced the likelihood of discovering compounds that directly bind Smo. Of the ~1.2x105 
compounds screened in this manner, four blocked Hh activity with IC50 values < 10 µM. 
Ciliobrevin A (or HPI-4, Hedgehog pathway inhibitor-4) was one of these four 
compounds. The chemical structure of this compound did not imply a mechanism of 
action, as its core structure, a benzoylacrylonitrile-substituted quinazolinone, differs from 
those usually observed among common inhibitor classes (e.g. kinase inhibitors). 
Extensive follow-up work was required to identify dynein as a target of this compound. 
This work began with validation that ciliobrevin A inhibited a protein in the Hh pathway 
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that was downstream of Smo. Analyses of reporter cell lines in which Hh signaling was 
constitutively active, including one expressing inhibitor-resistant allele of Smo, showed 
that the compound's action is epistatic to, and therefore "downstream" of, Smo.  
A clue to the target of this compound came from analysis of its effect on the 
primary cilium. Extended treatment with HPI-4 resulted in ciliary defects including cells 
with shortened or no primary cilia. This observation led to HPI-4 being named 
ciliobrevin(46). Upon closer investigation, it was noted that ciliobrevin A treatment led to 
Gli2 accumulation at the distal tip of the cilium even in the absence of Hh pathway 
activation, and caused similar accumulation of IFT88, consistent with inhibition of 
retrograde intraflagellar transport(46). Together, these data are consistent with ciliobrevin 
A acting on cytoplasmic dynein 2. 
Confirmation that the ciliobrevins were dynein inhibitors came from biochemical 
experiments showing inhibition of microtubule gliding driven by dynein 1 purified from 
bovine brain and of the ATPase activity of the recombinant rat dynein 1 motor 
domain(46). The half-maximal inhibitory concentration (IC50) for dynein in vitro was 
~30µM. At the time this research was conducted, dynein 2 was not well characterized 
biochemically and could not be obtained in quantities sufficient for biochemical assays, 
but ciliobrevin A has since been shown to block ATP hydrolysis by dynein 2 at low ATP 
concentrations(47). The ciliobrevins were the first small molecules that gave cellular 
phenotypes consistent with dynein inhibition and blocked dynein in vitro. As such they 
were the first selective cell-permeable small molecule probes of dynein function.  
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Two lines of evidence indicate that the ciliobrevins act at dynein's major ATPase 
site, AAA1(46). Ciliobrevin D, a close chemical derivative of ciliobrevin A, inhibited 
dynein in an ATP-competitive manner. Ciliobrevin A blocked vanadate-mediated 
photocleavage of recombinant dynein, which is consistent with direct displacement by 
ciliobrevin of ADP-vanadate at AAA1. We note, however, that direct competition cannot 
readily be distinguished from the effect of slow ADP-vanadate accumulation due to 
reduced ATPase activity. Furthermore, interpreting ATP-competition experiments is 
challenging for enzymes with multiple active sites. Additional work is needed to confirm 
the site(s) of ciliobrevin binding in dynein.  
The utility of the ciliobrevins as probes for dynein depends in part on how 
confidently their cellular effects can be assigned to dynein inhibition. Analysis of other 
pathways known to interact with the Hh pathway demonstrated that ciliobrevin A does 
not inhibit signaling associated with protein kinase A, phosphatidylinositol 3-kinase 
(PI3K)/Akt, mitogen activated protein kinase (MAPK), or the WNT pathway(44). In vitro, 
Ciliobrevin treatment at concentrations that fully inhibited dynein-driven microtubule 
gliding did not inhibit another microtubule-based motor protein (kinesin) or two other 
AAA+ proteins (p97, MCM2-7), indicating selective dynein inhibition. Additional 





Other dynein inhibitors 
In addition to the ciliobrevins, two compounds have been identified as modulators 
of dynein function. Both compounds described below have seen little use as probes for 
dynein.  
Nordihydroguaiaretic acid (NDGA): This compound, a component of herbal medicines, 
exhibits pleiotropic activities in cells, which can be ascribed to its anti-oxidant properties 
or to its inhibition of lipoxygenase(48). Some of the cellular effects of NDGA were noted 
to be independent of these properties, notably golgi complex disassembly and 
accumulation of ZW10 and EB1 at the centrosome(49). These effects have been related 
to potentiation of interactions between dynactin and some dynein-dynactin cargos(50). 
The mechanistic details of how NDGA alters dynein-dynactin cargo interactions are 
poorly understood and it is unclear if this effect is direct. Further biochemical 
characterization of the effect of NGDA is needed before it can be used as a probe of 
dynein function.  
Purealin: This natural product was isolated from a species of sea sponge and shown to 
inhibit the beating of isolated flagella(51). It was later shown to modestly (up to 50% at 
the highest concentration tested, 50µM) inhibit the microtubule-stimulated ATPase 
activity of cytoplasmic dynein in vitro. This activity was shown to be ATP-
uncompetitive(52).   
Use of the ciliobrevins 
We highlight a few examples of the use of ciliobrevins as probes of dynein 
biology. Other studies using ciliobrevins have been recently reviewed elsewhere(53). 
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Dynein 2 is required to build a primary cilium, and persistent inhibition of its 
function results in short or ‘stubby’ cilia(30). Acute blockade of dynein 2 can help dissect 
the role of dynein-driven retrograde intraflagellar transport in signaling dynamics in the 
intact cilium. In a cell-based assay where intraflagellar transport in a primary cilium 
could be directly observed using fluorescent tagging of IFT-88, treatment with ciliobrevin 
A or D blocked retrograde movement within cilia within 3 minutes(47, 54). The ability to 
rapidly inhibit dynein 2 allowed the uncoupling of intraflagellar transport from 
maintenance of ciliary architecture, which is largely unperturbed in the short-term 
inhibitor treatments. The somatostatin receptor (SSTR3), a cilium-based transmembrane 
protein, continued to move diffusively following acute arrest of intraflagellar transport 
using ciliobrevin D, indicating that motion of some ciliary signaling proteins is primarily 
diffusive. This finding was corroborated for both SSTR3 and Smo by rapid depletion of 
cellular ATP(54) and was later supported by ultra-high resolution tracking of Smo 
movement(55). 
The "immunological synapse" forms between antigen-presenting cells and T 
lymphocytes following recognition of a stimulatory antigen by the T cell receptor. In 
order for the T cell to mount a proper response at the immunological synapse, which 
includes the directed release of cytokines and cytotoxic substances toward the antigen 
presenting cell, T cells must rapidly rearrange and "polarize" components of their 
cytoplasm toward the synapse. Two studies elegantly used ciliobrevin D to examine the 
role of dynein in this dynamic process. In one study, treatment with ciliobrevin D, but not 
a related inactive control, reduced the polarization induced by T-cell-APC interactions. 
Addition of an inhibitor of non-muscle myosin further reduced polarization, indicating a 
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contribution from both dynein and myosin to this process(56). In the other study, 
ciliobrevin D treatment slowed the velocity at which centrosomes translocated in the 
cytosol toward the newly formed immunological synapse, and caused centrosomes to 
pause farther away (~1.5µm) from the synapse compared to treatments with a 
chemically-related inactive control compound (57). This study showed that dynein has a 
role in both rapid centrosome movement across the cytoplasm and in positioning the 
centrosome proximal to the immunological synapse. In both studies, the effect of 
ciliobrevin D on dynein was shown to be similar to the effect of other dynein disruptions.  
Ciliobrevins have also been used to study mechanisms of cell division. 
Longstanding models indicate that segregation of chromosomes during mitosis depends 
on microtubules connecting kinetochores to spindle poles. Two studies now show that 
this may not be absolutely required(58, 59). Using correlative light microscopy and 
electron microscopy, it was recently shown that, in the course of normal cell division, 
some chromosomes connected to the mitotic spindle by a microtubule bundle (K-fiber) 
that did not extend from chromosome to spindle pole(59). Instead these K-fibers ended 
distal to the pole at an intersection with another microtubule fiber. Such chromosomes 
continue moving toward the appropriate spindle pole. Though this distal K-fiber 
attachment occurs in normal cells, it is difficult to detect. Chromosomes attached to the 
spindle in this manner can be generated by laser microsurgical ablation of a normal K-
fiber, after which the free K-fiber stub rapidly (~ 30 s) connects with other microtubule 
fibers. Inhibition of dynein with a high dose of ciliobrevin (50µM) disrupts spindle pole 
formation. However, an intermediate ciliobrevin dose in which spindles can form (10µM), 
delays the resumption of chromosome movement after K-fiber severing(59). Another 
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study confirmed this finding by overexpressing a dynactin subunit to block dynein-cargo 
interaction(58). Together, these findings show that dynein is required for the retention 
and movement of K-fibers that do not extend to the spindle pole and their associated 
chromosomes. 
Finally, ciliobrevins are active in tissue preparations (from mice and chickens, for 
example)(60, 61). In particular, ciliobrevin was shown to block intra-axonal movement 
within neurons from chicken egg ganglia and to impair nerve growth factor (NGF) 
mediated regulation their structure(61).  
1.5 Other approaches that allow fast temporal control over dynein function 
Recently, two new approaches have been designed to probe dynein function in 
cells. The first method utilizes chemically induced dimerization to rapidly recruit dynein 
complexes to a selected cargo(62, 63). Chemical inducers of dimerization (CIDs) were 
first developed by Schreiber and colleagues based on studies of natural products 
rapamycin and FK506(64, 65). In particular, addition of rapamycin to cells can induce the 
dimerization of two proteins, FKBP and FRB (a domain of the mTOR kinase), within 
seconds(66). This approach, which has been used in a wide-range of cellular contexts, has 
been adapted to control dynein function(66). Specifically, a dynein cargo adaptor, BicD2, 
was fused to a FRB and a dynein cargo with known localization (eg. Pex3 for 
peroxisomal recruitment) was fused to FKBP12. Using this CID-based approach, 
researchers have studied the effect of rapid recruitment of dynein complexes to 
membrane-bound organelles such as mitochondria, peroxisomes, and endosomes or to the 
cell membrane (62, 63, 67, 68). The rapid onset of recruitment and the ability to localize 
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dynein to a specific cellular compartment allows careful analyses of the contribution of 
dynein to a given process. In one elegant example, rapamycin derivative-driven 
localization of dynein to the plasma membrane was used to show that cortical dynein 
controls the polarity of microtubules in developing axons(67).  
The second method combines induced dimerization with optogenetics to enable 
reversible recruitment of dynein to a defined cargo(68). In this system, illumination with 
blue light uncages a helix of a Light-Oxygen-Voltage domain (LovPEP), freeing it to 
bind an engineered PDZ domain (ePDZ)(69). These small (< 20 kDa) protein modules 
can be fused to proteins of interest and used to rapidly stimulate association upon 
exposure to the appropriate wavelength of light. In the case of the LovPEP-ePDZ system, 
association can be reversed (with rapid dissociation kinetics) upon turning off the 
excitation light. Further, use of precisely focused illumination makes it possible to recruit 
dynein complexes to a defined subcellular region, enabling spatial and temporal 
resolution of dynein's activity upon recruitment(68).  
These approaches are exciting new developments in the field. However, one 
limitation of these methods is that the function of engineered protein constructs must be 
examined, rather than directly probing the activity of the endogenous motor protein, as 
can be possible with cell-permeable chemical inhibitors.   
1.6 Outlook 
Ciliobrevins provide a useful starting point to develop new chemical inhibitors 
with improved properties. Currently, there are two main limitations of ciliobrevins. First, 
is their micromolar potency. This low potency makes it difficult to achieve target 
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specificity in cellular contexts, as doses that fully suppress dynein activity may approach 
~100 µM, a concentration at which the compound may interact with other proteins and 
suppress their activities. The second limitation of ciliobrevins is their low aqueous 
solubility (computed logarithm of the octanol:water partition coefficient [ClogP] ~4-5). 
This parameter is associated with decreased effective concentrations in cellular contexts 
and may account for the suppression of ciliobrevin activity by high-serum concentrations, 
such as those typically used for cell culture (70).  
As a first step toward discovering improved dynein inhibitors, we and our 
collaborators, generated and tested ~50 chemical derivatives of ciliobrevins(47). These 
compounds were screened for inhibition of purified full-length human cytoplasmic 
dyneins 1 and 2 with an eye toward the development of selective dynein 2 antagonists. 
Dynein-2 selective inhibitors could block the Hedgehog signaling pathway without 
inhibiting the many different cellular processes that depend on dynein 1 function. Most of 
the compounds synthesized differed from the parental compound at a single position, but 
left intact the cyano-acrylamide, quinazolinone, and dichlorobenzoyl groups present in 
ciliobrevins (47). A set of derivatives typified by compound 37 (Figure 1.5A) bearing 
bulky aryl ethers at the 7 position of the molecule retained activity toward dynein 2 while 
no longer inhibiting dynein 1, resulting in ~10 to > 20 fold isoform selectivity under the 
in vitro assay conditions, which employed low ATP concentrations (<1µM). It is 
noteworthy that inhibition of dynein under closer-to-physiologic ATP concentrations was 
not observed. Cell-based assays using these compounds demonstrated ~1.5 to 6-fold 
selective inhibition of dynein 2-dependent (e.g. intraflagellar transport, ciliogenesis) 
relative to dynein 1-associated processes (e.g. mitotic spindle assembly). It is possible 
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that the diminished selectivity of these compounds in the cellular context is a result of the 
ATP-sensitive nature of their inhibition or may reflect reduced availability in cytosol due 
to the high hydrophobicity of these compounds (ClogP for compound 37: ~ 6).  
Analysis of the ciliobrevin’s chemical structure indicates that it can isomerize 
about its central double bond (Figure 1.5B). If only a fraction of the ciliobrevins adopt 
the geometry the inhibits dynein, the overall potency will be proportionately reduced. If 
chemical modifications of the ciliobrevin scaffold changes the isomer preference of the 
acrylonitrile double bond, this potential variability in structure can confound structure-
activity-relationship analyses that would guide additional chemical modifications to 
improve properties. Therefore, an important next step is to restrict this potential 
isomerization, possibly by engineering in an additional cyclization of the core 





Figure 1.5 Structure of ciliobrevins. (A) Compound 37, a ciliobrevin derivative that selectively 
inhibits dynein 2. (B) The ciliobrevin scaffold may exist in two isomers about the indicated 
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Figure 1.6 Inhibitors of AAA+ proteins. Shown are the structures and inhibitory activities 
of: the first inhibitor of p97, DBeQ and its derivative CB-5083, the midasin inhibitor RBin-
2 and the dynein inhibitor ciliobrevin D. *at least three other classes of compounds that 
inhibit p97 have been described. 
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Selectively inhibiting a conserved site: lessons from the development of AAA+ inhibitors 
The likelihood that potent and selective probes for dynein can be developed is 
indicated by the recent discoveries of chemical inhibitors for two other AAA+ proteins, 
VCP/p97 and midasin.   
CB-5083 has been developed as a potent (IC50: 0.01µM) and selective inhibitor of 
p97 and is the first AAA+ inhibitor to reach clinical trials for treatment of a human 
disease(71)(72). This compound was developed by iterative modification(73) and 
testing(74) of hundreds of derivatives of DBeQ (dibenzyl quinazoline-2,4-diamine), a 
chemical inhibitor of VCP/p97 and was identified via in vitro high throughput 
screening(75, 76). In contrast to dynein, VCP/p97 can be generated in quantities 
sufficient for a large-scale initial screen and extensive biochemical follow-up work that 
helped in developing improved inhibitor analogs (77, 78). 
Midasin is an AAA+ enzyme required for the process of ribosome biogenesis. 
Like dynein, all six of its AAA+ subdomains are on a single large polypeptide of mass 
~0.5MDa. RBin-1 (ribozinoindole-1), a cell permeable chemical inhibitor, was identified 
from a high throughput screen of ~10,000 compounds(79). The target of this compound, 
which is a potent inhibitor of fission yeast saccharomyces pombe growth (IC50 0.14µM), 
was identified by analyses of resistance-conferring mutations. In particular, multiple 
different point mutations, which clustered near the likely interface of the AAA3-AAA4 
domains of midasin, were sufficient to confer resistance to Rbin-1 in cells. Testing of a 
series of analogs against both sensitive (wild-type) and resistant (midasin mutant) cell 
lines enabled the discovery of more potent analogs (Rbin-2, IC50: 0.014µM). RBin-2 
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inhibited the ATPase activity of purified full-length recombinant midasin. Importantly, a 
mutation in midasin that conferred resistance to Rbins in cells, was sufficient to suppress 
inhibition of ATPase activity, providing ‘gold standard’ proof that midasin is RBin’s 
direct physiological target.  
In summary, chemical inhibitors of dynein are likely to be powerful tools for 
dissecting this motor protein’s functions across different cell-types and organisms. The 
work described here suggests that an initial foundation is in place for additional research 
that will lead to better chemical probes. It is also possible that these studies may lead to 






Chemical structure-guided design of dynapyrazoles, potent 
cell-permeable dynein inhibitors with a unique mode of action 
Note to readers: the results discussed below arose from a collaborative effort between 
myself and several colleagues in the Kapoor Lab, at the Tri-Institutional Therapeutics 
Discovery Institute (TDI), at Stanford University, Northwestern University, and the 
California Institute of Technology. A closely related version was published in eLife (DOI: 
DOI: 10.7554/eLife.25174). With the permission of Prof. Kapoor, I have included work 
done by others in this thesis as it helps explain the rationale of my work and supports the 
conclusions I draw.  In the body of the text and in the methods section, I have noted who 
performed each experiment. I have also noted this information in the figure legends, 
where appropriate. Except for experiments credited explicitly to others, I performed all 




 The AAA+ (ATPases Associated with diverse cellular Activities) superfamily is 
comprised of ~100 proteins in humans(5)(80). These ATPases are essential for many 
cellular processes, including DNA replication, proteostasis, membrane remodeling, and 
cytoskeletal organization(9). Extensive cell biological and biochemical studies have 
revealed that these enzymes couple ATP hydrolysis to substrate remodeling and 
directional transport, processes that can occur on the timescale of seconds or minutes(81). 
Thus, small molecule inhibitors that can modulate AAA+ activity on similarly fast 
timescales are likely to be valuable tools to probe their cellular functions(82). Valosin-
containing protein(83) and dynein(46) are the only two human enzymes in this large 
superfamily for which well-characterized small molecule antagonists have been reported. 
Dyneins are microtubule-based motor proteins in the AAA+ family that have been 
divided into two classes, axonemal and cytoplasmic. Axonemal dyneins are required for 
the beating of flagella. Cytoplasmic dyneins, of which there are two isoforms (hereafter, 
dynein 1 and 2), are present in metazoan cells and are required for a wide range of 
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cellular processes(1, 2, 84). Transport of cargo along microtubules requires a balance of 
forces directed toward either end of the filament. While multiple motor proteins in the 
kinesin family provide the plus-end directed force to drive this motion, their activity in 
many contexts is opposed by only two cytoplasmic dyneins, the primary motor proteins 
transporting cargos towards the minus-end of microtubules(1). Dynein 1 has many 
functions in the cytoplasm, where it moves diverse cargoes ranging from mRNA 
molecules to whole organelles. In contrast, dynein 2’s functions are restricted to cilia and 
flagella. The primary cilium is an antenna-like organelle that protrudes from the cell 
surface, in which dynein 2 drives transport toward the base(34, 85). This process, known 
as intraflagellar transport, is required for Hedgehog signaling, a developmental signaling 
pathway(32, 34, 85). Cargos of both dynein isoforms can move at rates of >1 µm/s in 
cells(2) and therefore, fast-acting, reversible chemical inhibitors are likely to be useful 
probes for dynamic dynein-dependent cellular processes. 
Ciliobrevins were recently reported as the first selective, cell-permeable probes of 
dynein(46). Although other chemical antagonists of dynein have contributed to 
understanding the biochemistry of dynein, their use in cell biology has been limited 
because they are either not cell-permeable (e.g. vanadate) or non-selective in cells (e.g. 
EHNA)(11, 12, 21). Ciliobrevins were discovered as inhibitors of Hedgehog signaling 
and shown to block cytoplasmic dynein 1- and 2-dependent transport in cells(44). 
Ciliobrevins have been used as tools to examine the role of dynein in a number of 
processes, including formation of the immunological synapse, transport of signaling 
proteins in the primary cilium, axonal transport of transcription factors, and axon 
extension and branching in cultured neurons(54, 56, 57, 61). However, the use of 
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ciliobrevins has been limited by their low potency and suboptimal chemical properties, 
which is often noted for first-in-class compounds identified through high-throughput 
screening(53). Complete inhibition of dynein can require high doses (50-100µM) and 
selective protein target inhibition can be difficult to achieve at these high concentrations.  
The ciliobrevins are based on a benzoylacrylonitrile-substituted quinazolinone 
scaffold (Figure 2.1A). This type of acrylonitrile has the potential to react with 
nucleophiles, and instability of ciliobrevins during storage has been noted(61). The 
benzoylacrylonitrile core is required for in vitro and cellular activity, but this functional 
group has the potential to isomerize, and the ciliobrevin scaffold may exist as either of 
two isomers about the benzoylacrylonitrile olefin (C2 - C9, Figure 2.1A). The preferred 
isomer of this compound has not been determined and chemical modification of the 
quinazolinone or acyl groups, even distal to the acrylonitrile functionality, has the 
potential to affect the geometry of the compound's core. Together, these factors have 
made activity-guided modifications to improve compound potency challenging. Further, 
up to ~100-fold differences in potency have been noted between biochemical and cell 
based assays (0.2 µM – 30 µM for ciliobrevin D), raising concerns about target 
specificity. Design and chemical synthesis of alternative scaffolds that address these 
limitations and retain activity against dynein are needed. 
 Dynein is a large, ~4600 amino acid protein that contains six unique AAA 
ATPase domains(86). Many AAA+ enzymes function as homohexameric arrays of 
identical AAA domains, and thus all six of the ATPase sites are biochemically 
equivalent(87). However, for dyneins, each of the six unique AAA domains resides on a 
single polypeptide and can have a specialized role in motor protein function(8). In the 
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case of dynein 1, four of the six AAA domains contain the residues necessary for 
nucleotide binding; of these, only AAA1 and AAA3 substantially contribute to ATP 
hydrolysis and have been shown to be required for microtubule motility(8). Dynein’s 
ATPase activity is stimulated by interactions with microtubules and is thought to occur 
mainly at AAA1, while hydrolysis at AAA3 plays a regulatory role(88-90). Ciliobrevins 
have been shown to be ATP-competitive inhibitors of dynein(46), but it remains unclear 
which of the six AAA sites are modulated, adding to the challenges of inhibitor 
optimization. 
 Here, we characterize the conformation of ciliobrevins and design tricyclic 
pyrazoloquinazolinone derivatives that are more potent inhibitors of dynein. One 
derivative, which we name dynapyrazole-A inhibits dyneins 1 and 2 with similar 
potencies in vitro and in cellular assays. Biochemical analyses of this compound showed 
that while it inhibits the microtubule-stimulated ATPase activity of dynein, it does not 
potently block the microtubule-independent basal activity. This mode of activity is unlike 









Figure 2.1 Analysis of the conformation of the ciliobrevin scaffold. Note: this 
work was done by others: Structural analyses were performed by M. Nishitani 
(Takeda Pharmaceuticals, Japan), A. Ondrus (California Institutue of 
Technology), and A. Johnson (Stanford University). (A) E and Z isomers about the 
C2-C9 bond of ciliobrevin D are shown. Possible hydrogen-bond in the E 
configuration is indicated (dashed line). Selected atoms are numbered for 
reference. (B) Compound 1 was used for x-ray crystallography. (C) X-ray structure 
of 1. Displacement ellipsoids are shown at the 50% probability level. (D) Enlarged 
(2x) image of acrylonitrile moiety with selected bond lengths indicated (Å). 
Protons are shown to illustrate possible hydrogen-bonding interaction. Color 
legend: carbon-grey, hydrogen-white, nitrogen-blue, oxygen-red, chlorine-green. 
(E) Nuclear Overhauser effect spectroscopy (NOESY) spectrum for ciliobrevin D. 
A broad peak corresponding to interaction between Hb and the N1 proton is 
indicated. Protons corresponding to peaks in the spectrum of ciliobrevin D are 
indicated. Coupling is indicated by a double-headed arrow. A 1-dimensional 




To design new analogs with improved properties we analyzed the conformation of 
the ciliobrevin scaffold. For these studies we first used x-ray crystallography. Efforts to 
crystallize ciliobrevin D were unsuccessful; however compound 1, a derivative with a 2-
morpholinoethyl ether substitution, was synthesized using a previously described 
procedure and was found to readily crystallize (Figure 2.1B, C, D, crystallography was 
performed by M. Nishitani, Takeda Pharmaceuticals, Japan)(47). The x-ray data 
suggested that 1 exists as a single isomer with an E olefin configuration of the C2-C9 
double bond. The measured bond lengths are consistent with electrons in a -system 
delocalized across the benzoylacrylonitrile core (Figure 1D). The C2-C9 bond length 
(1.44 Å), which is longer than that of a typical olefin, indicates significant single bond 
character.  The proximity between O11 and N1-H suggests that the ciliobrevin structure 
is stabilized by an intramolecular hydrogen-bond between N1 and O11 (Figure 2.1A, 1D). 
A closely-related acylacrylonitrile-substituted quinazolinone was found to favor an 
alternative conformation, corresponding to a Z-olefin at C2-C9, that was also stabilized 
by intramolecular hydrogen-bonding(91). Taken together, these data indicate that the 
isomeric preference of the pharmacophore is likely to be sensitive to distal substitutions. 
As crystal packing may impact conformation, we turned to NMR spectroscopy to 
analyze the structure of the ciliobrevin scaffold in solution. A 1-dimensional proton NMR 
spectrum of ciliobrevin D showed a peak at 13.5 ppm, which could be assigned to a 
proton at one of the quinazolinone nitrogens(91) (Figure 2.1 Figure Supplement 1). The 
presence of this broad, downfield peak suggests that one exchangeable N-H proton is 
stabilized by a hydrogen-bonding interaction. A NOESY spectrum of ciliobrevin D 
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revealed all the expected resonances (Figure 1E, NOESY experiment was performed by 
A. Ondrus and A. Johnson, at Stanford University). In addition, we detected a coupling 
between the proton at 13.5 ppm and the proton at the 8-position of the quinazolinone, 
consistent with the proton at N1 being involved in hydrogen bonding. Together, these 
data suggest that ciliobrevin D has similar orientation in solution to that of 1 in the crystal, 
and the benzoylacrylonitile functional group favors an E-isomer configuration that is 
stabilized by hydrogen bonding (Figure 1E). 
We hypothesized that replacing the benzoylacrylonitrile core with a heterocyclic 
scaffold that maintained the observed ciliobrevin geometry could lead to improved 
dynein inhibitors. We reasoned that a tricyclic scaffold could replace the non-covalent 
N1-H-O11 interaction and maintain the overall ciliobrevin pharmacophore. We 
envisioned replacing the C2-C9 olefin and C10 ketone with either a pyrrole or pyrazole 
ring to afford such a tricyclic heterocycle (Figure 2.2A-C, synthesis was performed by 
colleagues at the TDI). We adapted established procedures to synthesize 2 and 3, which 
differ from known compounds only in the substitution pattern of the D ring (Figure 2.2A, 
2.2B)(92, 93). We also devised a synthetic route to a series of tricyclic analogs 
exemplified by 4, which relies on the condensation of a 2-fluorobenzoic acid methyl ester 
with a 4-cyano-aminopyrazole under basic conditions (Figure 2.2C). This strategy 
allowed convergent synthesis of the desired cyclized ciliobrevin analogs. 
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Figure 2.2 Synthesis of ciliobrevin D derivatives and analysis of their 
activity against dynein 2. Note: the work shown in A-C was done by others. 
Synthesis was performed by colleagues at the TDI. (A - C) Synthesis of 
ciliobrevin derivatives. (A) Pyrroloquinazolinone derivative. Reagents and 
conditions: (i) malononitrile, ammonium acetate, toluene, 100 °C, 13h, 72%; (ii) 
bromine, carbon tetrachloride, 70 °C, 9h, 38%; (iii) methyl anthranilate, 
isopropanol, 100 °C, 20h, 15%. Selected atoms are numbered for reference.  (B - 
C) Pyrazoloquinazolinone derivatives. Reagents and conditions: (iv) acetic acid,
150 °C (microwave), 30 min, 26%. (v) malononitrile, sodium hydride, 
tetrahydrofuran, 0 °C, 1h, 96%; (vi) dimethyl sulfate, N,N-
diisopropylethylamine, dioxane, 60 °C, 23h, 27%; (vii) hydrazine hydrate, 
ethanol, 80 °C, 6h, 82%; (viii) methyl 2-fluoro benzoate (or substituted 
derivative), potassium carbonate, dimethylformamide, 140 °C, 30 min, 11%. (D) 
Gel filtration trace (Superose 6) for GFP-dynein 2, with volume at elution peak 
indicated. V
o
, void volume. (E) SDS-PAGE analysis (Coomassie blue stain) of
GFP-dynein 2, ~0.5 µg protein loaded. (F) Schematic of microtubule motility 
assay. Anti-GFP antibody (Ab), GFP-dynein (dyn), and microtubule (MT) are 
indicated. (G) Time-lapse montage of fluorescent microtubules moving on GFP-
dynein 2-coated glass slides in the solvent control (2% DMSO) or in the 
presence of ciliobrevin D (20 µM). (H) Montages of fluorescent microtubules 
moving on GFP-dynein 2-coated glass slides in the presence of compounds 2-4 
(20 µM). (I) Mean velocity of dynein 2-driven microtubule gliding in the 
presence of control solvent (2% DMSO), ciliobrevin D, or compounds 2-4 (mean 
+ S.D., n ≥ 3). Number of microtubules quantified: DMSO-327, Cil. D-85, 2-98, 
3-90, 4-77. All motility assays were run at 1mM MgATP, 0.05 mg/mL casein, 
and 2% DMSO. For all montages, the interval between successive images is 2 


































































































































To test if these compounds inhibit dynein we employed a microtubule gliding 
assay. We first focused on human cytoplasmic dynein 2, the isoform involved in ciliary 
transport and Hedgehog signaling(32), as its inhibition in this assay by ciliobrevin D has 
not been previously demonstrated. We purified an N-terminally GFP-tagged motor-
domain construct of dynein 2 using an insect cell expression system(17). The GFP tag in 
this construct (GFP-dynein 2, amino acids 1091 - 4307) allowed immobilization on 
passivated glass coverslips used in microtubule gliding assays. This protein was obtained 
as a mono-disperse peak by gel filtration (Figure 2.2D, 2.2E). GFP-dynein 2, in the 
presence of ATP (1mM), moved microtubules with a velocity of 128 ± 14 nm/s (mean ± 
SD, Figure 2.2G). This activity is readily revealed by a time-series montage, which 
shows a fluorescently labeled microtubule being displaced ~3µm in 20 seconds (Figure 
2.2G). This rate is comparable to previous analyses of this construct(17). Ciliobrevin D 
(20µM) reduced the microtubule gliding velocity (Figure 2.2G), consistent with its 
inhibition of dynein 2-dependent processes in cells(46, 54). 
We next tested compounds 2 - 4 at 20 µM, a concentration at which ciliobrevin D 
slowed dynein 2-driven gliding to 83 ± 10 nm/s (Figure 2.2I). Compound 2 did not 
substantially change microtubule gliding velocity (126 ± 17 nm/s, Figure 2.2H, 2.2I). 
Compounds 3 and 4 inhibited dynein 2-driven gliding to a velocity comparable to that 
observed in the presence of ciliobrevin D at this same concentration. 
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Figure 2.3 Chemical structure analysis, design, and evaluation of 
pyrazoloquinazolinone derivatives of ciliobrevin. Note: the work shown in C 
and I was performed by others. X-ray crystallography was performed by M. 
Nishitani, Takeda Pharmaceuticals, Japan. Hedgehog pathway analysis was 
performed by C. Santarossa and L. Yu (graduate student and technician in 
Kapoor laboratory). (A) Superposition of the crystal structure of 1 with the 
computational model of 4 (green). (B) Pyrazoloquinazolinone ciliobrevin 
derivatives with cyclopropyl group. (C) Crystal structure of 5. Displacement 
ellipsoids are shown at the 50% probability level. (D) Superposition of the 
crystal structure of 1 with the crystal structure of 5 (cyan). (E) Montages of 
fluorescent microtubules moving on GFP-dynein 2-coated glass slides in the 
presence of compounds 5 - 8 (20 µM). The interval between successive images 
is 2 seconds and total time elapsed is 20s. Horizontal scale bar, 5 µm. (F) Mean 
velocity of dynein 2-driven microtubule gliding in the presence of compounds 5 
- 8 (mean + S.D., n ≥ 3). Number of microtubules quantified: 5-91, 6-63, 7-86, 
8-56. (G) Inhibition of GFP-dynein 2-driven motility by 8 and ciliobrevin D. IC
50
values: 8: 2.6 ± 1.3 µM (mean ± S.D., n = 3); ciliobrevin D: 20 µM (range: 19-
21 µM, n = 2). Velocity distribution histograms for inhibition of dynein-2 driven 
microtubule motility are presented in Figure 3 Figure Supplement 1. Number of 
microtubules quantified: 8: 10µM-36, 5µM-59, 2.5µM-98, 1.3µM-112, 0.6µM-
102, 0.3µM-126; Ciliobrevin D: 80µM-10, 40µM-47, 20µM-78, 10µM-85, 
5µM-99, 2.5µM-66, 1.3µM-80; (H) Inhibition of GFP-dynein 2-driven motility 
by 6 and 9. The chemical structure of 9 is shown. IC
50
 values: 6: 2.9 ± 0.6 µM
(mean ± S.D., n = 3). 9: 17.7µM (range: 17.2-18.2, n = 2). Number of 
microtubules quantified: 6: 20µM-38, 8µM-24, 3.2µM-48, 1.3µM-50, 0.5µM-
53; 9: 20µM-29, 8µM-54, 3.2µM-50, 1.3µM-54, 0.5µM-56. (I) Dose-dependent 
inhibition of luciferase reporter expression by ciliobrevin D and compound 7. 
IC
50
 values (mean ± S.D.): ciliobrevin D: 15.5 ± 3 µM (n = 4); 8: 1.9 ± 0.6 µM
(n = 5). For G, H, and I, IC50 values reported reflect the mean (with range or 
S.D.) of separate IC50 values obtained from independent dose-response analyses. 
Data were fit to a sigmoidal dose-response curve and constrained such that the 
value at saturating compound = 0. Individual data points presented reflect mean 
of values determined from n ≥ 2 independent replicates ± S.D. (G, I) or ± range 
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To improve the potency of compound 4 we compared its structure with that of 
ciliobrevin analogs. In particular, we superimposed the crystal structure of 1 with an 
energy-minimized structure of 4 computationally generated using Maestro (Schrödinger). 
This analysis revealed that the dichlorophenyl D ring of 4 projects from the 
pyrazoloquinazolinone core such that it is offset from the D ring of the ciliobrevin 
(Figure 2.3A). We reasoned that adding a single carbon atom between the 
pyrazoloquinazolinone and the phenyl ring may lead to closer alignment with ciliobrevin 
and that using a cyclopropyl spacer would restrict rotation of the resulting scaffold. Using 
our modular synthesis strategy for pyrazoloquinazolinones, we generated a set of 
ciliobrevin derivatives with this cyclopropyl group separating the aromatic ring systems 
(5 - 8, Figure 2.3B). Three of these compounds had substitutions at the 6-position of the 
quinazolinone (6, 7, and 8, Figure 2.3B), a modification that we have previously reported 
to improve the potencies of ciliobrevins(46). The crystal structure of 5 confirms that its D 
ring aligns with that of compound 1 better than the chlorophenyl ring of compound 4 
(Figure 2.3C, 2.3D). 
We tested whether compounds 5 - 8 (20µM) inhibited dynein 2-dependent 
microtubule gliding (Figure 2.3E, 2.3F). Compound 5 reduced velocity to 58 ± 14 nm/s, 
while addition of a trifluoromethyl group at the 6 position of the “A” ring in compound 6 
led to near-complete inhibition of gliding (6 ± 2 nm/s). By contrast, compound 7, with a 
methoxy group at the 6-position of the A ring, did not inhibit dynein 2-driven 
microtubule gliding (128 ± 21 nm/s, Figure 2.3E, 2.3F). Compound 8, with a 6-iodo 
substituent at the A ring, showed comparable activity to 6 (average gliding velocity: 6 ± 2 
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nm/s). For the two most active compounds (6, 8) as well as ciliobrevin D, we performed 
dose-dependent analyses.  We found 6- to 8-fold increases in potencies of compounds 6 
(IC50: 2.9 ± 0.6µM) and 8 (IC50: 2.6 ± 1.3 µM) relative to ciliobrevin D (IC50 of 20 ± 1.0 
µM) in this assay (Figure 3G, H). To our knowledge, 8 is the most potent inhibitor of 
dynein 2 published to date. Hereafter, we designate compound 8 as dynapyrazole-A and 
compound 6 as dynapyrazole-B. 
In order to directly test the effect of replacing the benzoylacrylonitrile-
quinazolinone system by a pyrazoloquinazolinone we also synthesized uncyclized 
congeners of dynapyrazoles. Due to poor solubility of a 6-iodo-substituted ciliobrevin 
derivative it was not possible to test its activity and compare it with that of compound 8. 
Comparisons between compound dynapyrazole-B (6) and 9, a 6-CF3-substituted 
ciliobrevin derivative (Figure 3H), show that cyclization leads to ~6-fold improvement in 
the potency of dynein 2 inhibition in the microtubule gliding assay. 
We next examined the inhibition of dynein 2 by dynapyrazole-A in cell-based 
assays. In cell culture, serum starvation results in the formation of primary cilia, which 
are required for Hedgehog signaling(32). Quiescent cells respond to the Hedgehog ligand 
or to an agonist and pathway activity can be measured using a Gli-driven luciferase 
reporter(45, 94). Expression of Hedgehog-driven luciferase reporter was inhibited by 
dynapyrazole-A (IC50: 1.9 ± 0.6 µM) ~8-fold more potently than ciliobrevin D (IC50: 15.5 
± 3 µM, Figure 3I). Cell death was observed at concentrations 10-fold above the IC50 for 
dynapyrazole-A (20µM) over the 28-hour time course of this experiment. In this assay 
we have also observed cell death at high ciliobrevin D concentrations (200µM, ~10x 
above its IC50).  To stimulate Hedgehog pathway activity we used the synthetic agonist of 
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smoothened (SAG)(45), which competes with many known Hedgehog pathway inhibitors 
for binding to Smoothened, a key protein in this signaling pathway(39). As dynapyrazole-
A inhibits Hedgehog signaling at high SAG concentrations (500 nM), it is likely to act 
downstream of Smoothened, as was previously noted for the ciliobrevins and consistent 
with inhibition of dynein 2(44, 46). 
The Hedgehog signaling pathway depends on dynein 2-driven retrograde 
intraflagellar transport in the primary cilium(95). We used time-lapse microscopy to 
examine the dynamics of fluorescently labeled intraflagellar transport protein-88 
(mNeonGreen-IFT88, Figure 2.4A; all experimental analysis of intraflagellar transport 
was performed by C. Santarossa, graduate student in the Kapoor Laboratory), an 
approach we have previously used to study the effect of ciliobrevins and derivatives(47, 
54). Time-lapse recordings of cells treated with control media revealed a steady flow of 
IFT88 punctae moving from cilium tip to base and vice versa, as expected. The wider end 
of the cilium was identified as its base, a convention suggested previously by others(96). 
We find that in cilia treated with dynapyrazole-A (5µM), retrograde-directed IFT88 
punctae were markedly slowed. In contrast, anterograde motion did not appear to be 
substantially altered in the presence of dynapyrazole-A. 
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Figure 2.4 Analysis of the effect of dynapyrazole-A (8) on intraflagellar 
transport. Note: all work in this figure was performed by C. Santarossa 
(graduate student in Kapoor Laboratory). (A) Schematic of cilium showing 
microtubule-based axoneme (blue) and dynein (black), and an intraflagellar 
transport particle (purple) containing mNeonGreen-IFT88 (green). Anterograde 
and retrograde transport directions are indicated. (B-C) Images from time-lapse 
series and associated kymographs showing motion of mNeonGreen-IFT88-
containing particles in primary cilia of living murine kidney cells (IMCD3). 
Cilium tip (red arrowhead) and base (black arrowhead) are indicated. Red 
(retrograde) and blue (anterograde) traces have been added to one kymograph 
per condition to illustrate particle tracks. Image scale bar, 3µm; Kymograph 
horizontal scale bar, 10 seconds; kymograph vertical scale bar, 3µm. (D-E) 
Velocity distribution histograms showing anterograde and retrograde velocities 
in the solvent control (0.3% DMSO, D) and in the presence of 5µM 8 (E) at five 
minutes after initiation of experiment. Analyses of cells treated with 5µM 8 for 
10 minutes are shown in Figure 4 Figure Supplement 1. Analyses of cells treated 
with 10µM 8 are shown in Figure 4, Figure Supplement 2. (F-G).  Intraflagellar 
transport velocities (F) and frequencies (G) after washout of dynapyrazole-A. 
Bars represent mean + S.D. Data analysis (Va, anterograde velocity, nm/s; Vr, 
retrograde velocity, nm/s; Fa, anterograde frequency, counts/minute; Fr, 
retrograde frequency, counts/minute; values are mean ± S.D. Na, number of 
anterograde particles analyzed; Nr, number of retrograde particles analyzed; C, 
number of cilia analyzed). DMSO, Va 694 ± 117, Vr 421 ± 156, Fa, 11.3 ± 3, Fr 
6.5 ± 4, Na 429, Nr 244, C 38; 5µM 8, Va 566 ± 116, Vr 156 ± 107, Fa, 8.5 ± 5, Fr 
4.1 ± 3, Na 443, Nr 211, C 52; Washout, Va 697 ± 149, Vr 467 ± 136, Fa, 14.2 ± 6, 
Fr 9.6 ± 7, Na 256, Nr 173, C 18. 	
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To quantitatively assess the effect of dynapyrazole-A treatment on intraflagellar 
transport, we analyzed time-lapse images of cilia using KymographDirect, an automated 
analysis algorithm that extracts particle velocities from kymographs(97). Previous 
analyses of the effect of dynein 2 inhibition using a temperature-sensitive mutant in 
chlamydomonas revealed that dynein 2 depletion causes a ~60-70% reduction in 
retrograde velocities and a ~20% reduction in anterograde velocities as well as 30-60% 
reductions in the frequency of particle transport(98). Under control conditions (0.3% 
DMSO, Figure 2.4B), anterograde particles moved with a speed of 694 ± 117 nm/s 
(Figure 2.4D, mean ± S.D., 429 particles, 38 cilia) and retrograde particles moved at 421 
± 156 nm/s (Figure 2.4D, 244 particles, 38 cilia), consistent with previous studies (54). 
Following addition of dynapyrazole-A to cells, the speed of retrograde particles was 
markedly reduced at five minutes, the fastest reliable time line for this experiment on our 
microscopy set-up (Figure 2.4C, 2.4E; 5µM 8: mean velocity 156 ± 107 nm/s, 211 
particles, 52 cilia). In contrast, anterograde particle velocities were only reduced by ~18% 
(Figure 2.4C and 2.4E, 5µM 8: 566 ± 116 nm/s, 443 particles, 52 cilia). After 10 minutes 
of treatment, reductions in velocities were similar to those at the 5 minute time point 
(Figure 2.4 Figure Supplement 1).  Treatment of cilia with a higher dynapyrazole-A 
concentration (10µM) slowed both retrograde- and anterograde-directed motion. Again, 
retrograde motion was more strongly inhibited (Figure 2.4 Figure Supplement 2). 
Dynapyrazole-A treatment (5µM and 10µM) also reduced the frequency, i.e. the number 
of particles moving across a cilium per minute, in both anterograde and retrograde 
directions (Figure 2.4G, Figure 2.4 Figure Supplement 2). We note that dynapyrazole-A, 
at concentrations close to the IC50 for inhibiting microtubule gliding in vitro, alters 
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intraflagellar transport in a manner similar to what has been observed following dynein 2 
loss-of-function in chlamydomonas(98). 
We next examined whether inhibition of intraflagellar transport by dynapyrazole-
A was reversed following washout of the compound. Ciliated cells treated with 
dynapyrazole-A (5µM, 5 minutes) were transferred to solvent-control media with serum 
(0.3% DMSO, 10% FBS) and incubated for an additional ten minutes. Both retrograde 
and anterograde velocities recovered to control levels (Figure 2.4F, retrograde: 467 ±136 
nm/s, 173 particles, 18 cilia; anterograde: 697 ± 149 nm/s, 256 particles, 18 cilia) as did 
transport frequencies (Figure 2.4G). When media with a lower serum concentration was 
used in washout experiments, retrograde velocities recovered only partially, suggesting 
that serum may accelerate the partitioning of this compound out of cells (Figure 2.4 
Figure Supplement 3). Taken together, our data suggest dynapyrazole-A is a useful 
reversible probe to study intraflagellar transport. 
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Figure 2.5. Inhibition of dynein 1 activity by dynapyrazole-A (8). Note: the 
work showin in E-O was performed by others. Lysosome motility analysis was 
performed by A. Serpinskaya and V. Gelfand (Northwestern University, Chicago, 
IL). (A) Gel filtration trace (Superose 6) for GFP-dynein 1, with volume at 
elution peak indicated. V
o
, void volume. (B) SDS-PAGE analysis (coomassie
blue stain) of GFP-dynein 1, ~0.5 µg protein loaded. (C) Montages of 
fluorescent microtubules moving on GFP-dynein 1-coated glass slides in the 
presence of 1mM ATP and either DMSO, ciliobrevin D or 8 (10µM). The 
interval between successive images is 2 seconds and total time elapsed is 20s. 
Horizontal scale bar, 5 µm. (D) Inhibition of GFP-dynein 1-driven motility by 8 
and ciliobrevin D (mean ± S.D., n = 3). IC
50
 values for 8: 2.3 ± 1.4 µM (n = 3);
ciliobrevin D: 15 ± 2.9 µM (n = 3). Number of microtubules quantified: 8: 
20µM-98, 10µM-105, 5µM-108, 2.5µM-97, 1.3µM-134, 0.6µM-99, 0.3µM-43, 
0.2µM-29; ciliobrevin D: 40µM-64, 20µM-74, 10µM-82, 5µM-79, 2.5µM-81, 
1.3µM-87. IC50 values reported reflect the mean (± S.D.) of separate IC50 values 
obtained from independent dose-response analyses. Data were fit to a sigmoidal 
dose-response curve and constrained such that the value at saturating compound 
> 0. All motility assays were performed at 1mM MgATP, 0.05 mg/mL casein, 
and 2% DMSO. Velocity distribution histograms for inhibition of dynein-1 
driven microtubule motility are presented in Figure 5 Figure Supplement 1. 
Analysis of microtubule attachment to dynein-coated coverslips is presented in 
Figure 5 Figure Supplement 2. (E - J) Images of CAD cell neurites stained with 
Lysotracker Red. in the presence of DMSO control (0.1%), 3.5 µM and 5 µM 
(8). Scale bar, 10µm. (E - G) Phase contrast microscopy images of CAD cells. 
(H-J) Overlay of successive images of lysosome motility in CAD cell neurites. 
60 images, spaced 1s apart, are stacked and successive images colored using FIJI 
according to the temporal color code shown. (K-M) Kymographs corresponding 
to images in H-J. The kymograph size is 60 seconds (vertical) by 37 µm 
(horizontal) and the anterograde and retrograde orientations are indicated. (N) 
Quantitation of lysosome velocity. (O) Quantitation of total lysosome 
displacement over the time course of imaging (1 min). Data are mean of n ≥ 2 
experiments with ≥150 particles counted per experiment. Number of frame-to-
frame velocities measured: DMSO-anterograde: 14167, DMSO-retrograde: 
14973, 3.5µM 8-anterograde: 11283, 3.5µM 8-retrograde: 11340, 5µM 8-
anterograde: 9449, 5µM 8-retrograde: 10458. For O, number of particles 
counted: DMSO-3770, 5µM 8-2400, 3.5µM 8-840. Error bars: S.D. (DMSO, 5 
µM 8), or range of values (3.5 µM 8).  
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We predicted that dynapyrazole-A, like ciliobrevin D, should also inhibit 
cytoplasmic dynein 1(47). To examine the inhibition of dynein 1 by dynapyrazole-A in 
vitro we generated recombinant human protein. We expressed and purified a GFP-tagged 
human dynein 1 (AA 1320-4646) construct similar to the one we used for GFP dynein 2. 
This protein migrated with a peak volume of 12.6 mL in size exclusion chromatography 
and SDS-PAGE analysis showed > 90% purity (Figure 2.5A, B). GFP-dynein 1 moves 
microtubules at 508 ± 60 nm/s (n = 5 independent experiments, 191 microtubules 
analyzed), a velocity expected based on studies of other mammalian dynein 1 homologs 
(99). Under these conditions ~97% of the filaments analyzed had velocities >50nm/s 
(Figure 2.5 Figure Supplement 1). Time-lapse montages showed that both ciliobrevin D 
and dynapyrazole-A slowed dynein-dependent microtubule gliding (Figure 2.5C). Dose-
dependent analysis indicated that dynapyrazole-A blocked GFP-dynein 1-driven motility 
with an IC50 of 2.3 ± 1.4 µM, ~6-fold more potently than ciliobrevin D (15 ± 2.9 µM, 
Figure 2.5D). Inhibition of dynein 1-dependent microtubule gliding by dynapyrazole-A 
was reversed following washout, as is also the case for dynein 2-dependent motility 
(Figure 2.5 Figure Supplement 3). As has been previously noted for ciliobrevin D, the 
potency of dynapyrazole-A was sensitive to the protein (e.g. blocking agent, serum) 
concentration in solution (Figure 2.5, Figure Supplement 4), likely due to the 
hydrophobicity of these compounds (calculated logarithm of octanol:water partition 
coefficient [ClogP]: ciliobrevin D: 4.5; dynapyrazole-A: 4.2)(46). We therefore focused 
our cell-based analyses of dynapyrazole-A on dynein 1-dependent processes in assays 
that do not require high serum concentrations. 
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Lysosome transport can be observed in the neurites of CAD cells, a murine cell 
line that displays neuron-like properties in serum-free cell culture media (Figure 2.5 E-M; 
all lysosome motion experiments were performed by A. Serpinskaya and V. Gelfand, 
Northwestern University)(100). This bidirectional transport of lysosomes requires 
kinesins and dynein 1 and can be observed by imaging live cells stained with the 
LysoTracker dye (1, 101). A coupling between anterograde and retrograde motion has 
been described for membrane-bound organelles, with disruption of dynein-driven motion 
blocking bi-directional organelle motility(102). We imaged control solvent (0.1%DMSO) 
treated cells and observed bidirectional motion of LysoTracker-labelled puncta (Figure 
2.5E, H, K). Overlays of successive images from a time-lapse series, color-coded for 
displacement, reveal organelle displacements (Figure 2.5 H - J). Quantitative analysis 
using kymographs shows that ~20% of particles move at speeds below 25 nm/s in both 
anterograde and retrograde directions under control conditions and a similar fraction of 
particles have velocities above 250 nm/s (Figure 2.5K, 2.5N). Treatment with 
dynapyrazole-A suppressed bidirectional motion. In particular, the percentage of 
retrograde-directed lysosomes moving slower than 25 nm/s increased to ~47% (3.5µM) 
and ~59% (5µM) and lowered the proportion of lysosomes moving at speeds > 250 nm/s 
to below 10%. We observed equivalent effects of dynapyrazole-A on anterograde motion 
(kymographs in 5K, L, M) velocities. In control cells, lysosomes with measureable 
displacements had trajectories that averaged 32 ± 11 µm (Figure 2.5O)(100). 
Dynapyrazole-A (3.5 µM, Figure 5I, 5L) reduced the average track length of moving 
particles to 15.7 ± 4.7 µm, which can be seen as white punctae that result from the 
overlay of multiple color-coded frames without particle translocation (Figure 2.5J, 2.5M). 
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A higher dose of dynapyrazole-A (5 µM) shortened the average track length of moving 
particles to 6.7 ± 2.7 µm.  We found that ATP levels in cells treated with dynapyrazole-A 
at concentrations that inhibited lysosome transport (5µM) were stable for up to 3 hours 
(Figure 2.5 Figure Supplement 5). Higher concentrations of dynapyrazole-A (15µM) 
lowered intracellular ATP levels by ~70% at 3 hrs (Figure 2.5 Figure Supplement 5). 
Together, these data suggest that at concentrations near its in vitro IC50, dynapyrazole-A 
suppresses lysosome transport in cells via inhibition of dynein 1. 
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Figure 2.6. Analysis of the mechanism of dynein inhibition by dynapyrazole-
A (8) (A) Basal ATPase activity of GFP-dynein in the solvent control (2% 
DMSO, n = 8) and in the presence of 8 (40µM, n = 4) and ciliobrevin D (40µM, 
n = 4). (B) SDS-PAGE analysis (coomassie blue stain) of His-dynein 1, ~0.5 µg 
protein loaded. Mass spectrometry showed that the impurity (~15%, triangles) is 
a fragment of dynein (Figure 6 Figure Supplement 1) (C) Basal ATPase activity 
of His-dynein in the solvent control (2% DMSO, n = 11) and in the presence of 8 
(40µM, n = 11) and ciliobrevin D (40µM, n = 5). (D) Microtubule-stimulated 
ATPase activity of His-dynein across a range of microtubule concentrations in 
the solvent control (2% DMSO) or in the presence of 30µM 8 (2.5 µM 
microtubules, n = 5; 8µM microtubules, n = 4; 8µM microtubules, 30µM 8, n = 
3; 15µM microtubules, 2% DMSO, n = 4; 15µM microtubules, 30µM 8, n = 3) 
(E) Dose-dependent inhibition of microtubule-stimulated His-dynein 1 ATPase 
activity by 8 (2.5 µM microtubules, IC
50
: 6.2 ± 1.6 µM, n = 3). (F) SDS-PAGE
analysis (coomassie blue stain) of dynein following irradiation with ultraviolet 
light at 365 nm. The components included in the photocleavage reaction loaded 
into each lane are indicated above the lane. Arrowheads indicate dynein 
photocleavage products. (G) Analysis of gel band intensity for photocleavage 
reactions. (H) Gel filtration traces (Superose 6) for His-dynein 1 wild-type and 
AAA3 Walker A mutant. Peak elution volumes are 12.2, and 12.4 mL, 
respectively. V
o
, void volume. (I) SDS-PAGE analysis (Coomassie blue stain) of
Walker A mutant His-dynein 1 protein, ~0.5 µg protein loaded. Mass 
spectrometry data confirming the presence of the K2601A mutation in this 
construct is shown in Figure 6 Supplement 5. (J) Basal and microtubule-
stimulated ATPase activity of the AAA3 Walker A-mutant His-dynein 1 in the 
solvent control (2% DMSO) and in the presence of 8 (30µM). (K) Inhibition of 
the basal ATPase activity of the AAA3 Walker A-mutant His-dynein 1 by 8 
(IC
50
: 5.5 ± 1.6 µM, n = 5) and ciliobrevin D (IC
50
: 38.4 ± 6.3 µM, n = 3). IC50 
values reported reflect the mean (±S.D.) of separate IC50 values obtained from 
independent dose-response analyses. For (E) and (K), data were fit to a four-
parameter sigmoidal dose-response curve in PRISM and constrained such the 
value at saturating compound > 0. All ATPase assays were performed at 1mM 
MgATP and 2% DMSO. All data presented are mean ± S.D. of n ≥ 3 data points, 
except in K, where replicate numbers for individual datapoints were as follows. 
8: 80µM-2, 40µM-5, 20µM-5, 10µM-5, 5µM-5, 2.5µM-5, 1.3µM-5, 0.6µM-2. 
Ciliobrevin D: 80µM-2, 40µM-3, 20µM-3, 10µM-3, 5µM-3, 2.5µM-3. 
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Dynein 1, whose biochemical activity has been extensively characterized, serves 
as a model for the mechano-chemistry of this motor protein family. Therefore, to dissect 
the mechanism of inhibition of dynein by dynapyrazole-A, we focused on this isoform. 
The basal ATPase activity of GFP-dynein was 0.62 ± 0.2 s-1 (Figure 2.6A, n = 8 
independent experiments, mean ± S.D.).  We also purified an N-terminally polyhistidine 
(His)-tagged dynein motor domain construct (AA 1320 - 4646) that was routinely 
obtained in five-fold higher yield than the GFP-tagged construct (Figure 2.6B). 
Following a three-step purification protocol, we obtained this protein with >80% purity. 
The specific activity of His-dynein 1 (0.66 ± 0.1 s-1, mean ± S.D. Figure 2.6C) was 
similar to that of GFP-dynein. The basal ATPase rates of these human dynein constructs 
were within the range observed by others for mammalian dyneins(103-105). We 
examined the inhibition of dynein 1’s ATPase activity by dynapyrazole-A. Remarkably, a 
high concentration of dynapyrazole-A (40µM) did not inhibit the basal ATPase activity 
of GFP-dynein 1 (Figure 6A) and weakly inhibited His-dynein 1 (~30% inhibition Figure 
2.6C). Under similar conditions, ciliobrevin D (40 µM) inhibited the ATPase activity of 
both GFP-dynein 1 and His-dynein 1 by ~70% (Figure 2.6A, 2.6C). The rather modest 
inhibition of dynein's ATPase activity by dynapyrazole-A was unexpected, as 
dynapyrazole-A can inhibit microtubule gliding at a 20-fold lower concentration. 
We next examined if dynapyrazole-A inhibits dynein 1’s microtubule-stimulated 
ATPase activity. We find that human dynein’s ATP hydrolysis rate is stimulated in a 
microtubule concentration-dependent manner (Figure 2.6D, 2.5 µM: 1.2 ± 0.05 s-1, n = 3; 
8µM: 1.5 ± 0.3 s-1, n = 4; 15µM: 2.2 ± 0.5 s-1, n = 4). At high microtubule concentrations 
dynapyrazole-A (30µM) inhibited the microtubule-stimulated ATPase activity to a 
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residual rate of ~0.5 s-1 (8 or 15 µM microtubules, Figure 2.6D). Dose-dependent analysis 
was carried out at a microtubule concentration (2.5µM) that gave two-fold stimulation of 
dynein. At increasing concentrations of dynapyrazole-A dynein’s microtubule-stimulated 
ATPase activity saturated at ~0.5s-1, despite the expected nearly complete occupancy of 
dynein molecules with dynapyrazole A at the enzyme concentrations used (Assuming Ki 
values in the ~2-5 µM range and with protein concentrations of <0.1 µM, occupancy of 
dynein should be 88-95% at 40 µM; Figure 2.6E). Fitting to this non-zero plateau value 
gave an IC50 of dynapyrazole-A of 6.2 ± 1.6 µM. In comparison, dose-dependent 
inhibition of dynein 1’s microtubule-stimulated ATPase activity by ciliobrevin D did not 
reveal a plateau up to the highest concentrations the compound remained soluble in these 
assay conditions (Figure 6 Figure Supplement 2). 
To better understand how dynapyrazole-A inhibits dynein activity, we monitored 
its effect on ADP-vanadate dependent photocleavage of dynein. In this assay, an 
established read-out of nucleotide binding at dynein's AAA1 site(19, 20), ultraviolet 
irradiation leads to ADP-vanadate-dependent photocleavage of dynein at the AAA1 site, 
resulting in two protein fragments(106). Using His-dynein 1, 100µM ATP, and 100µM 
vanadate, we consistently observed ~40% photocleavage of His-dynein 1 (Figure 2.6F, 
2.6G) and fragments consistent with cleavage at AAA1, as expected(19, 20). At a 
dynapyrazole-A concentration near its IC50 for in vitro dynein inhibition (4µM), ADP-
vanadate dependent photocleavage of dynein was reduced ~2.5 fold relative to controls 
(~17% photocleavage). These data are consistent with dynapyrazole-A binding at the 
AAA1 site.
54 
To further dissect how dynein is inhibited by dynapyrazole we expressed and 
purified a construct with a Walker A lysine-to-alanine substitution at AAA3 (K2601A), a 
mutation that disrupts nucleotide binding at AAA3(20, 107). We found that the mutant 
protein eluted during size exclusion chromatography with a major peak at a similar 
elution volume to that for the wild-type construct (12.4 mL for the mutant, 12.2 mL for 
wild-type, Figure 2.6H, I), suggesting that the mutations do not disrupt overall protein 
folding. We also purified a comparable AAA1 (K1912A) mutant, but this protein had 
~80-90% reduced ATPase activity, making analysis of its ATPase activity difficult 
(Figure 2.6 Figure Supplement 3). We found that the AAA3 mutant had basal activity 
that was elevated relative to wild-type (1.1 ± 0.2 s-1, n = 5), as has been previously shown 
for yeast dynein with a similar mutation(89). The ATPase activity of this mutant was 
stimulated by microtubules to 1.5s-1 (3µM microtubules) and 1.7 s-1 (11.5µM 
microtubules) (Figure 2.6J).  The reduced microtubule stimulation of the ATPase activity 
is consistent with findings for comparable dynein constructs from other organisms(20, 
89). 
Across the range of microtubule concentrations tested, dynapyrazole-A reduced 
the AAA3 mutant dynein’s ATPase activity by 70-80% (Figure 6J). Surprisingly, unlike 
what we observed for the wildtype protein, strong inhibition of the basal activity of this 
mutant construct was also observed (~ 70% inhibition; 30µM dynapyrazole-A). A dose-
dependent analysis showed that dynapyrazole-A inhibits the basal activity of the AAA3 
mutant with an IC50 of 5.5 ± 1.6µM while ciliobrevin D has an IC50 of 38 ± 6 µM (Figure 
2.6K). Even in the context of the AAA3 mutant enzyme, a residual ATPase activity of 
~0.2s-1 was observed at the highest dynapyrazole-A concentrations tested (Figure 2.6K). 
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It is noteworthy that dynapyrazole-A inhibits basal activity of the AAA3 mutant and the 
microtubule-stimulated ATPase activity of the wild-type enzyme with similar potency, 
suggesting that a common ATPase site, likely AAA1, might be inhibited in both contexts. 
2.3 Discussion 
In this study, we analyzed the structure of the ciliobrevins and designed tricyclic 
derivatives in which the benzoylacrylonitrile of ciliobrevin was replaced with a 
cyanopyrazole. These compounds inhibited dynein in vitro and in cells more potently 
than ciliobrevins and have improved chemical properties. We also find that 
dynapyrazole-A inhibits dynein by a mechanism that is distinct from that of ciliobrevins. 
We find that the pyrazoloquinazolinone scaffold of the dynapyrazoles addresses 
many of the limitations of the ciliobrevins. First, activated acrylonitriles, such as the 
benzoylacrylonitrile at the core of the ciliobrevin scaffold, have been shown to be 
susceptible to attack by intracellular nucleophiles, raising the possibility of unwanted 
reactivity of these dynein inhibitors(108). While ciliobrevins have been observed to be 
unstable under standard laboratory storage conditions, the pyrazoloquinazolinone of the 
dynapyrazoles is unlikely to be reactive or unstable but retains many of the electrostatic 
and steric elements present in ciliobrevin(61). Second, the potency of dynapyrazole-A is 
similar across in vitro and cell-based assays, consistent with dynein being its cellular 
target. This was not consistently observed for ciliobrevin analogs. Dynapyrazole-A and -
B inhibited dynein-dependent microtubule gliding six- to eight-fold more potently than 
ciliobrevins, however different mechanisms of inhibition make it difficult to relate this 
change in potency directly to an increased binding affinity. Third, the ciliobrevin scaffold 
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is present in chemical screening libraries and a close derivative has annotated anti-
malarial activity(109). In contrast, to our knowledge, the 2-aryl-substituted cyano-
pyrazoloquinazolinone structure of 4 has not previously been reported in a bioactive 
compound. The hydrophobicity of the dynapyrazoles remains a limitation that needs to be 
addressed. We note that the high ClogP value of dynapyrazole-A, which is similar to that 
of ciliobrevins, may explain why this compound, like ciliobrevin D, has reduced activity 
in the presence of high protein concentrations (eg. serum). Likewise, acute reversal of 
intraflagellar transport inhibition was most effective using cell culture medium with 
serum. We believe that the dynapyrazole scaffold will be valuable for further 
optimization of these chemical probes. 
In current models, the motion of membrane-bound organelles requires a balance 
of motors moving toward microtubule plus- and minus-ends (102). Studies across several 
cell types of different organelles have established that depletion or inhibition of dynein 
reduces bidirectional organelle motion(110-112). Remarkably, organelle motion 
following dynein depletion can be restored by add-back of a minus-end directed kinesin, 
suggesting that micromechanical coupling is involved and an opposing force is needed to 
activate directional motion of the motor proteins needed for the directional motion of 
these cellular cargoes (102, 113). These observations provide a plausible explanation for 
the bi-directional inhibition of lysosome motility upon dynapyrazole-A treatment. 
Although the individual cargos in the cilium are not likely membrane-bound, this 
intracellular transport is no less complex than organelle movement in the cytoplasm(114). 
We believe that dynapyrazole-A will be a useful tool to dissect how the length and shape 
57 
of the cilium is linked to directional transport and to tease apart the contributions of 
active transport and passive diffusion of proteins to Hedgehog signaling. 
Dynapyrazole-A blocks both dynein 1 and dynein 2. As dynein 1 plays a critical 
role in numerous cellular processes, its persistent inhibition is expected to be toxic to 
cells (Figure 2.6 Figure Supplement 5). However, acute inhibition may be useful in 
deciphering dynein function in different contexts. Can dynapyrazoles be chemically 
modified to develop inhibitors that are selective for dynein 1 or 2? Previously, we found 
that modest selectivity for inhibition of dynein 2 relative to dynein 1 can be achieved 
under certain conditions ([ATP] < 1 µM) by appending tolyl ethers at the 7-position of 
the ciliobrevin quinazolinone(47). However, inhibition of dynein's ATPase activity by 
these ciliobrevin analogs is suppressed at higher ATP concentrations (e.g. 100µM) in 
vitro. Studies of mammalian dynein 1 indicate that there are two ATP-binding sites with 
Km values separated by two orders of magnitude (~2 µM and ~600 µM(115)). It is 
possible that the observed selectivity is achieved by targeting the high-affinity ATPase 
site and therefore, at higher, close to physiologic ATP concentrations, the inhibition by 
these ciliobrevin analogs would be suppressed. In contrast, dynapyrazoles inhibit dynein 
at high ATP concentrations (1 mM), consistent with a different mode of inhibition. Also, 
substitution of this compound with a methyl ether at the 6-position abrogated dynein 
inhibition. These data suggest that the selectivity gains observed from appending tolyl 
ethers to the ciliobrevin scaffold are unlikely to be applicable to dynapyrazole and 
developing a dynein isoform-selective dynapyrazole derivative will require more 
extensive structure-activity relationship studies. 
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Of the six AAA sites in dynein, only mutations at AAA1 and AAA3 have been 
found to block motility(116). In current models, ATPase activity at AAA1 is linked to 
rigid-body movements of subdomains during individual steps of the motor protein along 
microtubule tracks, while nucleotide state at AAA3 modulates the activity at AAA1 (8). 
Three lines of evidence indicate that dynapyrazole-A targets the AAA1 site. First, 
dynapyrazole-A blocks ADP-vanadate dependent photocleavage at site 1. Second, 
dynapyrazole-A inhibits the activity of a dynein 1 construct with a mutation in the AAA3 
domain (Walker A lysine). In this construct, the ATPase activity is expected to be mainly 
due to the AAA1 site. Third, sequence comparisons indicate that the AAA1 sites in 
dynein 1 and 2 are highly conserved, while the other AAA sites are less conserved. In 
fact, the residues within 4Å of the bound nucleotide in AAA1 are identical between 
dynein 1 and 2 (Figure 6 Figure Supplement 5). This sequence similarity and our 
observation that dynapyrazole-A inhibits dynein 1 and 2 with comparable potency are 
consistent with a model in which this compound selectively inhibits hydrolysis of 
dynein’s AAA1 site. However, further biophysical and structural studies will be required 
to determine whether dynapyrazole-A binds at or near the AAA1 site. 
Our finding that dynapyrazole-A does not substantially inhibit ATP hydrolysis in 
the absence of microtubules suggests that, for dynein 1, the AAA1 site contributes to only 
a small fraction of this enzyme’s basal activity. We posit that a separate site, likely 
AAA3, accounts for the majority of dynein’s ATPase activity in the absence of 
microtubule. This site likely remains active even when ATPase activity at AAA1 is 
inhibited by dynapyrazoles. Currently, we cannot exclude the possibility that additional 
ATPase sites, such as AAA4, may also contribute partially to the basal ATPase activity 
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of dynein. The nucleotide state at AAA3 is known to regulate the ATPase cycle of AAA1 
when microtubules are present, with the apo- and ATP-bound states of AAA3 slowing 
overall hydrolysis and the ADP-bound state of AAA3 leading to rapid hydrolysis at 
AAA1 in wild-type dynein(88, 89). Our finding that the AAA3 mutant has elevated basal 
activity relative to the wild-type is consistent with the protein being in a state that mimics 
one in which hydrolysis at AAA1 is activated. While additional biophysical studies are 
needed to analyze this further, dynapyrazole-A is likely to be useful as tool for chemical 
“separation of function" to distinguish between dynein’s microtubule stimulated and 
basal activities in different contexts. 
While restricting conformational flexibility of ligands is a well-established 
strategy for improving potency, its successful application typically depends on structural 
data that reveal the compound conformation required for activity(117). In the case of the 
ciliobrevins the geometric constraints we designed were guided by conformational 
analysis of the compounds alone and afforded ~6-8-fold improvement in potency. We 
note that replacement of a scaffold prone to isomerization with a fixed tricyclic 
pyrazoloquinazolinone did not lead directly to improved potency. Rather, incorporation 
of a cyclopropyl group into the dynapyrazole scaffold was required, likely by better 
matching the shape of the ciliobrevin pharmacophore. Our unexpected finding that 
conformational restriction led to changes both in potency and mechanism of inhibition 
raises the question of whether alternative scaffolds with different conformational 
constrains could reveal still other modes of dynein inhibition. More broadly, 
conformational restriction may be an effective strategy for improving the few AAA+ 
inhibitors described to date. Compounds with distinct mechanisms of action, which may 
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result from these efforts, will be especially valuable for these multi-site enzymes whose 
activity is often regulated by intricate allosteric communication.
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2.4 Methods 
1. Chemical Synthesis: All chemical synthesis and structural characterization work was
performed by colleagues at the Tri-Institutional Therapeutics Discovery Institute (TDI) 
and at Takeda Pharmaceuticals, Japan. 
General chemical methods: Solvents and reagents were purchased from VWR or Sigma 
Aldrich. All reactions involving air- or moisture-sensitive compounds were performed 
under nitrogen atmosphere using dried glassware. 1H NMR spectra were recorded at 
500MHz on a Bruker Advance III HD 500 MHz NMR spectrometer equipped with a TCI 
cryogenic probe with enhanced 1H and 13C detection. Chemical shifts are reported in parts 
per million (ppm) and coupling constants (J) are expressed in hertz (Hz). All data were 
collected at 298K, and internally referenced for 1H to the residual chloroform signal at 
7.26 ppm; to DMSO signal at 2.50 ppm; or to TMS at 0 ppm. Flash chromatography 
purifications were performed on CombiFlash Rf (Teledyne ISCO) as the stationary phase. 
The LC-MS was performed on a Waters ACQUITY H-Class UPLC/MS with a PDA 
eLambda detector and QDa mass spectrometer. And the reactions under microwave 















To a mixture of (2E)-3-(2,4-dichlorophenyl)-2-(7-hydroxy-4-oxo-1H-quinazolin-2-
ylidene)-3-oxo-propanenitrile (82mg, 219µmol, synthesized as described 
previously)(47) and potassium carbonate (48.7mg, 351µmol) in dimethylformamide 
(10ml) was added 4-(2-chloroethyl)morpholine hydrochloride (37.13mg, 200µmol), and 
the resulting mixture was stirred at 80°C for 18h. The mixture was allowed to cool, and 
the filtrate was concentrated in vacuo. The residue was purified by column 
chromatography (ethyl acetate/methanol) to give (2E)-3-(2,4-dichlorophenyl)-2-[7-(2-
morpholinoethoxy)-4-oxo-1H-quinazolin-2-ylidene]-3-oxo-propanenitrile (50.20 mg, 
103.01 µmol, 52% yield). 1H NMR (500 MHz, DMSO-d6) δ 13.36 (s, 1H), 9.88 (s, 1H), 
7.95 (d, J = 8.8 Hz, 1H), 7.66 (d, J = 2.0 Hz, 1H), 7.50-7.41 (m, 2H), 7.05-6.95 (m, 1H), 
6.94-6.86 (m, 1H), 4.50 (s, 2H), 4.09-3.93 (m, 2H), 3.68 (d, J = 33.0 Hz, 2H), 3.57 (s, 
2H), 3.24 (s, 2H). LCMS m/z: 487.1 [M+H]+. 
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Supplemental Scheme 1: Synthesis of 2 based on literature precedent.(92)
2-[1-(2,4-dichlorophenyl)ethylidene]propanedinitrile 
To a solution of 1-(2,4-dichlorophenyl)ethanone (1.00 g, 5.29 mmol) in toluene (20 mL) - 
acetic acid (2 mL) were added malononitrile (349.45 mg, 5.29 mmol) and ammonium 
acetate (407mg, 5.29 mmol) at room temperature. The mixture was stirred at 100 °C for 
13 h. The mixture was neutralized with sat. NaHCO3 (aq). and extracted with ethyl 
















































filtered and concentrated in vacuo. The residue was purified by column chromatography 
(hexane/ethyl acetate) to give 2-[1-(2,4-dichlorophenyl)ethylidene]propanedinitrile (907 
mg, 3.83 mmol, 72% yield) as a colorless oil. 1H NMR (500 MHz, Chloroform-d) δ 7.57 
(s, 1H), 7.43 (d, J = 8.3 Hz, 1H), 7.19 (d, J = 8.3 Hz, 1H), 2.62 (s, 3H). LCMS m/z: 235.1 
[M-H]-. 
2-[2-bromo-1-(2,4-dichlorophenyl)ethylidene]propanedinitrile 
To a solution of 2-[1-(2,4-dichlorophenyl)ethylidene]propanedinitrile (310.50 mg, 1.31 
mmol) in carbon tetrachloride (4.00 mL) was added bromine (230 mg, 1.44 mmol) at 
room temperature. The mixture was stirred at room temperature for 15 min and at 70 °C 
for 8.5 h. The starting material remained, so bromine (620mg, 200µL, 3.88mmol) was 
added.  The mixture was stirred at 70 °C for 21 h.  The mixture was diluted with sat. 
NaS2O3 (aq). and extracted with dichloromethane. The combined organic layer was 
washed with sat. NaS2O3 (aq). and brine, dried over MgSO4, filtered and concentrated in 
vacuo. The residue was purified by column chromatography (hexane/ethyl acetate) to 
give 2-[2-bromo-1-(2,4-dichlorophenyl)ethylidene]propanedinitrile (157 mg, 497 µmol, 
38% yield) as a colorless oil. 1H NMR (500 MHz, Chloroform-d) δ7.59 (s, 1H), 7.47 





 2-(2,4-dichlorophenyl)-5-oxo-4H-pyrrolo[1,2-a]quinazoline-3-carbonitrile (2) 
To a solution of 2-[2-bromo-1-(2,4-dichlorophenyl)ethylidene]propanedinitrile (73.70 mg, 
233.24 µmol) in isopropyl alcohol (3.00 mL) was added methyl 2-aminobenzoate (70.51 
mg, 466.48 μmol) at room temperature. The mixture was stirred at 100 °C for 20 h. The 
mixture was concentrated. The residue was purified by column chromatography 
(hexane/ethyl acetate) to give 2-(2,4-dichlorophenyl)-5-oxo-4H-pyrrolo[1,2-
a]quinazoline-3-carbonitrile (12.4 mg, 35 µmol, 15% yield) as a colorless solid. 1H NMR
(500 MHz, Chloroform-d) δ 8.81 (s, 1H), 8.40 (d, J = 7.8 Hz, 1H), 7.84 (t, J = 7.8 
Hz, 1H), 7.66 (d, J = 8.3 Hz, 1H), 7.57 – 7.46 (m, 3H), 7.40 (s, 1H), 7.36 (d, J = 
8.2 Hz, 1H). LCMS m/z: 354.1 [M+H]+. 
2-(2,4-dichlorophenyl)-4H-pyrazolo[1,5-a]quinazolin-5-one (3) 
A mixture of 2-hydrazinobenzoic acid (43.32 mg, 284.7 µmol), 3-(2,4-dichlorophenyl)-3-
oxo-propanenitrile (41.20 mg, 192.48 µmol) and acetic acid (2.00 mL) was stirred at 
150°C under microwave irradiation for 30 min. The mixture was diluted with water and 















compound as a colorless solid (7.5 mg). The filtrate was extracted with ethyl acetate. The 
combined organic layer was washed with water and brine, dried over MgSO4, filtered 
and concentrated in vacuo. The solid was washed wth ethyl acetate to give the desired 
compound (9.4 mg). The combined solid was washed with hexane to give 2-(2,4-
dichlorophenyl)-4H-pyrazolo[1,5-a]quinazolin-5-one (16.4 mg, 49.7 µmol, 26% yield) as 
a colorless solid.1H NMR (500 MHz, DMSO-d6) δ 12.34 (s, 1H), 8.19 (dd, J = 11.4, 8.2 
Hz, 2H), 7.99 (d, J = 8.4 Hz, 1H), 7.94 (t, J = 7.7 Hz, 1H), 7.80 (s, 1H), 7.61 – 7.53 (m, 
2H), 6.42 (s, 1H). LCMS m/z: 329.9 [M+H]+. 
Supplemental Scheme 2: Synthesis of aminopyrazole precursor for 4 based on literature 
precedent for related compounds.(118) 
 
2-[(2,4-dichlorophenyl)-hydroxy-methylene]propanedinitrile 
To a stirred solution of propanedinitrile (4.71 g, 71.33 mmol) in THF (150.00 mL) were 
added sodium hydride (5.71 g, 142.66 mmol, 60% purity) at 0 °C. The mixture was 













































69.8 mmol, 10 mL) in THF (50 mL) was added to the mixture at 0 °C.  The mixture was 
stirred at room temperature for 4 h.  The mixture was diluted with 1N HCl (aq.) and 
extracted with ethyl acetate.  The combined organic layer was washed with water and 
brine, dried over MgSO4, filtered and concentrated in vacuo.  The residue was 
purified by column chromatography (ethyl acetate/hexanes) to give 2-[(2,4-
dichlorophenyl)-hydroxy-methylene]propanedinitrile (17.38 g, 72.70 mmol, 104% 
yield) as light yellow amorphous powder. This product was subject to the next reaction. 




A mixture of 2-[(2,4-dichlorophenyl)-hydroxy-methylene]propanedinitrile (17.38 g, 
72.70 mmol), dimethyl sulfate (18.34 g, 145.40 mmol, 13.79 mL)  and N-ethyl-N-
isopropyl-propan-2-amine (28.19 g, 218.10 mmol, 38.09 mL)  in dioxane (200 mL)  was 
stirred at 60 °C for 23 h. The reaction was cooled to room temperature and concentrated 
in vacuo. The residue was dissolved with ethyl acetate and quenched with water. The 
organic layer was separated, washed with brine, dried over MgSO4, filtered and 
concentrated in vacuo. The residue was purified by column chromatography 





methylene]propanedinitrile (3.19 g, 12.60 mmol, 17% yield)  as a brown solid. (Known 
compound, cas: 1188083-55-7). 1H NMR (500 MHz, Chloroform-d) δ 7.62 (d, J=1.9 
Hz, 1H), 7.49 (dd, J=8.3, 1.9 Hz, 1H), 7.34 (d, J=8.3 Hz, 1H), 3.85 (s, 3H). 
5-amino-3-(2,4-dichlorophenyl)-1H-pyrazole-4-carbonitrile 
The mixture of 2-[(2,4-dichlorophenyl)-methoxy-methylene]propanedinitrile (3.19 g, 
12.60 mmol) and hydrazine hydrate (694 mg, 13.86 mmol, 672 µL) in ethanol (50.00 
mL) was stirred at 80 °C for 4.5 h. Additional hydrazine hydrate (252.30 mg, 5.04 mmol, 
244.48 uL) was added to the mixture and it was stirred at 80 °C for 1.5 h. The reaction 
was concentrated in vacuo. The residue was washed with ethanol to give 5-amino-3-(2,4-
dichlorophenyl)-1H-pyrazole-4-carbonitrile (1.73 g, 6.84 mmol, 54% yield)  as an off-
white solid. 1H NMR: (500MHz, DMSO-d6) δ 12.31 (s, 1H), 7.76 (s, 1H), 7.58-7.41 (m, 
















A mixture of 5-amino-3-(2,4-dichlorophenyl)-1H-pyrazole-4-carbonitrile (100.00 mg, 
395.12 μmol), dipotassium carbonate (81.91 mg, 592.68 µmol) and methyl 2-
fluorobenzoate (73.08 mg, 474.14 µmol, 60.40 µL) in dimethylformamide (1.00 mL) was 
stirred at 140 °C  for 30 min. The mixture was poured into water, and extracted with ethyl 
acetate. The organic layer was washed with water and brine respectively, dried over 
MgSO4 and concentrated in vacuo. The residue was purified by silica-gel column 
chromatography (hexane/ethyl acetate) to give 2-(2,4-dichlorophenyl)-5-oxo-4H-
pyrazolo[1,5-a]quinazoline-3-carbonitrile (14.2 mg, 39.98 µmol, 10% yield)  as a white 
solid. 1H NMR: (500MHz, DMSO-d6) δ 8.09 (d, J=7.8Hz, 1H), 7.94 (d, J=8.2Hz 1H), 
7.83 (d, J=2.0Hz 1H), 7.73-7.56 (m, 3H), 7.40 (t, J=7.5Hz, 1H). LCMS m/z: 353.136 
[M-H]-.  
Supplemental Scheme 3: Synthesis of cyclopropyl-substituted aminopyrazole precursor 







































To a solution of 1-(4-chlorophenyl)cyclopropanecarboxylic acid (1, 10.00 g, 50.86 
mmol) in THF (100.00 mL) were added oxalyl chloride (7.75 g, 61 mmol, 5.33 
mL) and dimethylformamide (37.17 mg, 508.60 μmol, 39.54 uL). The mixture was 
stirred at room temperature for 0.5h. The mixture was concentrated in vacuo. The mixture 
was added to a solution of propanedinitrile (3.36 g, 50.86 mmol) and sodium hydride 
(4.07 g, 101.72 mmol, 60% purity) in THF (100 ml) at 0 °C. The mixture was stirred at 
room temperature for 1 h. The mixture was diluted with 1N HCl and extracted with ethyl 
acetate.  The combined organic layer was washed with water and brine, dried over 
Na2SO4, filtered and concentrated under reduced pressure.  The residue was 
purified by column chromatography (hexane/ethyl acetate) to give 2-((1-(4-
chlorophenyl)cyclopropyl)(hydroxy)methylene)malononitrile (12 g, 49 mmol, 96% 
yield) as a light yellow oil.  1H NMR (500 MHz, DMSO-d6) δ 7.36 – 7.30 (m, 2H), 7.22 







To a solution of 2-[1-(4-chlorophenyl)cyclopropanecarbonyl]propanedinitrile (2, 12.00 g, 
49.0 mmol) in dioxane (200 mL) and H2O (20 mL) were added dimethyl sulfate (18.56 g, 
147.1 mmol, 13.9 mL) and NaHCO3 (20.60 g, 245.20 mmol). The mixture was stirred 
at 100 °C for 5 hour. The mixture was poured into water, and extracted with ethyl acetate. 
The organic layer was washed with brine, dried over Na2SO4 and concentrated in vacuo. 
The residue was purified by column chromatography (hexane/ethyl acetate) to give 2-((1-
(4-chlorophenyl)cyclopropyl)(methoxy)methylene)malononitrile (3.38 g, 13.1 mmol, 
27% yield) as a yellow oil. 1H NMR (500 MHz, DMSO-d6) δ 7.55 – 7.45 (m, 2H), 7.33 – 
7.22 (m, 2H), 4.04 (s, 3H), 1.80 – 1.71 (m, 2H), 1.68 – 1.61 (m, 2H). LCMS m/z: not 
detected. 
5-Amino-3-[1-(4-chlorophenyl)cyclopropyl]-1H-pyrazole-4-carbonitrile 
To a solution of 2-[[1-(4-chlorophenyl)cyclopropyl]-methoxy-methylene]propanedinitrile 
(3, 3.38 g, 13.07 mmol) in ethanol (100.00 mL) was added hydrazine hydrate (981.43 mg, 
19.61 mmol). The mixture was stirred at 80 °C for 2 hour. The mixture was concentrated 
in vacuo. The residue was purified by column chromatography (hexane/ethyl acetate) to 









10.71 mmol, 82% yield) as a white powder.  1H NMR (500 MHz, DMSO-d6) δ 11.73 (s, 
1H), 7.35 (d, J = 8.0 Hz, 2H), 7.27 – 7.16 (m, 2H), 6.28 (s, 2H), 1.43 – 1.13 (m, 4H). 
LCMS m/z: 259 [M+H]+.   
2-[1-(4-chlorophenyl)cyclopropyl]-5-oxo-4H-pyrazolo[1,5-a]quinazoline-3-
carbonitrile (5) 
A mixture of 5-amino-3-[1-(4-chlorophenyl)cyclopropyl]-1H-pyrazole-4-carbonitrile 
(100.00 mg, 386.53 μmol), dipotassium carbonate (80.13 mg, 579.80 μmol) and methyl 
2-fluorobenzoate (71.50 mg, 463.84 μmol, 59.09 uL) in dimethylformamide (1.00 mL) 
was stirred at 140 °C  for 30 min. The mixture was poured into water, and extracted with 
ethyl acetate. The organic layer was washed with water and brine respectively, dried over 
MgSO4 and concentrated in vacuo. The residue was purified by flash chromatography 
(ethyl acetate/hexane) to give 2-[1-(4-chlorophenyl)cyclopropyl]-5-oxo-4H-pyrazolo[1,5-
a]quinazoline-3-carbonitrile (16 mg, 44µmol, 11% yield)  as a white solid. 1H NMR (500
MHz, DMSO-d6) δ 13.23 (s, 1H), 8.17 (d, J=7.9 Hz, 1H), 8.10 (d, J=8.2 Hz, 1H), 7.95 (t, 
J=7.8 Hz, 1H), 7.59 (t, J=7.6 Hz, 1H), 7.38 (d, J=8.2 Hz, 2H), 7.32 (d, J=8.3 Hz, 2H), 









A mixture of 5-amino-3-[1-(4-chlorophenyl)cyclopropyl]-1H-pyrazole-4-carbonitrile 
(80.00 mg, 309.23 μmol) , methyl 2-fluoro-5-(trifluoromethyl)benzoate (75.56 mg, 
340.15 μmol)  and dipotassium;carbonate (64.11 mg, 463.85 
μmol)  in dimethylformamide (1.00 mL)  was stirred at 140 °C for 30 min under 
microwave irradiation. The mixture was poured into water, and extracted with ethyl 
acetate. The organic layer was washed successively with water and brine, dried over 
MgSO4 and concentrated in vacuo. The residue was purified by column chromatography 
(ethyl acetate/hexane) to give a mixture. The amorphous material was triturated with 
acetonitrile and the white precipitate was collected to give 2-[1-(4-
chlorophenyl)cyclopropyl]-5-oxo-7-(trifluoromethyl)-4H-pyrazolo[1,5-a]quinazoline-3-
carbonitrile (26.20 mg, 61.10 μmol, 19.76% yield) as a white solid. 1H NMR (500 MHz, 
DMSO-d6) δ 13.49 (s, 1H), 8.36 (s, 1H), 8.25 (d, J= 1.3 Hz, 2H), 7.42 – 7.35 (m, 2H), 










A mixture of 5-amino-3-[1-(4-chlorophenyl)cyclopropyl]-1H-pyrazole-4-carbonitrile 
(127.71 mg, 493.65 μmol), dipotassium;carbonate (102.34 mg, 740.47 μmol) and methyl 
2-fluoro-5-methoxy-benzoate (100.00 mg, 543.01 μmol) in dimethylformamide (3.00 
mL) was stirred at 140 °C  for 40 hours. The mixture was poured into water, and 
extracted with ethyl acetate. The organic layer was washed with water and brine 
respectively, dried over MgSO4 and concentrated in vacuo. The residue was purified 
column chromatography (ethyl acetate/hexane) to give 2-[1-(4-
chlorophenyl)cyclopropyl]-7-methoxy-5-oxo-4H-pyrazolo[1,5-a]quinazoline-3-
carbonitrile (9 mg, 24 μmol, 5% yield)  as a white solid. 1H NMR (500 MHz, DMSO-d6) 
δ 13.24 (s, 1H), 8.03 (d, J= 9.0 Hz, 1H), 7.61 – 7.48 (m, 2H), 7.39 – 7.23 (m, 4H), 3.89 (s, 
















A mixture of 5-amino-3-[1-(4-chlorophenyl)cyclopropyl]-1H-pyrazole-4-carbonitrile 
(498.89 mg, 1.93 mmol), methyl 2-fluoro-5-iodo-benzoate (600.00 mg, 2.14 
mmol)  and dipotassium carbonate (444.20 mg, 3.21 mmol) in dimethylformamide (10.00 
mL)  was stirred at 150 °C for 1 h under microwave irradiation. The reaction was cooled 
to room temperature and poured into water. The white precipitate was collected and 
washed with ethyl acetate to give 2-[1-(4-chlorophenyl)cyclopropyl]-7-iodo-5-oxo-4H-
pyrazolo[1,5-a]quinazoline-3-carbonitrile (400 mg, 822 μmol, 38% yield)  as a white 
solid. 1H NMR (500 MHz, Chloroform-d) δ 9.78 (s, 1H), 8.65 (d, J= 2.0 Hz, 1H), 8.15 
(dd, J= 8.7, 2.0 Hz, 1H), 7.91 (d, J= 8.6 Hz, 1H), 7.43 – 7.32 (m, 4H), 1.64 (d, J= 2.4 Hz, 
2H, overlaps with a peak for residual water), 1.41 (q, J= 4.6 Hz, 2H). LCMS m/z: 487.0 
[M+H]+. 

















































To a solution of sodium methoxide (0.5 M, 2.44 mL) was added 2-chloroacetonitrile (423 
mg, 5.6 mmol). The mixture was stirred at 25 °C for 30 min. A solution of 2-amino-5-
(trifluoromethyl)benzoic acid (1.00 g, 4.9 mmol) in MeOH (7.0 mL) was added to the 
mixture. The mixture was stirred at rt for 12 h. The resulting solid was collected by 
filtration to give 2-(chloromethyl)-6-(trifluoromethyl)-1H-quinazolin-4-one (422 mg, 
1.61 mmol, 33% yield) as a white solid. 1H NMR (500 MHz, DMSO-d6) δ 12.98 (s, 1H), 
8.38 (s, 1H), 8.17 (d, J = 8.4 Hz, 1H), 7.90 (dd, J = 8.6, 2.4 Hz, 1H), 4.61 (d, J = 2.6 Hz, 
2H). LCMS m/z: 263.03 [M+H]+. 
2-(4-oxo-6-(trifluoromethyl)-1,4-dihydroquinazolin-2-yl)acetonitrile 
To a solution of 2-(chloromethyl)-6-(trifluoromethyl)-1H-quinazolin-4-one (410 mg, 1.56 
mmol) in DMSO (5.0 mL) was added sodium cyanide (153 mg, 3.12 mmol). The mixture 
was stirred at 25 °C for 3 hour. The mixture was poured into aqueous ammonium 
chloride, and extracted with ethyl acetate. The organic layer was washed with brine, dried 
over Na2SO4 and concentrated in vacuo. The residue was purified by column 
chromatography (ethyl acetate/hexane) to give 2-[4-oxo-6-(trifluoromethyl)-1H-
quinazolin-2-yl]acetonitrile (145 mg, 573 μmol, 37% yield) as a pale yellow solid. 1H 














– 7.86 (m, 1H), 4.26 (d, J = 2.6 Hz, 2H). LCMS m/z: 254.13 [M+H]+.
(E)-3-(2,4-dichlorophenyl)-3-oxo-2-(4-oxo-6-(trifluoromethyl)-3,4-
dihydroquinazolin-2(1H)-ylidene)propanenitrile (9) 
To a mixture of 2-[4-oxo-6-(trifluoromethyl)-3H-quinazolin-2-yl]acetonitrile (145 mg, 
573 μmol)in dioxane (4.0 mL) were added 2,4-dichlorobenzoyl chloride (144 mg, 687 
μmol) and triethylamine (64 mg, 630umol) at 100 °C . The mixture was stirred for 15 
hour at 100 °C.  The mixture was poured into water, and extracted with EtOAc. The 
organic layer was washed with brine, dried over Na2SO4 and concentrated in vacuo. The 
resulting solid was collected by filtration using ethyl acetate to give (2E)-3-(2,4-
dichlorophenyl)-3-oxo-2-[4-oxo-6-(trifluoromethyl)-1H-quinazolin-2-
ylidene]propanenitrile (159 mg, 373 μmol, 65% yield) as a pale yellow solid. 1H NMR 
(500 MHz, DMSO-d6) δ 13.66 (s, 1H), 8.23 (s, 1H), 7.91 (d, J = 8.5 Hz, 1H), 7.67 (q, J = 
1.9 Hz, 1H), 7.56 (d, J = 8.7 Hz, 1H), 7.47 (tdd, J = 8.8, 5.8, 1.7 Hz, 2H). LCMS m/z: 
428.08 [M+H]+. 
2. X-ray Crystallography of compounds 1 and 5: X-ray crystallography was performed by
colleagues at Takeda Pharmaceuticals, Japan. 
For compound 1, measurements were made on a Rigaku R-AXIS RAPID-191R 











by direct methods with SIR2008(119) and was refined using full-matrix least-squares on 
F2 with SHELXL-2013.(120) All non-H atoms were refined with anisotropic 
displacement parameters. The solvent area was disordered, no satisfactory model could 
be refined. This disordered density was taken into account with the SQUEEZE procedure, 
as implemented in PLATON.(121) For compound 5, measurements were made on a 
Rigaku XtaLAB P200 diffractometer using graphite monochromated Cu-Ka radiation. 
The structure was solved by direct methods with SIR2008(119) and was refined using 
full-matrix least-squares on F2 with SHELXL-2014/7.(120) All non-H atoms were 
refined with anisotropic displacement parameters. Supplementary crystallographic data 
for compound 1 and 5 have been deposited in the Cambridge Crystallographic Data 
Centre (CCDC) with accession numbers CCDC 1510769 (1) and CCDC 1510770 (5), 
respectively. These data can be obtained free of charge from the CCDC via the internet: 
http://www.ccdc.cam.ac.uk/Community/Requestastructure/Pages/DataRequest.aspx?. 
ORTEP drawing of 1, thermal ellipsoids are drawn at 20% probability. Color code: black: 













Crystal data for 1: C23H20Cl2N4O4, MW = 487.34; crystal size, 0.21 x 0.10 x 0.07 mm; 
colorless, block; monoclinic, space group P21/c, a = 14.2322(6) Å, b = 6.7917(3) Å, c = 
25.2715(18) Å, α = γ = 90°, β = 90.494(6)°, V = 2442.7(2) Å3, Z = 4, Dx = 1.325 g/cm3, 
T = 100 K, μ = 2.698 mm-1, λ = 1.54187 Å, R1 = 0.098, wR2 = 0.201. 
ORTEP of 5, thermal ellipsoids are drawn at 30% probability. Color code: black: carbon; 
blue: nitrogen; yellow: chlorine; red: oxygen. 
Crystal data for 5: C20H13ClN4O, MW = 360.80; crystal size, 0.23 x 0.05 x 0.03 mm; 
colourless, needle; monoclinic, space group P21/c, a = 10.32080(19) Å, b = 4.91042(7) Å, 
c = 34.5332(5) Å, β = 90.6463(16)°, α = γ = 90°, V = 1750.01(5) Å3, Z = 4, Dx = 1.369 








3. Protein expression and purification: I performed all protein purification.
GFP-human cytoplasmic dynein 2 (AA 1091-4307, uniprot: Q8NCM8), which bears an 
N-terminal protein A tag, followed by tobacco etch virus (TEV) protease-cleavable linker, 
followed by a GFP tag, was expressed using the baculovirus/insect cell expression system 
and purified as described previously(17) with a number of modifications. An Sf9 insect 
cell pellet was resuspended in lysis buffer (30 mM HEPES pH with KOH to 7.4, 50 mM 
KOAc, 2 mM MgOAc2, 0.2 mM EGTA, 10% (v/v) glycerol, 300 mM KCl, 0.2 mM ATP, 
1 mM DTT and 2 mM PMSF+ protease inhibitor cocktail (cOmpleteTM Roche) and lysed 
using a dounce homonizer. The lysate was clarified by centrifugation at 160,000g and 
then incubated with IgG-sepharose beads beads for 90 minutes at 4°. The beads were 
washed with 12 bed volumes of lysis buffer and 12 bed volumes of buffer B (50 mM Tris 
HCl pH 8.0, 150 mM KOAc, 2 mM MgOAc2, 1 mM EGTA, 10% v/v glycerol, 1 mM 
DTT, and 0.2 mM ATP). TEV protease was added to the bead slurry and incubated at 4° 
for 8 hours with rotation. Cleaved soluble protein was collected, concentrated, and loaded 
onto a gel filtration chromatography column (Superose 6, GE Healthcare). The protein 
was eluted in buffer C (20 mM Tris HCl pH 8.0, 100 mM KOAc, 2 mM MgOAc2, 1 mM 
EGTA, 10% v/v glycerol, 1 mM DTT, 50 µM ATP), peak fractions were collected, 
concentrated, aliquoted, and then frozen in liquid nitrogen. 
GFP-human cytoplasmic dynein 1 (AA 1320-4646 with additional valine [at position 
4647], uniprot Q14204), which, like the GFP-dynein 2 construct, bears N-terminal 
protein A tag, followed by a TEV-cleavable linker, followed by a GFP tag, was expressed 
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using the baculovirus/insect cell expression system and purified using a similar procedure 
to that described for GFP-dynein 2 with the following modifications: 
• The lysis buffer was: 30 mM HEPES (pH 7.5 with KOH), 200 mM NaCl, 1 mM
DTT, 1 mM PMSF, protease inhibitor cocktail (HaltTM, Thermo).
• Lysis was accomplished by addition of 0.2% triton X-100 followed by incubation
on ice for 15 minutes. 
• Buffers B and C were replaced with a buffer with the following composition: 50
mM Tris HCl (pH 7.8),150 mM KOAc, 2 mM Mg(OAc)2, 1 mM EGTA, 1 mM 
EDTA, 10% glycerol, 0.1 mM ATP,  1 mM DTT. 
• TEV protease was incubated with the bead slurry for 90 minutes on wet ice
without agitation. 
• The protein was not concentrated.
6x-His-tagged human cytoplasmic dynein 1 (wild-type, K1912A, K2601A, AA 1320-
4646, uniprot: Q14204), proteins which contain N-terminal hexahistixine (6x-His), 
followed by tobacco etch virus (TEV) protease-cleavable linker were expressed using the 
baculovirus/insect cell expression system and purified as follows. An Sf9 cell pellet was 
resuspended in a buffer containing, 30mM HEPES pH 7.6, 200mM NaCl, 10mM 
imidazole, 1mM TCEP, 2mM PMSF, and protease inhibitor cocktails (HALT, Thermo-
Fisher and cOmpleteTM, Roche) and lysed by the addition of Triton X-100 to a final 
concentration of 0.2%. The lysate was clarified by centrifugation at 140,000g and then 
incubated with Ni-NTA beads for 2h at 4°. The beads were washed with 75 bed volumes 
of lysis buffer and bound proteins were eluted with buffer containing 30mM HEPES pH 
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7.5, 100mM NaCl, 500mM imidazole, and 1mM TCEP. Eluate fractions containing 
protein were diluted into buffer B (50mM Tris HCl pH7.8, 150mM KOAc, 2mM 
Mg(OAc)2, 1mM EGTA, 1mM EDTA, 0.1mM ATP, 1mM DTT) and loaded onto a Mono 
Q anion exchange column (GE Healthcare). The column was eluted using a salt gradient 
from 150 to 750mM KOAc over 20 column volumes. Peak fractions were concentrated 
using a centrifugal concentrator (Amicon) and subjected to size exclusion 
chromatography on a Superose 6 column using buffer B. For K1912A and K2601A 
proteins, the ion exchange chromatography step was omitted and NiNTA-eluate fractions 
were pooled and subjected directly to size exclusion chromatography.  Gel filtration 
revealed a monodisperse peak at an elution volume of 12.2 mL (wild-type) 12.3ml 
(K1912A), and 12.4ml (K2601A), consistent with the expected molecular weight.  Peak 
fractions were pooled, supplemented with glycerol to a final concentration of 20%, and 
snap frozen. The protein yield was ~1-2 mg of dynein 1 wild-type or mutants per 1L of 
Sf9 culture. Cleavage of the TEV-cleavable linker following binding to Ni-NTA beads 
lead to protein precipitation. 
4. Microtubule motility assays: I performed all microtubule motility assays
Reaction setup: A coverslip-based motility assay was adapted from similar assays 
reported previously.(17, 46) A flow chamber assembled on a pre-cleaned microscope 
coverslide (3-5 µl chamber volume) was hydrated with buffer A (25 mM PIPES, 30 mM 
KCl, 5 mM MgCl2, 1 mM EGTA, 0.01% Triton X-100, 1 mM DTT, 20 µM taxol, pH 7.0 
with KOH). Anti-GFP antibody (0.4 mg/ml, affinity purified rabbit antibody) was flowed 
into the chamber and allowed to adhere non-specifically to the glass for 20 seconds. The 
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surface was blocked using 0.5 mg/ml α-casein in buffer A. Excess protein was then 
washed away with buffer A. GFP-dynein motor domain was diluted in buffer A 
supplemented with 1 mM DTT and 0.1 mM ATP (2 mM DTT final; GFP-dynein 2 
diluted to: 180 nM; GFP-dynein 1 diluted to: 60 nM), flowed into the chamber and 
allowed to bind for 20 seconds. Excess protein was washed away with buffer A. Reaction 
mix (25 mM PIPES, 90 mM KCl, 6 mM MgCl2, 1 mM EGTA, 0.01% Triton X-100, 3 
mM DTT, 20 µM taxol, 1 mM ATP, 1x oxygen scavenging system components [4.5 
mg/ml glucose, 35 µg/ml catalase, 200 µg/ml glucose oxidase], 2% final DMSO [v/v] 
with compounds at appropriate concentrations, 0.05 mg/ml α-casein, microtubules, pH 
7.0 with KOH) was flowed into the chamber using ~4 chamber volumes. For experiments 
shown in Figure 4 Supplement 1, α-casein concentration in reaction mix was 0.5 mg/ml 
and all other parameters were held constant. 
For reversibility experiments, motility in the presence of 5µM 8 was observed as above, 
and upon completion of imaging, the chamber, fresh buffer A supplemented with 1mM 
ATP was flowed into the chamber and incubated for one minute; this wash and 
incubation cycle was repeated twice. Reaction mix containing DMSO (no compound) 
was flowed into the chamber using ~4 chamber volumes. The chamber was sealed with 
valap and returned to the microscope. 
Microscopy conditions: Following addition of reaction mix, microtubules were allowed 
to bind for 5 minutes before imaging. For reversibility experiments, microtubules were 
allowed to bind for 10 minutes before imaging. Videos were taken on a Zeiss Axiovert 
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200M wide-field microscope equipped with a Zeiss 100x/1.45 NA α-Plan-Fluar objective. 
Data were captured with an EM-CCD camera (iXon DU-897, Andor Technology) with a 
0.2-second exposure time and frame rate of 0.25-0.5/second. Four 10-20 second videos 
were captured per experimental condition. Velocities were measured using the 
kymograph tool in FIJI.(122) Data analysis is discussed below under "8. General data 
analysis procedures." 
5. ATPase Assays: I performed all ATPase assays
ATPase activity of dynein 
ATPase assays using recombinant Dynein 1 (wild-type and mutants) were performed in a 
buffer containing 25mM PIPES pH7.0, 30mM KCl, 1mM EGTA, 5mM MgCl2, 0.01% 
triton X-100, 1mM DTT, and 20-30µM taxol (if microtubules were present). For typical 
conditions, enzyme was incubated with varying concentrations of inhibitor in buffer 
containing 2% DMSO for 10 minutes in a volume of 10 μL. When microtubules were 
present, they were polymerized by stepwise addition of taxol and high concentrations of 
DMSO (30% final during polymerization reactions), and re-suspended following 
centrifugation in ATPase buffer to a concentration up to 3-fold above the final 
concentration used in the reaction. For microtubule-stimulated reactions in dose-response 
format, reactions were assembled by 1:1:1 mixture of 3x enzyme stock, 3x compound 
stock (in buffer with 6% DMSO), and 3x microtubule stock to each well. For 
microtubule-stimulated ATPase assays at tubulin concentrations >2.5µM, enzyme stock 
was supplemented with compound stock in pure DMSO (resulting in an intermediate 
DMSO concentration of 6%), and then the microtubule stock was added. Final enzyme 
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concentrations were 30-100nM for GFP-dynein 1, wild-type 6x-His-dynein 1, and 
K2601A 6x-His-dynein 1 and up to 500nM for K1912A 6x-His-dynein 1. The final 
DMSO concentration was 2% in all ATPase assays performed. 
Assembled reaction mixtures (including enzyme, compound, and microtubules, if 
present) were incubated for 10 minutes before addition of ATP. Each ATPase reaction 
was initiated by addition of 2 μL of a 6x ATP stock containing trace γ-32P ATP (6000 
Ci/mmol, 10mCi/mL, Perkin Elmer) and allowed to proceed for a time predetermined to 
lie within the linear range of the assay (20-30 minutes). For typical conditions, ATP was 
used at a final concentration of 1 mM. Reactions were quenched by the addition of 12µL 
100 mM EDTA, and 2 μL of each quenched reaction was spotted onto PEI-cellulose TLC 
plates (Millipore). Plates were developed in a glass chamber with a freshly prepared 
solution of 150 mM formic acid and 150 mM LiCl, dried, exposed to a storage phosphor 
tray (GE Healthsciences), and scanned on a Typhoon imaging system (GE 
Healthsciences). The fraction of γ-phosphate hydrolyzed in each condition was quantified 
using ImageJ. 
6. Ultraviolet light and ADP-vanadate-dependent photocleavage of dynein: I performed
all ADP-vanadate photocleavage assays. 
30µL reactions were prepared in 96-well plates as follows. ATPase buffer was 
supplemented with concentrated stocks of His-dynein 1 (90nM final), compound 8 (4µM 
final) or an equivalent amount of solvent carrier (3.3% DMSO), followed by a 10 minute 
incubation at room temperature. ATP (0.1mM final) was added and the mixtures were 
incubated 5 minutes at room temperature. NaVO3 (0.1mM final) was added and the 
mixtures were again incubated 5 minutes at room temperature. Vanadate was deliberately 
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omitted from one well. The plate was then transferred to ice and irradiated with 365 nm 
light for 15 minutes with the lamp positioned 10cm above the plate (Spectroline Maxima 
ML-3500S lamp). Following addition of SDS-PAGE loading buffer and heating (95°, 5 
minutes), individual reactions were resolved on hand-poured 8% tris-glycine 
polyacrylamide gels. Gels were stained (Coomassie blue), imaged using a Li-Cor 
Odyssey, and band intensities were analyzed using FIJI. 
7. Assays of hedgehog pathway activity: Assays of Hedgehog pathway activity were
performed by Cristina Santarossa and Lola Yu. 
NIH-3T3 cells stably expressing a luciferase reporter downstream of a Gli binding site 
(Shh-Light2 cells, RRID: CVCL_2721) were maintained in DMEM with 10% bovine calf 
serum (BCS). Cells were seeded at a density of 30,000 cells/well in 96-well tissue 
culture-treated plates (Corning, cat #353072) in 100 μL in DMEM + 10% BCS, and 
incubated for 48 hours(94). Wells were washed briefly with PBS. Next 100 μL of low 
serum media (DMEM + 0.5% BCS) containing either 0.2% DMSO, 500 nM of 
smoothened agonist (SAG), or 500 nM SAG in the presence of serial threefold dilutions 
of each inhibitor starting from 20 μM were added to the wells. After 28 - 32 hours of 
inhibitor treatment, cells were washed with 50 μL PBS and lysed for > 30 min in 30 μL 
Passive Lysis Buffer (Promega Dual Luciferase kit, cat E1910). 5 μL of each lysate was 
transferred to white, solid-bottom 96-well plates (Greiner, cat #655075), followed by 
rapid addition (within 30 s) of 30 μL of Luciferase Assay Reagent using a multichannel 
pipette. Luminescence for each condition was read using a Synergy Neo plate reader (5 s 
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integration time per well). Cell line identity was confirmed by measurement of the degree 
of response to Hedgehog pathway stimulation by the synthetic agonist SAG and using 
previously-published values from our groups and others as references(44, 46).
8. Cytotoxicity assays: I performed cytotoxicity assays.
Murine inner medullary collecting duct (IMCD3) cells stably expressing mNeonGreen-
IFT88 were maintained in DMEM/F12 supplemented with 10% FBS. Cells were 
described previously(54) and cell line identity was confirmed by the proper localization 
and motility of mNeonGreen IFT88 puncta, in reference to published analyses from our 
groups and from the work of others(54, 96). Cells were seeded in a 96 well plate at a 
density of 5 x 103 cells / well. Following overnight incubation, low-serum media (0.2% 
FBS) containing solvent control (0.3% DMSO) or compound. At fixed time points, 
CellTiter-Glo 2.0 (Promega) reagent was added to the wells, mixed by pipetting, and 
transferred to a white, opaque 96 well plate. After a 10-minute incubation, luminescence 
for each condition was read using a Synergy Neo plate reader (1 s integration time per 
well). 
9. Intraflagellar transport assays: Intraflagellar transport assays were performed by
Cristina Santarossa. 
Murine inner medullary collecting duct (IMCD3) cells stably expressing mNeonGreen-
IFT88 were maintained in DMEM/F12 supplemented with 10% FBS. Cells were 
typically passaged fewer than 10 times following thawing of frozen stocks. Cells were 
described previously(54). 6 x 105 cells were seeded onto 22mm coverslips in a 6 well 
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plate and incubated for 24 hours at 37°C. The media was then replaced with DMEM/F12 
+ 0.2% FBS and cells were incubated 24 hours to promote cilium formation. Immediately 
prior to imaging, media was replaced with phenol red-free media (Leibovitz's L-15 + 
0.2% FBS) containing either carrier solvent control (0.3% DMSO) or compound. IFT88 
transport was observed using a TE2000-E spinning disk confocal microscope (Nikon 
PlanApo 100x/1.45 objective lens) fitted with a Photometrics Cascade II (EMCCD 512) 
camera and imaged at a frame rate of 2 frames/second. Kymographs were generated in 
ImageJ using KymographClear and the velocities of mNeonGreen-IFT88 foci 
movements were quantified by KymographDirect(97). 
For washout experiments, cells were exposed to a 5 minute compound treatment as 
described above. Cells were then washed twice with 5 mL of L-15 supplemented with 
10% FBS (or 0.2% FBS) and 0.3% DMSO. A five minute incubation followed each 
wash. For short term washout experiments, imaging was performed as described above 
immediately after the second five minute wash and incubation step had been completed. 
For longer-duration washout experiments, following the second wash incubation, cells 
were incubated at 37° a further 50 minutes and then imaged. 
10. Lysosome motility assays: These assays were performed by Dr. Anna Serpinskaya
and Dr. Vladimir Gelfand at Northwestern University. 
CAD cells (catecholaminergic neuronal tumor cell line, RRID:CVCL_0199) were 
maintained in DMEM/F12 medium with 10% Fetal Bovine Serum(100). Cell line identity 
was confirmed by the morphological response to serum withdrawal (i.e. neurite 
formation), a previously-documented characteristic of this cell line(100). 24 hours before 
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the experiment cells were plated on coverslips in serum-free medium to induce neurite 
formation. Cells were treated with inhibitors or control solvent (0.1% DMSO final in all 
experiments) for 60 min, then lysosomes were labeled with 0.1 µM (final concentration) 
LysoTracker Red DND-99 (Molecular Probes) and used for microscopy immediately 
after LysoTracker addition.
Microscopy was performed using a Nikon TE-2000 inverted microscope equipped with a 
LED X-Cite illuminator (Lumen Dynamics) at 37 degrees. Images were acquired with a 
Hamamatsu ORCA-Flash 4.0 camera driven by MetaMorph software at a rate of 1 frame 
per second for 1 minute. Lysosome motility in neurites was analyzed using Diatrack 
software (http://www.diatrack.org/), particle velocities were measured from frame to 
frame and the total length of trajectories divided by the number of analyzed organelles 
was calculated for every experimental condition. 
11. General data analysis procedures:
Microtubule velocity measurements: the tracks of microtubules were traced and 
converted to kymographs (x axis-displacement, y axis-time) using the kymograph 
function of FIJI (RRID: SCR_002285). The angle formed between an edge of a
microtubule and the horizontal was measured. This angle, θ, was converted into velocity 
using the following relationship:
velocity = 1/|tangent(θ)| * (unit pixel distance)/(time interval between frames) 
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The calibrated pixel distance was 0.152 µm and the time interval between frames was 
either 2 or 4 seconds. The velocities of at least 7 microtubules were measured per field of 
view, if sufficient tracks could be found. In cases where fewer than 7 microtubules were 
found in a field of view, velocities of all microtubules on the coverslip were measured. 
~30 microtubule velocities were measured for a given condition and their mean was 
reported as the average microtubule velocity. 
Microtubule number counting: The number of microtubules bound to a coverslip in the 
first frame of a movie were counted manually. 
Curve fitting: Where dose-response experiments are fit and IC50values given, these are 
obtained as follows: Individual experiments are treated as separate. The data are fit to a 
sigmoidal dose-response curve of the form (Y=Bottom + (Top-
Bottom)/(1+10^((LogIC50-X)*HillSlope)). All variables were allowed to float freely 
with the exception of the variable denoted "bottom", which was constrained to be > 0. 
The separate IC50 values obtained from fits to each individual experiment's dataset were 
averaged together and presented as a mean with range (Figure 3G, 3H) or standard 
deviation (Figure 3I, 5D, 6E, 6K). 
Statistical analysis of intraflagellar transport frequencies:  Run frequencies output directly 
from KymographDirect were tabulated across all cilia imaged in a given condition (see 
Figure 4, Figure Supplement 2). For each of two experimental conditions (5µM 8, 10µM 
8) and the respective controls, an un-paired T-test was performed for the difference of
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means control and compound treatment. This analysis was performed for each direction 
of motion. 
Quantification of ADP-vanadate dependent photocleavage of dynein was performed as 
follows: Scanned gels were analyzed with FIJI, and fraction cleaved quantified as 
follows: 
Fraction cleaved = (intensity of band at 250kDa) / 
(intensity of band at 250kDa + intensity of band at ~350kDa) 
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Chapter 3: 
Dynapyrazole and its chemical derivatives inhibit dynein via 
distinct mechanisms 
Note to readers: the results discussed below arose from a collaborative effort between 
myself and several colleagues in the Kapoor Lab and at the Tri-Institutional Therapeutics 
Discovery Institute (TDI). I have included this work as it helps explain the rationale of 
my work and supports the conclusions I draw.  In the body of the text and in the methods 
section, I have noted who performed each experiment. I have also noted this information 
in the figure legends, where appropriate. Except for experiments credited explicitly to 
others, I performed all experiments and analysis. 
3.1 Introduction 
While the dynapyrazoles constitute a step toward the improvement of cytoplasmic 
dynein 1 and 2 antagonists, a number of limitations remain. The activity of dynapyrazoles 
is reduced in settings with high protein concentrations, which restricts their use in many 
cell culture settings, where the use of serum is often required. Furthermore, the potency 
of dynapyrazoles A and B remains modest, with concentrations in the 3-10µM range 
typically required to observe cellular phenotypes. Cytotoxicity is another limitation of the 
dynapyrazoles. Treatment at a dynapyrazole A concentration of 15µM depletes cellular 
ATP levels within hours. This toxicity may represent an inherent limitation of inhibition 
of cytoplasmic dynein 1, which plays multiple roles in cellular physiology(123). A 
consequence of the cytotoxicity is that it limits the window of time and the concentration 
range over which these compounds can be used to study the cell-biological roles of the 
cytoplasmic dyneins. 
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3.2 Chemical analysis of ciliobrevins and dynapyrazoles inform synthesis of new 
inhibitors 
As a first step toward addressing the liabilities of the dynapyrazoles, I sought to 
identify dynapyrazole derivatives with improved potency. I revisited the chemical 
analysis that led to the design and synthesis of this compound class, incorporating 
structure-activity data from both the ciliobrevins and its pyrrolo- and 
pyrazoloquinazolinone derivatives(46, 47, 124). The structure-activity-relationship 
analysis of the ciliobrevin and pyrrolo/pyrazoloquinazolinone scaffolds with respect to 
cytoplasmic dynein 2, as judged by inhibition of purified proteins or of the Hedgehog 
signaling pathway, is summarized in Figure 3.1. Overall, the structure-activity-
relationship landscape for the ciliobrevin scaffold showed that substitutions of the nitrile 
or the carbonyl groups at C4 and C10 led to loss of inhibition (Figure 3.1A). 
Modifications at the D ring were tolerated only if they retained halogens at the 2 and 4 
positions of the ring. Compounds with modifications at C6 and C7 were generally active 
inhibitors some had improved potency and selectivity(47). A caveat to interpreting these 
data is that it is unknown whether any of these changes alter the preferred olefin isomer at 
C2-C9 
In contrast, fewer analogs in the pyrrolo/pyrazoloquinazolinone compound series 
have been synthesized, making analysis of structure-activity-relationship trends more 
difficult. Features that could be assigned as important for activity include a nitrogen at 
position 11, without which inhibition of dynein 2 was abolished, and the cyclopropyl-
phenyl substituent at C10, which improved inhibition relative to the 2,4-dichlorphenyl 
substituent at the same position (See data in Chapter 2). A pyrazoloquinazolinone lacking 
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a nitrile at C9 inhibited dynein 2, however the contribution of the nitrile group in the 
context of more potent compounds such as dynapyrazoles A and B was not assessed. 
Synthesis and testing of additional analogs will be required to more clearly assign the 

























































Figure 3.1 Analysis of ciliobrevin and dynapyrazole structure-activity 
trends and proposed core pharmacophore. (A) Ciliobrevin compounds 
and activity trends with position numbers indicated. (B) Dynapyrazole 
componds and activity trends with position numbers indicated. (C) The 
chemical structure of the dynapyrazoles, with dotted circle indicating 
proposed aminopyrazole-cyclopropyl-chlorophenyl pharmacophore. (A) and 
(B) are based on analysis of data from Firestone et al., See et al., and 
Chapter 2. 
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As analysis of the effect of specific substitutions on dynapyrazoles did not give 
rise to predictions for how to improve compound potency, likely because too few analogs 
were available for analysis, I next examined the differences between the ciliobrevin and 
dynapyrazole scaffolds. When substitutions at the A and B rings were held constant, the a 
compound with the pyrazoloquinazolinone-cyclopropyl-chlorophenyl scaffold 
(dynapyrazole B) inhibited dynein 2 ~6 fold more potently than the comparable 
ciliobrevin derivative (Figure 2.3H, Chapter 2). This key observation suggested that the 
cyclopropyl-chlorophenyl substituted cyano-aminopyrazole fragment of the 
dynapyrazoles may constitute an improved pharmacophore for dynein inhibition relative 
to the benzoylarylonitrile of the ciliobrevins (proposed pharmacophore highlighted in 
Figure 3.1C). This fragment contains or mimics several of the elements of the ciliobrevin 
scaffold identified as important for inhibition. However, the spatial relationship among 
these groups differs slightly (Chapter 2, Figure 3D), which could account for improved 
inhibition, as has been observed previously in efforts increase inhibitor potency by 
synthesis of geometrically constrained derivatives(117). 
This chapter describes progress toward improved derivatives of the dynapyrazoles 
discovered through a chemical-synthesis campaign focused on elaboration of the 
proposed aminopyrazole pharmacophore. The biochemical mode of inhibition of dynein 
by these dynapyrazole derivatives is analyzed and compared with that of the 
dynapyrazole A. The majority of synthesis was conducted in collaboration with our 
colleagues at the Tri-Institutional Therapeutics Discovery Institute (TDI). This effort led 
to biochemical and structural characterization of a new pyrazolo-pyrimidinone dynein 
inhibitor, which is discussed in this chapter. 
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3.3 Identification and biochemical characterization of TDI 3016 
To test if aminopyrazole-containing dynapyrazole derivatives could more potently 
inhibit dynein, a set of compounds bearing a 3-alkyl, 4-cynao, 5-amino pyrazole core 
were synthesized. AP-1 was identified as a starting point for compounds containing this 
aminopyrazole core, a synthetic route was developed to bicyclic derivatives with a 
dihydropyrazolo[1,5-a]pyrimidine-3-carbonitrile core (Figure 3.2A; synthesis was 
performed by colleagues at the TDI). 20 compounds in this series (2µM) for were tested 
for inhibition of Hedgehog pathway activity using a Gli-driven luciferase reporter system 
that has previously been used to identify and characterize inhibitors of cytoplasmic 
dyneins (Figure 2B, compound structures and screening data are tabulated in Appendix 
Table 3.1, Hedgehog assays were performed by Lola Yu and Cristina Santarossa, 
technician and graudate student in the Kapoor Laboratory)(46, 124). Within this series, 
compounds with aryl or aryl-ether substitutions at the 6 position of the 
pyrazolopyrimidine core were identified as the strongest inhibitors of Hedgehog pathway 
activity. The most potent compound in this series, TDI 3016, inhibited Hedgehog 




Figure 3.2 Synthesis and testing of pyazolopyrimidine-containing dynapyrazole 
derivatives. Note: experiments shown in this figure were performed by others. 
Synthesis was performed at the TDI. C. Santarossa and L. Yu performed Hedgehog 
pathway assays. (A) Synthesis of bicyclic dynapyrazole derivatives from common 
precursor AP-1. TsOH: paratoluenelsulfonic acid. n-BuOH: n-butanol. (B) Effect of 
bicyclic dynapyrazole derivatives of Hedgehog pathway activity in a Gli-driven 
luciferase reporter assay system. Compounds were tested at 2µM. Data are mean ± 
range of n = 2 independent experiments. The structure of TDI 3016 is shown. 
Appendix 3.1 shows structures of individual compounds showin in historgram. (C) 
Analysis of Hedgehog pathway inhibition by TDI 3016. Data are mean ± S.D. of n = 3 
separate experiments and were fit to a sigmoidal dose-response curve using Prism. 
Data for this figure were generated by collaborators.  
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 Figure 3.3 Effect of TDI 3016 on dynein 1-driven microtubule glding. Inhibition of 
(A) recombinant GFP-dynein-1 or (B) bovine dynein 1-driven motility by TDI 3016. 
Data are mean ± range of n = 2 separate experiments and were fit to a sigmoidal dose-
response curve using Prism. (C) Analysis of the number of microtubules associated with 
coverslips in microtubule gliding assays. The number of microtubules was counted in 
four separate fields of view in each experiment. (D) Inhibition of recombinant GFP-
dynein 2-driven motility by TDI 3016. Data are mean ± range of n = 2 separate 
experiments and were fit to a sigmoidal dose-response curve using Prism. Motility 
assays in (A) and (B) were performed at 1mM MgATP and 0.05mg/ml casein, while 
those in (D) were performed at 2mM MgATP and 0.5mg/ml casein. 
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3.4 Analysis of TDI 3016 in biochemical assays 
Several biochemical assays were used to characterize the effect of TDI 3016 on 
cytoplasmic dynein 1. This dynein isoform was selected for comparison because it is a 
model for dyneins in general and results could be compared to previous analyses of the 
ciliobrevins and the dynapyrazoles. Microtubule gliding assays were used first, as they 
represent a biochemical reconstitution of dynein’s cellular function, namely, to drive 
motion along microtubules. Subsequently, the effect of TDI 3016 on dynein’s ATP 
hydrolysis was assessed using both wild-type and mutant dynein constructs. Finally, the 
effect of this compound on ADP-vanadate-dependent photocleavage of dynein by 
ultraviolet light was tested. This assay enables dissection of the effect of nucleotide 
engagement at dynein’s AAA1 ATPase site. Together, these assays can illuminate the 
mode of dynein inhibition, and were previously used to demonstrate that Dynapyrazole A 
and ciliobrevins inhibit dynein via a distinct mechanism (Chapter 2). 
In the microtubule gliding assay, recombinant human dynein motor domains or 
purified bovine brain dynein are immobilized to glass coverslips. Addition of 
microtubules and ATP leads to translocation of microtubules toward their plus-ends as a 
consequence of ensembles of dynein heads moving toward the minus ends. I first 
assessed the effect of TDI 3016 on microtubule motion driven by recombinant human 
dynein 1 motor domain with an N-terminal GFP tag (GFP-dynein). Under solvent control 
conditions (1mM ATP, 2% DMSO), this enzyme moved microtubules with an average 
velocity of 434 nm/s (432-436, n = 2), in line with previous analyses (Chapter 2, Figure 
2.5C). TDI 3016 (0.2-20µM) blocked GFP-dynein 1-driven microtubule gliding with an 
IC50 of 2.0µM (1.9-2.1, n = 2, Figure 3.3C). A decrease in the number of microtubules 
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bound to the coverslip was noted at higher concentrations of TDI 3016, in contrast to 
previous observations with dynapyrazole A in similar assays (Figure 3.3C). 
I next tested the effect of TDI 3016 on microtubule gliding driven by bovine 
dynein. This preparation from brain extracts contains full-length dynein (~4600 amino 
acids, ~500KDa) and ~10 accessory factors(125). In this setting, dynein is expected to 
exist as a complex containing two heavy chains and several accessory proteins (molecular 
weight >1MDa). However, despite the differences between this preparation and the GFP-
dynein 1 preparation, bovine dynein drives microtubule guiding at 537nm/s (518-556, n = 
2, Figure 3.3B), a velocity comparable to the isolated recombinant GFP-dynein 1 motor 
domain. Microtubule gliding driven by bovine dynein was inhibited by TDI 3016 with an 
IC50 of 2.4µM (2.3-2.5, n = 2). The number of microtubules bound to the coverslide was 
decreased at high TDI 3016 concentrations (20µM). A similar pattern was observed for 
inhibition of GFP-dynein 2-driven microtubule gliding, namely, that the number of 
microtubules bound to the coverslip was decreased at concentrations of TDI 3016 at or 
above 20µM. The IC50 for inhibition of dynein 2 by TDI 3016 was 16µM (14.5-17.5, n = 
2, Figure 3.3D), however this value is not directly comparable to the values measured for 
dynein 1, as the assays were performed at higher [ATP] and higher [casein], and the latter 
has caused 3-5-fold decreases in potency for related compounds (e.g. dynapyrazole A), as 
may be expected for compounds with high ClogP values (ClogP for TDI 3016: 4.2). If 
microtubule binding were suppressed by TDI 3016, then it is possible that the decrease in 
microtubule velocity is related to a decrease in the number of available binding sites. 
Such a decrease in binding sites has been shown to reduce microtubule gliding velocity 
even if the translocation rate associated with any individual dynein motor is not 
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reduced(126, 127). In order to dissect the contribution of dynein-microtubule affinity 
changes caused by TDI 3016 from direct effects on dynein-driven microtubule gliding 
velocity, it will be necessary to perform a deeper biophysical analysis that allows the 
direct measurement of binding affinity. 
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Figure 3.4 Effect of TDI 3016 on the ATPase activity of dynein 1. (A) Dose-
dependent inhibition of basal (black) and microtubule-stimulated (red) ATPase activity 
of wild-type His-dynein 1 by TDI 3016. (B) Dose-dependent inhibition of AAA3 mutant 
His-dynein 1 by TDI 3016. Data are mean ± S.D. of n = 3 experiments and were fit to a 
sigmoidal dose-response curve in Prism. ATPase assays were performed at 1mM Mg-
ATP and 2% DMSO. 
Figure 3.5 Effect of TDI 3016 on ADP-vanadate-dependent photocleavage of 
dynein 1. (A) SDS-PAGE analysis (Coomassie blue) of dynein 1 following irradiation 
with ultraviolet light at 365nm. Components of reaction loaded into each lane are noted 
above gel. Arrowheads indicate proteolysis products. (B) Analysis of gel band intensity 
for photocleavage reactions.  
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While microtubule gliding assays report on dynein’s ability to cause directional 
motion of microtubules, they do not directly reflect ATP hydrolysis rates. I therefore 
analyzed the effect of TDI 3016 (0.6-40µM) on the basal and microtubule-stimulated 
ATPase activities of an N-terminally hexahistidine tagged human dynein 1 motor domain 
(His-dynein 1). Doses up to 10µM did not decrease His-dynein 1’s basal ATPase activity, 
but higher concentrations (20µM and 40µM) reduced the basal activity to 0.31 ± 0.11s-1 
and 0.06 ± 0.02s-1, respectively (Figure 3.4A). Microtubules (2.5µM) stimulated dynein’s 
ATPase activity to ~1s-1. TDI 3016 (0.6-40µM) reduced dynein’s microtubule-stimulated 
ATPase activity, with inhibition to a rate of 0.2s-1 at the highest concentration tested 
(40µM). It is notable that, in the presence of microtubules, an intermediate concentration 
of TDI 3016 (10µM) reduced dynein’s ATPase activity to 0.66 ± 0.08s-1, a value similar 
to the basal ATPase rate (0.68 ± 0.03s-1, Figure 3.4A). Next, I tested whether TDI 3016 
inhibits a dynein 1 construct with a Walker A lysine-to-alanine mutation in its AAA3 
binding site. The basal ATPase activity of this construct is expected to arise mostly from 
hydrolysis at AAA1(20, 89). TDI 3016 inhibited this mutant with an IC50 of 6.7 ± 0.7µM 
(Figure 3.4B, n = 3, mean ± S.D.) For another compound with a similar scaffold, TDI 
4692, I observed similar patterns of biochemical activity with ~3-4 fold higher potency 
(Data presented in Appendix 3.2). As it was not consistently active in cell-based assays, 
this compound is not likely to be suitable as a probe for dynein, and subsequent analysis 
focused on TDI 3016. 
To further examine the mechanism of dynein inhibition by TDI 3016, I assessed 
whether it blocks ADP-vanadate-dependent photocleavage. Thas assay has previously 
utilized to monitor nucleotide engagement at dynein’s AAA1 ATPase site(20, 46, 106, 
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124). When dynein was treated with control solvent (3% DMSO) and incubated with 
1mM ATP and 1mM vanadate, 15 minute ultraviolet irradiation caused 66 ± 1% cleavage 
(3.3A, B, n = 3, mean ± S.D.). Pre-treatment with TDI 3016 (10µM) reduced 
photocleavage to 13 ± 3%. Lower concentrations of TDI 3016 blocked photocleavage to 
a lesser degree (3.5A, B). 
3.5 Negative stain electron microscopy analysis of the effect of compounds on dynein 
structure 
Decades of research into the structure of dynein have shed light on a series of 
mechanical movements of domains within the dynein heavy chain and illustrated how 
these are coupled to and regulated by nucleotide occupancy at dynein’s ATPase sites, 
primarily AAA1(8, 86). The linker region of dynein has been identified as central 
element in dynein’s chemomechanical cycle. This bundle composed primarily of 
overlapping a-helices emanates from the AAA ring of dynein, crosses above it, making
interactions with AAA subdomains, and then extends toward the N-terminal tail of 
dynein. A key step in dynein’s chemomechanical cycle is the “power stroke” in which the 
linker transitions from a bent, “pre-powerstroke” geometry, to a straight “post-
powerstroke” geometry. ATP binding at AAA1 is proposed to induce the bent pre-
powerstroke state, while phosphate release following ATP hydrolysis is associated with 
straightening of the linker(86). The combination of this linker motion with binding and 
unbinding to the microtubule track (also a nucleotide-state-dependent process) leads to 






Figure 3.6 Structural analysis dynein using negative stain electron 
microscopy. Electron microscopy grid preparation and image 
acquisition were performed by Zhen Chen (graduate student in Kapoor 
Laboratory).  (A) Schematic depiction of the dynein motor domain 
illustrating the protruding microtubule binding domain and GFP-linker. 
(B) Images from negative stain electron microscopy. GFP-dynein 1 was 
pre-incubated with control solvent (0.5% DMSO), ATP (1mM), and 
sodium vanadate (1mM) before fixation. Top row: raw images of 
individual particles. Bottom row: vector pointing to each protrusion is 
emphasized in yellow. The angle between these two vectors is measured. 
(C) Histogram showing distribution of angles. q was measured for 1000 
particles.  
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Structural studies using negative stain electron microscopy provided an early view 
into  this nucleotide state-dependent regulation of dynein's conformation(128). The 
microtubule binding domain and the linker/tail of dynein protrude from the ring-shaped 
AAA domain. Using a GFP-labeled dynein motor domain construct with a ~500 amino 
acid long linker, it is possible to observe both structures emanating from the AAA+ ring 
by negative stain electron microscopy and measure the angle between them (θ, Figure 
3.6A). Previous studies have shown that the nucleotide-free (apo) and ADP-bound states 
are characterized by a small θ (~40°), which corresponds with a post-powerstroke linker 
state(128). In contrast, binding of ADP-vanadate, an ATP hydrolysis transition-state 
mimetic, is associated with a bimodal distribution of θ, with peaks at ~40° and ~145° in 
an approximate ratio of 3:2, with the large-angle component reflecting the pre-
powerstroke state of dynein. I sought to use a similar electron microscopy-based assay to 
determine the impact of compound treatment on the chemomechanical cycle of dynein. I 
performed electron microscopy on GFP-dynein 1 samples stained with uranyl formate 
(Figure 3.6B, all electron microscopy image acquisition and grid preparation was 
performed by Zhen Chen; I performed image analysis and sample preparation). In the 
ADP-V state (obtained by incubation with 1mM ATP and 1mM Na3VO4, solvent control: 
0.5% DMSO), I observed a bimodal distribution of angles, with one peak at 37° 
accounting for ~60% of particles and a second peak at 125° accounting for the remaining 
40% of particles (Figure 3.4C). These distributions are similar to those previously 
observed for dynein 1 from dictyostelium(128). 
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Figure 3.7 Analysis of the effect of TDI 3016 on dynein structure 
using negative stain electron microscopy. Electron microscopy grid 
preparation and image acquisition were performed by Zhen Chen 
(graduate student in Kapoor Laboratory).  (A) Structure of TDI 3016. 
(B) Images from negative stain electron microscopy. GFP-dynein 1 was 
pre-incubated with TDI 3016 (10µM), ATP (1mM), and sodium vanadate 
(1mM) before fixation. Top row: raw images of individual particles. 
Bottom row: vector pointing to each protrusion is emphasized in yellow. 
The angle between these two vectors is measured. (C) Histogram 
showing distribution of angles. q was measured for > 1000 particles.
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I next analyzed the effect of TDI 3016 and dynapyrazole A on the structure of 
GFP-dynein 1. Dynein was treated with TDI 3016 (10µM) before addition ATP and 
vanadate and subsequent fixation. The angle separating the two protrusions was measured 
for ~1000 particles. A unimodal distribution of angles was observed, with a peak 
frequency at ~35° (Figure 3.7C). 79.7% of particles had θ < 90°. In contrast, for the 
solvent control condition, 58.3% of particles had θ < 90°. The distribution of angles 
between the microtubule binding domain and liker of dynein 1 in the presence of TDI 
3016 and ADP-vanadate was similar to that observed by others for ADP- and apo-states, 
and are in line with the observation that this compound blocks ADP-vanadate dependent 
photocleavage of dynein (Figure 3.5). (A comparable experiment performed for TDI 
4692 and a similar structural effect was observed, see Appendix 3.2.) Taken together, 
these data suggest that TDI 3016 prevents dynein from adopting a pre-powerstroke 
geometry. 
A similar analysis was performed for dynapyrazole A. Unlike TDI 3016, the 
distribution of angles was bimodal, with frequency peaks at ~37° and ~140° (Figure 
3.9C). 49.0% of particles had microtubule binding domain-linker angles < 90°, a value 
slightly smaller than observed in the solvent control. The bimodal distribution of angles 
suggested that dynapyrazole A did not block the ability of dynein to adopt a pre-
powerstroke geometry, which was unexpected, as this compound also blocked ADP-
vanadate dependent photocleavage. Experiments are ongoing to determine the effect of 
both dynapyrazole A and TDI 3016 on the geometry of dynein 1 in other nucleotide 
states. 
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Figure 3.8 Analysis of the effect of dynapyrazole A on dynein 
structure using negative stain electron microscopy. Electron 
microscopy grid preparation and image acquisition were performed by 
Zhen Chen (graduate student in Kapoor Laboratory).  (A) Structure of 
dynapyrazole A. (B) Images from negative stain electron microscopy. 
GFP-dynein 1 was pre-incubated with dynapyrazole A (10µM), ATP 
(1mM), and sodium vanadate (1mM) before fixation. Top row: raw 
images of individual particles. Bottom row: vector pointing to each 
protrusion is emphasized in yellow. The angle between these two vectors 
is measured. (C) Histogram showing distribution of angles. q was
measured for > 1000 particles.  
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3.6 Discussion 
The work described in this chapter centers on the re-analysis of the structure of 
the dynapyrazoles. These compounds, in turn, were synthesized as part of an effort to 
create "locked" derivatives of the first cell-permeable dynein inhibitors, the ciliobrevins. 
In considering the fusion of isomerizable benzoylacrylonitrile scaffold of the ciliobrevins 
as a pyrazoloquinazolinone that could not isomerize, it was assumed that the spatial 
relationship between all four newly-formed rings (A-D, see figure 3.1B) was necessary 
for dynein inhibition. The results obtained in this chapter challenge this assumption and 
suggest instead that the cyanoaminopyrazole-cyclopropyl group-phenyl ring system (C-D 
rings in the dynapyrazole nomenclature) is essential for dynein binding and that structural 
variation is tolerated at the sites of the A and B rings. In combination with the previous 
findings for the dynapyrazole scaffold, I now find that two different heterocyclic 
scaffolds based on this cyanoaminopyrazole core have bioactivity consistent with dynein 
1 inhibition, as summarized in Figure 3.7. The biochemical and structural analyses 
performed for these compounds suggest that the mechanism of inhibition by these two 
compound classes are different. A caveat to the classification proposed in Figure 3.7 is 
that these trends have been established across a limited subset of compounds within a 
given structural class. Comparison of more compounds within each scaffold class would 
be required in order to better demarcate the boundaries between the two classes and the 
















Dynapyrazole A TDI 3016
-Hedgehog pathway inhibition
-Intraflagellar transport inhibition
-Lysosome motion inhibition 
-Cytotoxic
-ATPase inhibition to basal level
      (dynein 1 IC50 ~5µM)
-Microtubule gliding inhibition
      (dynein 1 and 2 IC50 ~3µM)
-EM: no effect on distribution of
 angles in ADP-V state.
-Hedgehog pathway inhibition
-Cytotoxic
-ATPase inhibition to near-zero
     (dynein 1)
-Microtubule gliding inhibition
      (dynein 1 IC50 ~2µM)
-EM: blocks ADP-V induced
 change in dynein structure.
Figure 3.9 Overview aminopyrazole-containing dynein inhibitors. 
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The set of bicyclic compounds similar to TDI 3016 inhibit the Hedgehog pathway 
and block dynein 1 and 2 in vitro in a number of assays, but show biochemical behavior 
separate from that of the dynapyrazoles. (Another compound with a similar bicyclic 
scaffold showed similar activity, see Appendix 3.2.) The most prominent difference 
between these compounds is their effect on the structure of dynein, as observed by 
negative stain electron microscopy. TDI 3016 caused the enzyme to be locked in an ADP 
or apo-like state in the presence of ATP and vanadate. In contrast, dynapyrazole A did 
not substantially alter the distribution of dynein geometries compared to the DMSO 
control in the ADP-vanadate state; experiments in other nucleotide states will be required 
to observe whether this compound alters dynein’s structure. Other biochemical assays 
were also consistent with different mechanisms of inhibition. For instance, while the 
dynapyrazoles inhibit the microtubule stimulated ATPase activity dynein to a residual 
activity of ~0.5s-1 and do not show substantial inhibition of the basal activity (at 
concentrations up to 40µM), TDI 3016 inhibits both the basal and microtubule-stimulated 
ATPase activity to nearly zero at high concentrations (e.g. 40µM). Furthermore, while 
the dynapyrazoles inhibit motility, ADP-vanadate dependent photocleavage, and 
microtubule-stimulated ATP hydrolysis at low-micromolar concentrations (~3-5µM), 
TDI 3016 more potently inhibited microtubule gliding than ATP hydrolysis or vanadate-
dependent photocleavage. Finally, dynapyrazole A did not significantly reduce 
microtubule binding in motility assays while TDI 3016 did. Taken together, these data 
suggest that TDI 3016 and dynapyrazoles both act at dynein 1's AAA1 site, but inhibit 
dynein by different mechanisms. Nucleotide occupancy at AAA1 is known to affect both 
dynein's microtubule affinity and its linker geometry(86), so it is possible that upon 
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binding of each of these compounds, dynein mimics a different nucleotide state (e.g. ATP 
bound vs. ADP bound). Further structural analyses are ongoing and will be valuable to 
elucidate the commonalities and differences between inhibition of dynein by 
dynapyrazoles and pyrazolopyrimidines such as TDI 3016. 
This effort would benefit especially from development of an assay that allows 
measurement of binding affinity between compounds and dynein. To date, all assays used 
to observe dynein inhibition in vitro have been activity-based: basal and microtubule-
stimulated ATPase activity, motility, and ADP-vanadate dependent photocleavage. These 
assays do not report directly on binding affinity and their outcome may be misleading—
e.g. failure of dynapyrazole A to inhibit the basal ATPase activity of dynein 1 could be 
taken to mean that dynapyrazole A does not substantially inhibit dynein unless multiple 
other assay types are performed. In contrast, a binding assay would measure a 
biophysical parameter that is less likely to report on the convolution of multiple 
biochemical and structural transitions. This would be particularly valuable in the case of 
dynein 2, an enzyme for which it has been difficult to identify conditions that lead to 
consistent microtubule stimulation, likely reflecting poor understanding of how to mimic 
the complex interplay between dynein 2, its cargo, any opposing motors, and the 
cellular/ciliary milieu in biochemical settings(129). With a readout of compound binding 
affinity, it would be possible to more confidently ascertain whether the different patterns 
of inhibition caused by the dynapyrazoles and TDI 3016 reflect bona fide differences in 
mechanism or, alternatively, reflect the combined effects of differences in affinity and 
solubility in the setting of a complex multi-site enzyme. 
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3.7 Materials and methods: 
Several experiments were performed as reported in Chapter 2. These include: 
protein purification, motility assays with recombinant GFP-dynein 1, ATPase assays, and 
ADP-vanadate dependent photocleaveage assays. 
Motility assays with bovine dynein: motility assays were performed essentially as 
described in Chapter 2, with the exception that bovine dynein was used and was 
immobilized directly on the glass coverslips, without the use of antbodies. Bovine dynein 
was the “sucrose fraction” from the preparation described by Bingham and 
colleagues(125), and was prepared by previous members of the Kapoor laboratory. 
Electron microscopy: GFP-dynein 1 protein was expressed in insect cells and purified as 
described previously (Chapter 2). Following elution from IgG sepharose beads, ~300µl 
aliquots were frozen in liquid nitrogen. On the day of electron microscopy experiments, 
one aliquot was thawed and subjected to size exclusion chromatography (Superose 6) 
using the following gel filtration buffer: 50 mM TrisHCl pH 8.0, 150mM KOAc, 2mM 
MgOAc, 1mM EGTA, 0.1mM DTT. The peak fraction was collected and diluted in gel 
filtration buffer; dilution factors were determined empirically at the outset of each grid 
preparation session. 20µl eactions were set up in Eppendorf tubes as follows. Protein and 
buffer were added, to an initial volume of 14µl. Next, 2µl buffer containing 5% DMSO 
(either control solvent or with appropriate compounds at 100µM) was added, the reaction 
mixed by pipetting up and down, and the reaction allowed to mix for 3 minutes. 2µl of 
ATP at 10mM in buffer was added, mixed by pipetting up and down, and the reaction 
allowed to mix for 3 minutes. Finally, 2µl sodium vanadate at 10mM in buffer was added 
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mixed by pipetting up and down, and the reaction allowed to mix for 3 minutes. Samples 
were then added to copper-coated grids (Part number, company). Grids were dried with 
filter paper, then stained by dipping in uranyl formate solution two times. Grids were 
washed two times with deionized water and then dried. Images were acquired using a 
Philips CM10 electron microscope. Grid preparation and image acquisition were 
performed by Zhen Chen. 
Image analysis was performed as follows: particles for which two protrusions 
could be observed extending from a central ring-shaped structure were selected using 
Boxer (EMAN)(130). Stacks of particles selected in this manner were analyzed manually 
using FIJI. The angle between the tip of one protrusion, the center of the ring and the tip 
of the other protrusion was measured using the Angle Tool. 
Work done by collaborators: 




Discovery of quinazoline-based dynein inhibitors 
Note to readers: screening library synthesis and assembly were performed by Tommaso 
Cupido (Postodoctoral fellow in the Kapoor Laboratory) while some ATPase assays were 
performed by Lola Yu (technician in the Kapoor Laboratory).  In the body of the text and 
in the methods section, I have noted contributions by others to this work where 
appropriate. I have also noted this information in the figure legends, where appropriate. 
Except for experiments credited explicitly to others, I performed all experiments and 
analysis. 
4.1 Introduction 
The discovery of new small-molecule ligands for proteins frequently relies on 
screening of large (often ~104) sets of small molecules in search of compounds that cause 
desired chemical or biochemical outcomes. The chances of success of such a high-
throughput screening campaign becomes likelier as library diversity and size 
increase(131). Indeed, many validated probes and clinical drugs have been developed 
following initial discovery via high-throughput screening(131). However, in the case of 
human cytoplasmic dynein 1, a large enzyme with a relatively low ATP hydrolysis rate 
(<1s-1), limited protein availability can restrict screening throughput. For instance, a 
protein preparation yielding 1mg of dynein (molecular weight 5x105) is sufficient for 800 
assay wells (assuming enzyme concentration of 100nM and assay volume of 25µl). Thus, 
a protein preparation larger than most routinely performed for recombinant human 
cytoplasmic dynein 1 is only sufficient to screen ~400 compounds (assuming assays are 
run in duplicate), making it operationally challenging to screen even modest size 
commercial screening libraries of 103-104 compounds.  
When screening large libraries is intractable, focused libraries enriched with 
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“privileged” scaffolds are a valuable alternative. This term was coined in 1988 to mean 
“a single molecular framework able to provide ligands for diverse receptors”(132). 
Screening libraries can be designed to incorporate only compounds with a desired 
chemical feature known to be privileged, which is expected to raise the screening hit 
rate(133, 134). Privileged features in compound libraries can include as a heterocycle or 
hydrogen-bonding motif already known to bind a certain protein type or cause a desired 
cellular phenotype. We focused our library on a set of 2,4-diaminoquinazolines 
chemically similar to DBeQ (N2,N4- dibenzylquinazoline-2,4-diamine), the first potent
small molecule antagonist of the AAA+ enzyme P97(75). We and others had identified 
this compound as an antagonist of other enzymes in the AAA+ enzyme family, including 
Vps4, RuvBL1(76), and spastin (Tommaso Cupido, manuscript in preparation). We 
hypothesized that a compound library composed of quinazolines with substitutions at the 
2- and 4-positions of the quinazoline core would be likely to contain antagonists ofhuman 
cytoplasmic dyneins 1 and 2. 
4.2 Results 
Screening plates were assembled containing compounds synthesized in-house 
following established procedures (compound synthesis and plate assembly was 
performed by Dr. Tommaso Cupido) as well as commercially-availiable compounds. 
Two compound plates with ~160 2,4-diaminoquinazolines were screened for inhibition of 
the basal ATPase activity of cytoplasmic dynein 1. The inter-replicate reproducibility 
values (r2) were 0.63 and 0.76 for plates one and two, respectively (See Table 4.1 and 
Chapter 4 Methods for other screening parameters). For dynein 1, plate 1, three 
compounds showed >30% inhibition at 10µM. Due to the low number of active 
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compounds identified in plate 1, a higher compound concentration (20µM) was used for 
the screen of plate 2. Six compounds on this plate inhibited dynein 1 by >50% at 20µM. 
A higher screening concentration (50µM) was used for dynein 2 against plate 1 and four 
compounds caused >40% inhibition at 50µM. 
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Table 4.1 Statistical parameters of screens for inhibitors of cytoplasmic dyneins. 




Figure 1: Structure-activity trends for 



















Analysis of the overall structure-activity relationship across the quinazolines on 
the two plates revealed a number of recurring motifs in the hit compounds that inhibited 
dynein 1 (Figure 4.1; full screening dataset is provided in Appendix 4.1). At the 2-
position of the quinazoline, aniline-like substitutions bearing electronegative groups at 
the 3-position were common among screening hits. Recurring groups at the quinazoline 
2-position included 6-aminoindoles, 3-hydroxy anilines, and 3-fluoroanilines. The 
piperazine moiety, both methylated and non-methylated at the distal amine was found in 
multiple screening hits. In contrast, because of the lower degree of variability at the 
quinazoline 4-position within the compounds screened, it was more difficult to describe a 
trend at this position. However, hits tended to have hydrophobic substituents at the 4-
position, including multiple hits containing a benzyl group (which was the most common 
4-position substituent within the screening library), as well as o-isopropyl-phenyl, and 
cycloheptyl. Other substituents at the 4-position of hit compounds included piperadyl, 
pyrrolidyl, and indazolyl moieties. Finally, almost all screening hits had unsubstituted 
quinazoline phenyl rings, although it should be noted that this was the most common 
quinazoline type within the screening collection. The only hit with a substituted 
quinazoline phenyl ring contained a fluorine substituent at the quinazoline 8-position (see 
below, TC183b). Of note, only one compound with a core hetererocycle that was not a 
quinazoline was identified as a hit for dynein 1: JNJ7706621, a compound which has 
shown inhibition of a number of other AAA+ enzymes (Appendix 4.2 shows measured 
IC50 values inhibition of other AAA+ enzymes by this compound). 
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Figure 4.2 Structure-activity trends for inhibitors of cytoplasmic dynein 2 
Figure 2: Screening hits for inhibitors of cytoplasmic dynein 2
N
N




















not hit in dynein 1 screen
Table 4.2 Analysis of inhibition of dynein 1 by diaminoquinazolines. Note: a subset of 
ATPase assay experiments summarized here were performed by L. Yu (technician in Kapoor 
Laboratory). ATPase assays were performed at 0.3mM ATP using the NADH-coupled 
enzyme assay system. IC50 values were obtaining by fitting dose-response data to a four-
parameter sigmoidal curve of the mathematical form: Y=Bottom + (Top-
Bottom)/(1+10^((LogIC50-X)*HillSlope)). All compounds shown were screening hits 
except TC 416, which was synthesized in the course of follow-up studies. TC 212 is a 
mixture of two isomers at position R2. 
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Of the four compounds that showed >40% inhibition of cytoplasmic dynein 2, 
two were also identified as hits in the screen of AAA plate 1 against cytoplasmic dynein 
1, while one, DBeQ, is a known antagonist of several other AAA+ ATPases (Figure 4.2). 
The fourth compound was excluded from further examination after routine LC/MS 
analysis to confirm compound identity and purity showed that the compound had 
degraded. 
Screening follow-up 
For the most active hits identified through screening assays, preliminary follow-
up consisted of performing 6-8 point dose-response curves for inhibition of dynein 1 
(some ATPase assays were performed by Lola Yu, technician in Kapoor Laboratory). 
Emphasis was placed on dynein 1 because, at the time of these experiments, this isoform 
was more readily available. These analyses are summarized in Table 4.2. Limited 
additional follow-up was also performed for dynein 2, which shall be described below. 
In the course of the dose-dependent analyses, TC 097 was identified as the most 
potent compound discovered in the screen, with an IC50 value of 7.0 ± 1.5µM (mean ± 
S.D., n = 6). This compound did not inhibit dynein 2 in screening assays (100% residual 
activity, range 90%-110%, n = 2). The rank ordering of IC50 values matched the activities 
observed across both screening plates. The modest potency of inhibition motivated the 
synthesis of more diaminoquinazoline derivatives, in search of dynein inhibitors with 
improved potency. Additionally, it was noted that inhibition by the diaminoquinazolines 
was more pronounced in the presence of 25-50mM ammonium sulfate, and that inhibition 




























Figure 4.3: Synthetic approach to 2,4-diaminoquinazolines
Figure 4.3 Synthetic approach to 2, 4-diaminoquinazolines 
Synthesis details are provided in Appendix 4.3. 
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Compound synthesis and evaluation 
A number of structure-activity relationship trends were evident from the screen of 
~160 2,4-diaminoquianzolines against dynein 1. I hypothesized that combining the 
features that tended to be found in active molecules would lead to compounds with 
improved potency. To test this hypothesis, I synthesized a focused set of 2,4-
diaminoquinazolines with combinations of substituents found among the most active 
screening hits. 
Figure 4.2 shows the synthetic approach used to synthesize 2,4-
diaminoquinazolines (full synthesis details are provided in appendix 4.3). The 4-position 
chlorine was first replaced by reaction with the desired R1-substituent amine at room 
temperature under basic conditions. The product, a 2-chloro, 4-aminoquinazoline, 
generally precipitated and could be recovered by filtration. The second substituent was 
appended by reaction of an R2-substituted amine with the 2-chloro, 4-aminoquinazoline 
intermediate in refluxing n-butanol. Products generally precipitated upon cooling or 
following addition of hexane to the reaction mixture. Though 2-piperazine-substituted 
compounds (such as TC 421, 423, 424 and 425) were an exception to this trend, these 
could also be purified without the need for column chromatography. This approach 
enabled synthesis of desired diaminoquinaozlines, with yields of ~1 - 80% over 2 steps 
from commercially-accessible starting materials. Compounds with alternative 
heterocyclic cores (eg. pyrido-pyrimidines, pyrazolo-pyrimidines, purines, and thieno-
pyrimidines) could also be synthesized in a similar fashion. 
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Following synthesis and chemical characterization, compounds were screened for 
inhibition of the ATPase activity of dynein 1. 27 of 28 compounds screened showed < 
50 % inhibition at or near 10µM (8µM was used for 4 of these compounds) and only 7 of 
28 compounds screened showed > 25% inhibition at 10µM. The only compound that 
caused >50% inhibition was TC416, a quinazoline with a 6-aminoindole substituent at 
the 2 position and a cumylamine substituent at the 4 position. This compound was 
analyzed in a dose-response format and had an IC50 value for inhibition of dynein 1 of 
7.16µM (7.15-7.18, n = 2, Table 4.2), which was comparable to TC085, the most closely-
related initial screening hit. As no diaminoquinazoline could be identified with improved 
potency relative to TC 097/ TC 085, these two screening hits were selected for further 
analysis. 
Motility assays 
To better understand the effect dynein inhibition by TC 097 and other 
diaminoquinazoline inhibitors, I turned to a microtubule motility assay. In this assay, 
dynein is immobilized on a microscope coverslide and ensembles of dynein molecules 
translocate microtubules in an ATP hydrolysis-dependent manner (Figure 4.4A). I first 
assessed the effect of TC 097 on microtubule motility driven by bovine dynein. This 
enzyme preparation contains the native dynein 1 heavy chain as well as 10-15 of 
accessory factors identifiable by SDS-PAGE and Coomassie staining (“sucrose 
fraction”)(125). Further purification of the semi-pure sucrose fraction dynein complex is 
possible, and yields dynein heavy chain with a minimal set of two to three accessory 
factors. However, because of the high yields and ready availability of the sucrose fraction, 
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this preparation was used to test whether diaminoquinazolines inhibit dynein-driven 
microtubule motility. 
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Figure 4.4 Analysis of effect of TC 097 on dynein-driven microtubule gliding. (A) 
Schematic of motility assay with bovine dynein. Dynein is directly immobilized on the 
coverslip. (B) Time-lapse montages of fluorescent microtubules moving on bovine 
dynein-coated glass slides in the presence of control solvent (2% DMSO), TC 097 
(50µM) or following washout of TC 097. (C) Mean  microtubule velocities in the 
presence of solvent control (2% DMSO), a range of TC 097 concentrations, or 
following washout. Values are given as mean ± range for n = 2 independent 
experiments. Motility assays were run at 0.3mM MgATP, with 0.5mg/ml casein. 
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Under control conditions, bovine dynein moved microtubules at an average 
velocity of 0.62 ± 0.06 µm/s (ATP = 2mM, mean ± S.D., n = 3, Figure 4.4B and 4.4C), 
which was comparable to the velocity observed for other preparations of mammalian 
brain dynein(24, 104). Addition of TC 097 (50µM) slowed the average microtubule 
velocity to 0.12 ± 0.02 µm/s (n = 3). Washout of the reaction chamber with buffer 
containing solvent control only (DMSO, 2%) followed by addition of control reaction 
mix containing microtubules, ATP, but no inhibitor, led to recovery of microtubule 
gliding velocity (0.47 µm/s, range: 0.43 - 0.52 µm/s, n = 2). Approximately 50% 
microtubule gliding inhibition was observed at an intermediate concentration of TC 097 
(15µM), while no inhibition was observed at a lower concentration (5µM, Figure 4.4C). 
Analysis of the mechanism of dynein inhibition by 2,4-diaminoquinazolines 
To determine which of dynein’s ATPase sites was inhibited by TC 097, I utilized 
a dynein construct with a mutation in its AAA3 site (Chapter 2). In this construct the 
Walker A lysine of this site, was replaced with alanine. This mutation is known to disrupt 
nucleotide binding within a given ATPase site, and similar mutations have previously 
been introduced in dyneins from other species to study the role of nucleotide binding at 
AAA3 on the mechanochemical properties of dynein (purification details and extended 
discussion can be found in chapter 2)(20, 89). TC097 inhibited both wild-type and AAA3 
mutant dynein enzymes with comparable potency (Figure 4.5A, IC50 for AAA3 mutant 
enzyme is 10.3 ± 2.3µM, n = 3, two tailed Student’s T-test with Welch’s correction for 
difference between mean IC50 values: P = 0.12). This finding is consistent with a common 






Figure 4.5 Analysis of the 
mechanism of inhibition of 
dynein by diaminoquinazolines. 
(A) Comparison of inhibiton of 
wild-type and AAA3 mutant His-
dynein by TC097. Assays were 
performed at 0.3mM MgATP in a 
steady state ATPase assay. Values 
are mean ± range for n ≥ 2 
independent experiments and were 
fit to a sigmoidal dose-response 
curve using Prism. IC50 values: 
wild-type His-dynein-8.5µM (8.4-
8.6, n = 2). AAA3 mutant His-
dynein-10.3µM (8.3-12.9, n = 3). 
(B) SDS-PAGE analysis 
(Coomassie blue) of dynein 1 
following irradiation with 
ultraviolet light at 365nm. 
Components of reaction loaded into 
each lane are noted above gel. 
Arrowheads indicate proteolysis 
products. (C) Analysis of gel band 
intensity for photocleavage 
reactions. Values are mean ± range. 
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Figure 4.6 Inhibition of dynein across a range of ATP concentrations. (A) Plot of 
His-dynein 1 ATPase activity across a range of ATP concentrations. Data are fit to the 
Michaelis-Menten model. (B) Same data as (A) but data are fit to a two active site 
model, whose mathematical expression is shown. For both (A) and (B), lower plot 
represents same data as upper plot, but X-axis values are shown on a logarithmic 
scale. ATPase rates were measured using a steady-state assay system in the absence of 
ammonium sulfate. (C) Plot of GFP-dynein 2 ATPase activity across a range of ATP 
concentrations. Data were fit to a two active site model, as in (B). ATPase rates were 
measured using a steady-state assay system in the presence (25mM) or absence of 
ammonium sulfate. (D) Effect of dynapyrazole A on the microtubule-stimulated 
ATPase activity of His-dynein 1 at three ATP concentrations. Rates were measured 
using a non-steady state radioactive ATPase assay and values were fit to a sigmoidal 
dose-response curve. All ATPase activity values are presented as mean ± range for n = 
2 experiments.   
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To further characterize the site of inhibition by 2,4-diaminoquinazolines, we 
examined the effect of the two most potent compounds on ADP-vanadate-dependent 
photocleavage of dynein 1. This assay has been used over decades of research into the 
biochemistry of dynein as a readout of nucleotide engagement in dynein’s AAA1 ATPase 
site(106). Briefly, when incubated in buffer containing ATP (or ADP) and vanadate, 
dynein binds to a covalent adduct formed by ADP and vanadate. Irradiation with 
ultraviolet light leads to oxidative photocleavage of dynein into two peptides that occurs 
at AAA1. When dynein 1 was incubated with solvent control (5% DMSO), 200µM ATP, 
and 20µM vanadate, 72% photocleavage was observed (69-76%, n = 2), and cleaved 
peptide masses were consistent with photolysis of dynein at AAA1 (Figure 4.5B and 
4.5C). Treatment with either TC085 or TC097 (25µM each) reduced photocleavage to 
26% (20-31%, n = 2) and 36% (33-38%, n = 2) respectively, suggesting that these 
compounds act by inhibiting nucleotide association with AAA1 of dynein. 
Diaminoquinazolines have been shown by others to be ATP-competitive 
inhibitors of AAA+ proteins(75), so I tested whether TC 097 inhibited dynein in an ATP-
competitive fashion. Using a steady state ATPase assay, I measured the ATPase activity 
of dynein 1 across a range of ATP concentrations (~10µM-8mM). In the solvent control, 
dynein ATPase activity ranged from ~0.3s-1 to ~2.5s-1 (Figure 4.6A and B). Two models 
were fit to the data: the Michaelis-Menten model (4.6A) and a 2-site binding model (with 
an expression given mathematically by the addition of two separate Michaelis-Menten 
expressions 4.6B). Comparison of these two models using the extra sum-of-squares F test, 
which corrects for the effect of additional fitting parameters, indicated that the data are 
better fit by a two binding site model (P < 0.0001, Figure 4.6A vs. 4.6B, data presented in 
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logarithmic scale, 4.6A and B, bottom panels). Fit to a two-site binding model revealed a 
high affinity binding site (Km, Hi: 14µM VMax, Hi: 1.0s-1) and a low-affinity binding site (Km,
Lo: >10,000µM VMax, Lo: 3.2s-1). Addition of TC097 (30µM) to the [ATP] versus ATPase 
activity titrations for dynein 1 decreased hydrolysis activity across the range of ATP 
concentrations tested, although it should be noted that decreases in ATPase activity were 
less pronounced than in previous dose-response analyses, likely as a result of the 
omission of ammonium sulfate from these titrations. Data were again better fit by a two-
site binding model (P = 0.0001). 
A similar trend was observed for ATP titrations with dynein 2: activity trends 
were consistent with two binding sites with Km values separated by >2 orders of 
magnitude. For dynein 2 it was further noted that addition of ammonium sulfate 
(~25mM) to the ATPase assay shifted the Km of the high affinity ATPase site by ~10-fold 
without shifting the apparent Vmax, Hi (4.6C). Finally, to establish a basis for comparison, 
the effect of dynapyrazole A on dynein’s microtubule-stimulated ATPase activities was 
measured at three ATP concentrations (Figure 4.6D, 62.5µM, 250µM, and 1000µM). 
Inhibition was partial at the highest dynapyrazole A concentration tested (40µM), as had 
been previously noted. Fitting to the residual ATPase activities revealed that IC50 values 
for inhibition were 3.8µM (1.9-5.7), 3.0µM (2.8-3.3), and 5.5µM (5.1-6.0) at 62.5µM, 
250µM, and 1000µM, respectively (mean and range, n = 2). Thus, a clear trend toward 
decreased inhibition was not observed as ATP concentrations increased, although the 










































Figure 4.7 Comparison of the effect of TC 085 on the ATPase activities of dynein 
1 and dynein 2. Note: a subset of the ATPase assays shown in this figure were 
performed by L. Yu (technician in the Kapoor Laboratory). The ATPase activities of 
His-dynein 1 and GFP-dynein 2 were measured in the presence of TC 085 (0.5-
125µM) using a steady-state ATPase assay in the presence of 25mM ammonium 
sulfate.  Values represent mean ± S.D. of n ≥ 3 separate experiments. Data were fit to 
a sigmoidal dose-response curve using Prism. 
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Inhibition of dynein 2 
To characterize the effect of diaminoquinazolines on dynein 2, dose-response 
assays were performed with TC085, one of the three hit compounds for this isoform. This 
compound reduced dynein 2 ATPase activity by ~48% at the highest dose tested (125µM, 
Figure 4.7). When the dose-response data were fit to a sigmoidal curve with lower 
plateau allowed to float freely, an IC50 value of 8.0µM was obtained. The difference 
between residual activities of dynein 1 and dynein 2 at the highest compound 
concentration tested was statistically significant (P = 0.007). Further analysis will be 
required to understand why the effect of TC085 inhibits these two dynein isoforms with 
comparable IC50s but with different residual activities at high compound concentrations. 
4.3 Discussion 
In this chapter I report the results of a screen of a focused library of ~160 
diaminoquinazoline-based compounds for inhibitors of the basal ATPase activity of 
cytoplasmic dynein 1. Of the compounds screened, two were validated as dynein 
inhibitors with IC50 values at or below 10µM and activity across two or more 
complementary biochemical assays of dynein inhibition. Three other compounds 
identified through the screen inhibited dynein 1 with IC50 values below 40µM. Thus, 
defining a “hit” as a compound that can be starting point for further chemical inhibitor 
optimization, the hit rate for this assay was ~3%, well above the hit rate expected for 
conventional high-throughput screening of a large compound library(0.1-1%)(135). This 
can be interpreted as evidence in support of the hypothesis that diaminoquinazolines are a 
privileged scaffold for inhibition of enzymes in the AAA+ protein family. 
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Although the privileged scaffold-based approach to dynein inhibitor discovery has 
shown early promise, much additional work lies ahead. Further development of any 
diaminoquinazoline as a probe for dynein 1 will likely require careful counter-screening 
against other AAA+ proteins to exclude compounds that inhibit multiple enzymes in the 
family. I note that diaminoquinazoline analogs generated based on the structure-activity 
data arising from this screen did not yield any compounds with improved potency. 
However, these synthetic efforts were limited (<30 compounds). It is probable that more 
extensive analog synthesis efforts with TC 097/085 as starting points can lead to more 
potent inhibitors. This is especially true if additional structural and biochemical data can 
be integrated into the iterative process of design, synthesis, and testing. 
Two lines of evidence support a model in which TC097 and TC085 inhibit the 
ATP hydrolysis at AAA1 of dynein 1. First, these compounds block ADP-vanadate 
dependent photocleavage of dynein, suggesting they disrupt nucleotide binding at AAA1. 
Second, they block the ATP hydrolysis of the AAA3 walker A lysine-to-alanine mutant, 
a construct whose ATPase activity is expected to arise mostly from AAA1. 
If both the dynapyrazoles and the diaminoquinazolines act at AAA1, then why do 
dynapyrazoles show modest inhibition of the basal ATPase rate of dynein (~30%) while 
the diaminoquinazolines show near >80% inhibition? One explanation may be that the 
conditions under which these assays were performed were different: the dynapyrazoles 
were tested in a radioactive ATPase assay while the diaminoquinazolines were tested in a 
steady-state ATPase assay containing a coupled-enzyme system and high concentrations 
of ammonium sulfate (25-50mM). When TC 097 was tested in an otherwise-similar 
buffer without ammonium sulfate, the degree of inhibition at ~30µM TC097 was reduced 
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from ~80% (25mM ammonium sulfate, see Figure 4.5A) to ~35% (0 ammonium sulfate, 
see Figure 4.6A/B, note concentrations in the 0.1-1mM ATP range). I propose that 
ammonium sulfate may modulate the basal activity of dynein, raising the relative 
contribution of AAA1 to the basal hydrolysis. This could be due to the sulfate anion, 
which can mimic phosphate, inhibiting the AAA3 site via product inhibition. Direct 
evidence of the diaminoquinazoline binding site (eg. via structural or crosslinking-and-
proteomics approaches) will be critical to fully understand the mechanism of inhibition of 
these compounds. 
Another question raised by the mechanistic analysis of diaminoquinazoline 
inhibition is whether these compounds can be said to be ATP-competitive. In the well-
established model of substrate competitive enzyme inhibition for single-site enzymes, 
such an inhibitior would be expected to shift the enzyme’s Km without affecting its Vmax. 
IC50 values would be expected to increase with increasing substrate concentration. When 
ATP titration data in the presence and absence of compound are fit to the Michaelis-
Menten model for a single site enzyme, TC 097 appears to be simply ATP competitive, 
with 30µM TC097 raising the Km from ~100µM to ~500µM without significantly altering 
the Vmax. However, the data do not appear to be well-fit by the Michaelis-Menten 
expression, and are better fit by a two-site model. When this model is applied, the 
inhibition pattern is less clear, with TC 097 causing changes to the Km and Vmax of both 
high- and low-affinity sites. In comparison, ammonium sulfate causes a ~10 fold decrease 
in the Km, hi of dynein 2, without shifting the Vmax, hi or either Km or Vmax of the low-affinity 
site (see figure 4.6 C). These data suggest that some compounds do cause “simple” 
substrate competitive inhibition (analogous to what would be expected from interaction 
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with a single-site enzyme) in the setting of dynein’s two active sites. However when the 
two-site model is considered, both TC097 and dynapyrazole A do not show ATP-
competitive patterns of inhibition, despite both blocking ADP-vanadate photocleavage, 
consistent with disruption of nucleotide binding at AAA1. It is possible that the complex 
allosteric regulation of AAA1 by other ATPase sites on dynein, which has been 
demonstrated by multiple other groups(88, 89), obscures ATP competition with inhibitor 
binding as nucleotide concentrations are titrated up. However, the possibility of other 
non-nucleotide competitive mechanisms of inhibition for both diaminoquinazolines and 
dynapyrazoles has not been rigorously excluded. 
A longstanding goal has been to develop isoform-selective dynein 2 inhibitors. 
Although this screen and subsequent biochemical characterization did not yield any 
compounds fitting this profile, they did uncover three dynein 2 antagonists and principles 
that could raise the chance of success in the future. Dose-response analysis for one of 
these compounds, TC 085, revealed a plateau of ~50% inhibition that was not exceeded 
up to the limit of compound solubility (~125µM). Taking this non-zero residual activity 
into account, the IC50 of TC 085 was found to be similar between dynein 1 and dynein 2 
(8µM). One plausible explanation for this is that the high affinity ATPase site identified 
for dynein 2 (for which the measured Km is ~200nM in the absence of ammonium sulfate 
and 8µM at 25mM ammonium sulfate) may contribute a larger fraction of overall 
ATPase activity than the comparable site on dynein 1 at the ATP concentration at which 
dose-response assays were conducted (300µM). It is likely that screens can be adapted to 
capitalize on the apparent two-site nature of dynein 2. For instance, more screening hits 
might be expected, counterintuitively, by performing screening assays at higher [ATP]. 
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This is because as a larger fraction of ATPase activity would be expected to come from 
the low-affinity site, and it is more likely to identify compounds that can compete with 
binding at a site with ATP affinity >1mM than at a site with ATP affinity <1µM. Finally, 
the finding that TC 097 shows dynein 1 selective inhibition while TC 085 inhibits both 
dyneins 1 and 2 with similar potency suggests that the binding sites on each enzyme for 
diaminoquinazolines have slightly different structure-activity-relationship landscapes. 
These differences can be likely be exploited through an iterative process of analog 
synthesis and isoform selectivity testing. 
4.4 Methods 
Library assembly: ~200 compounds were synthesized or purchased from commercial 
sources and arrayed in two 384-well plates at stock concentrations of 5, 1, and 0.2mM. 
Compound synthesis and plate assembly were performed by Dr. Tommaso Cupido. 
Compound identities and their locations on screening plates are presented in Appendix 
4.1. 
Protein purification: Wild-type and AAA3 mutant His-dynein 1, motor domain 
constructs of wild-type human dynein 1 with hexahistidine tags at their N-termini, were 
purified as described in previous chapters (chapter 2). Bovine brain dynein was purified 
by previous members of the Kapoor laboratory following the procedure of Bingham et 
al(125). 
ATPase assays 
Screens and follow-up ATPase assays were performed using an NADH-coupled 
assay system. 
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The ATPase activity of each of dynein 1 or dynein 2 was measured using an 
NADH-coupled assay in which ATP was regenerated and kept at a constant concentration 
with concomitant oxidation of NADH to NAD+. NADH fluorescence was monitored and 
its rate was an indirect readout of ATP hydrolysis. Assays were performed with final 
NADH-coupled assay components as follows: pyruvate kinase (Sigma Aldrich cat. P1506 
for reactions with ammonium sulfate, P9136 for reactions without ammonium sulfate) 5 
U/ml, lactate dehydrogenase (Sigma Aldrich cat. L1254) 5U/ml, potassium 
phosphoneolpyruvate 0.8 - 1mM, disodium nicotinamide adenine dinucleotide (Sigma 
Aldrich, N7140) 150 – 210 µM. 
Final reaction mixes contained 50-150nM dynein 1 or 25-50nM dynein 2. The 
buffer composition was: 25mM PIPES pH7, 30mM KCl, 1mM EGTA, 5mM MgCl2, 
0.01% triton-X-100, 1mM DTT. Because pyruvate kinase was obtained as a suspension 
in 3.2M ammonium sulfate, final concentrations of ammonium sulfate were 25mM 
(except for reactions shown in Figure 4.6, which for which an alternative pyruvate kinase 
source was used). Reaction mixes all contained bovine serum albumin at 0.1mg/ml and 
MgATP at 0.3mM (or variable ATP for reactions shown in 4.6), 2% (v/v) DMSO in the 
presence or absence of test compounds. NADH fluorescence was measured at 10-45 
second intervals over a 20-30 minute time course using a synergy NEO microplate reader. 
The rate of NADH consumption was determined from a linear regression of the NADH 
fluorescence data. The rate of NADH consumption was used as a measure of ATP 
hydrolysis activity and was converted to ATPase rate using conversion factors 
determined from analysis of the decrease in NADH fluorescence caused by addition of 
known amounts of ADP. 
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Screening was performed using the above-described ATPase assay conditions, but 
buffers and compounds were dispensed using automated robotics, with the assistance of 
staff at the High Throughput Resource Center (Rockefeller University). For each plate 
screened, eight wells were used as solvent (un-inhibited) controls and eight wells were 
used as no-enzyme controls. Screening data is presented in Appendix 4.1. 
ATPase assays for dynapyrazole A were performed as described in Chapter 2. 
Calculation of Z': Z’, a measure of the effect size within a screening assay, was 
calculated as follows: 
Z’ = 1- [3*(s.d.no-inhibitor + s.d.no enzyme)/(meanno-inhibitor - meanno enzyme)] 
Conditions were optimized such that Z’ values were > 0.5. 
Assays performed as described in previous chapters: ADP-vanadate dependent 
photocleavage assays and bovine dynein-driven motility assays were performed 
essentially as described in previous chapters. 
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Chapter 5: 
Conclusion and outlook—toward chemical genetics of dynein 
5.1 Dynein inhibitor trends 
Reviewing the data for the three classes of dynein antagonists disclosed in this 
work within in the context of the four dynein antagonists described previously by others 
(vanadate(11, 12), EHNA(21, 22), ciliobrevins(46), and tolyl-ether substituted-
ciliobrevins(47)) can help illuminate general features and underlying principles relevant 
to dynein inhibition (data summarized in Table 5.1). In vitro IC50 values for dynein 
inhibition ranged from ~1µM (vanadate) to >200µM (EHNA), but using these values to 
compare inhibitors is complicated by the variable conditions and under which inhibition 
was measured and the different dynein sources used. A Ki value was only estimated for 
one of these dynein antagonists (EHNA, ~74µM)(22).  
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ATP competition)
TC 097
(this work) ~8µM dynein 1 ATPase inhibition No data
Site: AAA1 

















































Table 5.1 Analysis of dynein inhibitors in the literature and in this work. 
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With regard to the mechanism of inhibiton, nucleotide-competitive inhibition 
consistent with the Cheng-Prusoff relationship was not observed for any of the 
compounds, with the exception of ciliobrevin D(46, 136). The un-competitive mechanism 
of inhibition for vanadate may be explained by a requirement for ADP to be bound in the 
AAA1 site before vanadate binding can occur(11). Vanadate is known to inhibit dynein 
via formation of an ADP-vanadate adduct that mimics the transition state of ATP 
hydrolysis at AAA1 of dynein(17). However, the absence of substrate-competitive 
inhibition noted for the other dynein antagonists is surprising in light of two previous 
observations. First EHNA inhibits another enzyme (adenosine deaminase) in a substrate-
competitive manner(137), in line with what might be anticipated for a compound that 
contains the adenine nucleobase. Second, diaminoquinazolines have been shown to be 
ATP-competitive inhibitors of AAA+ ATPases(75). It is possible that multiple 
compounds with known substrate-competitive mechanisms (for other enzymes) bind 
dynein at allosteric sites distant from dynein’s nucleotide binding pockets, and only direct 
binding site identification (see below) will be able to conclusively exclude this alternative. 
However, taking all the available mechanistic data together, I propose that in the case of 
dynein, apparently non-ATP-competitive inhibition may occur even when the mechanism 
involves inhibitor binding at the nucleotide binding site. This may be a feature of dynein, 
a multi-active-site enzyme whose ATPase sites can regulate one another’s activity(88, 
89), and potentially other enzymes like it. 
Across the seven dynein inhibitors in Table 5.1, the site of binding is only known 
conclusively for one compound, vanadate, for which x-ray crystallography and 
complementary biochemical evidence indicate binding to AAA1(17, 20). Biochemical 
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data including experiments comparing basal and microtubule-stimulated hydrolysis, 
analyses of inhibition of mutant dynein enzymes, and ADP-vanadate photocleavage 
assays suggest that four other compounds (ciliobrevins, dynapyrazoles, TDI-3016 and its 
relatives, and diaminoquinazolines), also act by inhibiting AAA1. This is consistent with, 
but does not guarantee binding to AAA1. Data for EHNA and tolyl-ether substituted 
ciliovrevins do not support assignment of a site of inhibition. 
Why is inhibition at AAA1 a common feature of dynein inhibitors characterized 
to date? Two explanations seem most plausible. 
First, AAA1 may be the only site with low enough ATP affinity to be readily 
inhibited. Several lines of evidence support this suggestion. Nucleotide binding at both 
AAA1 and AAA3 has been shown to be required for dynein 1 activity(20). Some 
analyses (including those shown in Chapter 4) are consistent with those two sites having 
nucleotide affinities separated by ~2 orders of magnitude(115), although other analyses 
have not found such behavior(104, 105), and affinities have not been conclusively 
assigned to either site. It has also been proposed that tight binding to ADP is required for 
full dynein activity(138). More recent analyses using yeast dyneins have made clear that 
the presence of ADP in AAA3 is required for dynein to undergo a productive 
chemomechanical cycle(88) and have further shown that binding of ADP to AAA3 can 
persist through multiple (~20) cycles of ATP hydrolysis at AAA1(89), implying 
relatively slow release of ADP from AAA3 compared to AAA1. The slow release of 
ADP may drive high nucleotide affinity at AAA3 (Kd = Koff/Kon).  AllFrom the 
perspective of inhibitor identification, tight binding of either ATP or ADP to AAA3, 
would make finding an antagonist of this site within a collection of screening compounds 
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considerably less likely than identifying one that blocks a site with 20-1000-fold lower 
nucleotide affinity. 
A second explanation for why dynein inhibitors discovered to date tend to inhibit 
AAA1 is that when AAA1 is blocked the effect is easy to appreciate—dynein driven 
motion stops—and that the effect of AAA3 inhibition is likely to be more nuanced. 
Perturbations at AAA3 have been analyzed by multiple research groups across different 
biochemical assay systems. Replacement of the AAA3 Walker A lysine with threonine 
slowed dynein driven motility but did not affect ADP-vanadate dependent photocleavage 
at AAA1 and, unexpectedly, potentiated photocleavage at AAA4(20). Mutation of the 
same residue to alanine increased dynein’s basal ATPase activity (116)(Chapter 2). While 
this mutation slowed dynein motion, the velocity recovered as salt concentrations were 
raised to physiologic levels(89). In the course of the same analysis, the slowly-
hydrolyzable nucleotide mimetic was shown to inhibit AAA3 and to be hydrolyzed by 
AAA1 at ~1/4 the rate of ATP hydrolysis. Analysis of processive dynein motion revealed 
that AAA3 inhibition by ATPgS caused an increase in the likelihood of pausing, and only
partially slowed running velocities between pauses(89). Taking these biochemical 
observations together, it is clear that inhibitor binding at AAA3 could cause biochemical 
effects that do not, at first pass, appear to be inhibition, such as activation of dynein’s 
basal ATPase activity. While the effect on simpler assays of dynein activity (eg. ATPase, 
ADP-vanadate photocleavage) may be difficult to discern,  inhibition of dynein at AAA3 
would be expected to cause a measureable effect on the processive motility of the human 
dynein holo-complex, as was noted in the analysis of disease-causing mutations occurring 
outside of AAA1(139). Assaying processive motility of human dynein is technically 
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complex and not likely to be a viable approach to inhibitor discovery. Despite the 
biochemical nuances surrounding AAA3 inhibition, a compound that blocks activity of 
this site is likely to disrupt dynein function in cells(107). Researchers performing 
phenotype-based screens for compounds that inhibit dynein would do well to remember 
the complexities associated with AAA3 inhibition before discarding a compound with 
promising cellular activity that does not cause straightforward effects when tested for 
dynein inhibition in vitro. 
5.2 Future directions 
In the following section, I propose a few lines of research that may help address 
the open questions arising from the work described in this thesis, and in doing so, could 
improve the utility of known dynein inhibitors and spur advances toward development of 
new inhibitors. 
In the short term, carefully sorting out the differences in the effect of inhibition by 
dynapyrazoles and pyrazolopyrimdinone-based derivatives such as TDI 3016 is a top 
priority. TDI 3016 causes dynein 1 to adopt a post-powerstroke state even in the presence 
of ADP-vanadate while dynapyrazole does not. As a next step, the effect of these 
compounds should be tested in other nucleotide states. Is the apo-like state induced by 
TDI 3016 maintained in the absence of nucleotide? Can a nucleotide state be found in 
which the dynapyrazole changes dynein geometry relative to the DMSO control? One 
possibility is that, in the nucleotide-free state, where a small angle is expected between 
the microtubule binding domain and the linker, dynapyrazole A treatment might dynein 
to adopt a geometry with a large q. In parallel, it will be valuable to assess if TDI 3016
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and dynapyrazole A affect dynein’s affinity for microtubules using an assay that more 
robustly measures this interaction—as multiple factors can confound the interpretation of 
the number of microtubules bound to the coverslip in microtubule gliding assays. If the 
compounds do indeed cause different effects on dynein’s affinity to microtubules, it 
would be tantalizing to dissect the cellular effects of compounds acting with these two 
separate mechanisms. 
Conclusively identifying the binding site of either dynapyrazoles or TDI 3016 
will help clarify the mechanistic distinctions between these two compound classes. While 
present data are consistent with inhibition occurring at AAA1, it is not certain that either 
compound binds within the ATP binding site or even in this domain. Incorporating 
binding site information with available structural information, and modeling techniques, 
it may be possible to develop an accurate model that could then be refined using 
structure-activity data, and directed mutagenesis. One of the most direct approaches to 
identifying the binding site of dynein inhibitors is to covalently bind a compound to 
dynein, proteolytically digest the enzyme, the and then to “fish” the peptide-compound 
adduct out of the resulting complex mixture of peptides using affinity precipitation and/or 
proteomic deconvolution approaches(140). Generally, the disadvantage of binding site 
identification via formation of a covalent bond followed by proteomic analysis is the 
requirement that a compound be modified with both a reactive group and a chemical 
handle for affinity tagging (often diazirines and alkynes, respectively) while retaining the 
bioactivity of the parental compound(140). Identifying and synthesizing active 
compounds with the appropriate groups can often be limiting and can require extensive 
structure-activity relationship data. Fortunately, the structure-activity data already in hand 
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suggest that such could be identified using TDI 3148, which contains an alkyne and has 
comparable activity to TDI 3016 in terms of Hedgehog pathway inhibition, as a starting 













possible compounds to use 









Figure 5.1 Proposed compounds to use for binding site identification using proteomic 
approaches. TDI 3148 inhibits Hedgehog pathway activity and is structurally related to TDI 
3016. Compounds in box are proposed based on established structure-activity relationships. 
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A valuable step beyond locating the dynapyrazole/TDI 3016 binding site on 
dynein will be to identify mutations that confer resistance to compound binding. Ideally, 
this mutation should be "silent" in that it blocks compound binding to dynein but does not 
otherwise affect dynein’s function. Resistance-conferring mutations have been identified 
using structural(141), genetic (e.g. analysis of sequence conservation across enzyme 
families)(142), and selection-based approaches(42, 143). In the case of dynein, where 
structural data regarding compound binding are still lacking and the putative compound 
binding site (AAA1) is conserved (see Chapter 1 Figure 1 and Appendix 2.1, Figure 6-5), 
selection-based approaches to identifying resistance mutations are the most promising. If 
a resistance-conferring mutation can be shown to decrease compound binding to a given 
target in vitro and insertion of that mutation into an otherwise-sensitive cell line blocks 
the effect of compound treatment, then the mutation has been shown to be sufficient for 
resistance and the compound’s effect can be confidently assigned as due to binding of the 
sensitive enzyme. In the case of dynein, identification of a resistance-conferring mutation 
could be used to distinguish whether the cytotoxicity observed at high concentrations of 
dynapyrazole A (eg. 15µM, 3 hour treatment, see Chapter 2) is due to dynein inhibition 
or engagement of another target. If treatment of cells expressing the resistant dynein 
allele with dynapyrazole A does not cause cytotoxicity, then the toxicity would be 
understood to be a consequence of dynein inhibition. This approach has been referred to 
as the “gold standard” for validation of physiologic target engagement by a small 
molecule inhibitor(79, 144). 
Finally, it will be valuable to continue exploring the chemical space surrounding 
the dynapyrazole and TDI 3016 scaffolds. Doing so may help to identify compounds with 
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improved potency or solubility. Increased potency and solubility will, in turn decrease the 
likelihood that compound activity is reduced in the presence of high protein 
concentrations (i.e. in cell culture conditions with 10% serum), which at present is a 
major limitation for both compound classes. Progress toward any of the four interlocking 
goals described above will solidify the foundation necessary to use these compounds to 
study dynein with precision, and, will constitute progress toward the ultimate goal of 




Appendix 2.1: Supplemental figures associated with chapter 
2— Chemical structure-guided design of dynapyrazoles, potent 
cell-permeable dynein inhibitors with a unique mode of action 
Figure 1 Figure Supplement 1: 1H NMR spectrum of ciliobrevin D. NMR taken on a 
600 MHz instrument, DMSO-d6. (A) Full spectrum. (B) Enlarged view of the aromatic 
region. (C) Enlarged view highlighting peak at 13.5 ppm. 
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Figure 3 Figure Supplement 1: Microtubule velocity distribution histograms for dynein-
2 driven motion in the presence of different concentrations of 8. At least 36 microtubules 








Figure 4 Figure Supplement 1: Analysis of intraflagellar transport following 10-minute 
exposure to dynapyrazole-A. (A) Velocity distribution histograms showing anterograde 
and retrograde velocities in the solvent control (0.3% DMSO) and in the presence of 5µM 
8 (B) at 10 minutes after treatment. (C) Analysis of intraflagellar transport particle 
frequencies. Data analysis (Va, anterograde velocity, nm/s; Vr, retrograde velocity, nm/s; 
Fa, anterograde frequency, counts/minute; Fr, retrograde frequency, counts/minute; values 
are mean ± S.D. Na, number of anterograde particles analyzed; Nr, number of retrograde 
particles analyzed; C, number of cilia analyzed). DMSO, Va 655 ± 124, Vr 354 ± 134, Fa 
10.2 ± 3, Fr 5.9 ± 3, Na, 276; Nr 145, C 18; 5µM 8, Va 572 ± 121, Vr 202 ± 180, Fa 6.9 ± 4, 




Figure 4 Figure Supplement 2:  Analysis of intraflagellar transport at higher 
dynapyrazole-A concentrations. (A) Still images from time-lapse series and associated 
kymographs showing motion of mNeonGreen-IFT88-containing particles in 
representative primary cilia treated with 10µM 8. Still image scale bar, 3µm; interval 
between frames, 0.5 seconds. Kymograph horizontal scale bar, 10 seconds; vertical scale 
is identical to cilium image. (B) Velocity distribution histograms for anterograde and 
retrograde motion. (C) Analysis of particle frequency in the presence of 10µM 8. Data 
analysis (Va, anterograde velocity, nm/s; Vr, retrograde velocity, nm/s; Fa, anterograde 
frequency, counts/minute; Fr, retrograde frequency, counts/minute; values are mean ± 
S.D. Na, number of anterograde particles analyzed; Nr, number of retrograde particles 
analyzed; C, number of cilia analyzed). 10µM 8, Va 466 ± 183, Vr 121 ± 78, Fa 6.8 ± 4, Fr 
4.0 ± 2, Na 143, Nr 85, C 21. 
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Figure 4 Figure Supplement 3: The effect of serum concentration on washout of 
dynapyrazole-A in intraflagellar transport assays. (A) mNeonGreen-IFT88 particle 
velocities following washout of dynapyrazole-A for 1 hour in media with either low 
serum (0.2% FBS) or high serum (10% FBS). (B) Particle frequencies following low-
serum and high-serum washout. Reference values for solvent control (0.3% DMSO) and 
inhibited/pre wash-out (5µM 8) states are shown as checked bars in both (A and B). 
These values are also shown in Figure 4F and 4G, respectively, and are included here for 
reference. Bars represent mean ± S.D. Data analysis (Va, anterograde velocity, nm/s; Vr, 
retrograde velocity, nm/s; Fa, anterograde frequency, counts/minute; Fr, retrograde 
frequency, counts/minute; values are mean ± S.D. Na, number of anterograde particles 
analyzed; Nr, number of retrograde particles analyzed; C, number of cilia analyzed). 0.2% 
FBS washout, Va 620 ± 134, Vr 219 ± 117, Fa 10.1 ± 4, Fr 5.2 ± 2, Na 111, Nr 57, C 11. 












Figure 5 Figure Supplement 1:  Microtubule velocity distribution histograms for 
dynein-1 driven motion associated with different concentrations of 8. At least 88 






















Figure 5 Figure Supplement 2:  Analysis of the number of microtubules associated with 
coverslips in microtubule gliding assays. (A, B) Images from time-lapse movies of 
microtubule motility driven by GFP-dynein 2 (A) or GFP-dynein 1 (B) at 1 mM MgATP. 
Scale bar, 10 µm. (C) Quantification of microtubule number. Each data point represents 
the average count of microtubules in 4 fields of view in a single independent experiment.  








Figure 5 Figure Supplement 3: Reversibility of inhibition by 8. The GFP-dynein 1 and 
GFP-dynein 2 motility assays were conducted at 1mM ATP and 0.05mg/ml casein. 
Chambers exposed to inhibitor (5µM 8) were imaged and then buffer A (see motility 
methods) supplemented with 1mM ATP was flowed into the chamber, followed by a one 
minute incubation. This process was repeated twice and then reaction mix containing 2% 
DMSO and 1mM ATP was flowed into the chamber using ~4 chamber volumes and the 
chambers were then sealed. Time-lapse movies of the washout condition were taken 10-
15 minutes after last addition of reaction mix. Data shown reflect average of n = 3 





Figure 5 Figure Supplement 3: Analysis of the effect of blocking agent on inhibition. 
The GFP-dynein 1 motility assay was conducted at 1mM ATP in a reaction mix 
containing 0.5 mg/ml casein. Mean data from 3 experiments are shown (± S.D). In the 
presence of 0.5mg/ml casein, the IC50 was 10.5 ± 4.6 µM (n = 3, mean of 3 separate IC50 
fits, ±  S.D.). Curves shown represent fit to average value for a given compound 
concentration. The curve shown in grey reflects the same data as used in Figure 5D (IC50 
= 2.3 µM). 
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Figure 5 Figure Supplement 5: Analysis of the effect of dynapyrazole-A on 
intracellular ATP concentrations. IMCD3 cells incubated in either low-serum (A-0.2% 
FBS) or serum-free (B) media were treated with dynapyrazole-A (5µM, 15µM) over the 
course of 3 hours. Cellular ATP content was measured using the CellTiter-glo assay 

















Figure 6 Figure Supplement 1: Mass spectrometry-based analysis of wild-type His-
dynein 1. Protein sample was run on an SDS-PAGE gel. The largest band at >350KDa 
and a minor band (indicated with triangles in Figure 6B) were excised from a gel 
separately and analyzed. Peptides identified by mass spectrometry are indicated (green 
bars, schematic generated using Proteome Discoverer 1.4, Thermo Scientific). Common 
contaminants are excluded (e.g. trypsin, keratin).  The minor band was also identified as 






Figure 6 Figure Supplement 2: Dose-dependent inhibition of microtubule-stimulated 
His-dynein 1 ATPase activity by ciliobrevin D (2.5 µM microtubules). Data are presented 
as mean ± range, n ≥ 2.  
Figure 6 Figure Supplement 3: Purification and testing of His-dynein 1 with Walker A 
mutation in AAA1. Gel filtration trace (Superose 6) for His-dynein 1 with K1912A 
(AAA1 Walker A lysine to alanine), with volume at elution peak indicated. SDS-PAGE 
analysis (Coomassie stain) of this protein, ~0.5 µg protein loaded. Vo, void volume. The 
ATPase activity for this enzyme was measured as 0.05-0.1s-1, and was < 2x above 
background hydrolysis in the absence of enzyme.  
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Figure 6 Figure Supplement 4: Mass spectrometry-based analysis of His-dynein 1 with 
Walker A mutation in AAA3. Protein samples of wild-type and mutant (K2601A, AAA3 
Walker A lysine to alanine) were run in separate lanes of an SDS-PAGE gel. Gel bands 
for each protein were excised, trypsinized, and peptides allowing for the differentiation 
of dynein 1 wild-type and mutant (all in the Walker A region) as were peptides that could 
serve as a loading control were targeted in a parallel reaction monitoring experiment(145). 
Data were analyzed using Skyline(146) combined with ProteomeDiscoverer 1.4 (Thermo 
Fisher) and Mascot (Matrix Science). For each protein, peptide counts for the peptides 
GPPGSGATMTLFSALR, GPPGSGK, and TMTLFSALR, were divided by the sum of 
counts for all three peptides and this value is presented below. GPPGSGATMLFSALR 
peptide is expected in the AAA3 mutant while GPPGSGK and TMTLFSALR are 
expected in the wild-type enzyme.  
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Figure 6 Figure Supplement 5: Sequence analysis of human cytoplasmic dynein 
isoforms 1 and 2. Alignments were performed using the ClustalW algorithm for the 
following protein fragments: (A) human dynein 1 AAA1 (T1882-Y2193) and human 
dynein 1 AAA3 (T2571-L2911) (B) human dynein 1 AAA1 (T1882-Y2193) and human 
dynein 2 AAA1 (T1665-I1954). Residues in in black boxes are identical across isoforms. 
Red stars denote residues < 4Å from the nucleotide (ADP-Vanadate) in AAA1 of human 
dynein 2 (PDB 4RH7). Some residues within this 4Å shell are not included in this 
sequence alignment because they are located in adjacent AAA domains. Domain 
boundaries were chosen based on analysis of available crystal structures and sequence 
alignments. Uniprot accession numbers: dynein 1-Q14204 dynein 2-Q8NCM8. 
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Appendix 3.1  
Structure-activity trends for compounds with aminopyrazole 
core 
R1/R2 TDI number
% Resid. Hh. 
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Appendix 3.2:  
Biochemical analysis of the effect of TDI 4692 on dynein 1 
Legend for appendix 3.2: (A) Chemical structure of TDI 4692. (B) Dose-dependent 
inhibition of basal (black) and microtubule-stimulated (grey) ATPase activity of wild-
type His-dynein 1 by TDI 4692. Data are mean ± range. of n = 2 experiments and were fit 
to a sigmoidal dose-response curve in Prism. ATPase assays were performed at 1mM 
Mg-ATP and 2% DMSO. (C) SDS-PAGE analysis (Coomassie blue) of dynein 1 
following irradiation with ultraviolet light at 365nm. Components of reaction loaded into 
each lane are noted above gel. Arrowheads indicate proteolysis products. (D) Analysis of 
gel band intensity for photocleavage reactions. Data are mean ± S.D. of n = 3 
experiments. (E) Inhibition of recombinant GFP-dynein 1. Data are mean ± S.D. of n = 3 
separate experiments and were fit to a sigmoidal dose-response curve using Prism. (F) 
Reversibility of inhibition by TDI 4692 in microtubule gliding assay. Data are mean + 
range of n = 2 experiments. (G-H) Images from negative stain electron microscopy. GFP-
dynein 1 was pre-incubated with TDI 4692 (4µM), ATP (1mM), and sodium vanadate 
(1mM) before fixation. (G) raw images of individual particles. (H) vector pointing to 
each protrusion is emphasized in yellow. The angle between these two vectors is 
measured. (I) Histogram showing distribution of angles. q was measured for > 1000
particles. Electron microscopy grid preparation and image acquisition were performed 
by Zhen Chen. 
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(continued on following page) 
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Appendix 4.1  
Screening for inhibitors of the ATPase activity of dynein 
Plate maps: Compounds were arrayed in triplicate, with each well for a given compound 
containing a different concentration. DMSO stock concentrations were 5mM, 1mM, and 
0.2mM. For every set of three boxes for a given compound, the compound name is given 
in the leftmost, and the compound number is given in the other two. Compound identities 
are tabulated at the end of this appendix. 
Plate 1: 
Plate 2: 
Screening results: Data presented on the following pages are the mean residual ATPase 
activity value of replicate screens. Value is presented as a fraction of enzyme activity in 
the DMSO control wells. Please note that for plate 1, the compound in B16/17 is at 10x 
the intended concentration. In light of this error, this compound was not considered a 
screening hit and was not examined in follow-up assays. 
[uM] 50 10 2 50 10 2 50 10 2 50 10 2 50 10 2 50 10 2
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19
A Linsitinib 1 1 GDC-0941 3 3 Dactolisib 5 5 RIBIN-ZC3 7 7 CilD 9 9 DBeQ 11 11 dmso
B Sorafenib 2 2 Iniparib 4 4 Vemurafenib 6 6 RIBIN-ZC1-3 8 8 HPI-102 10 10 TC12 12 12 dmso
C TC13 13 13 TC17 15 15 TC19 17 17 TC25 19 19 TC28 21 21 ML240(TC31) 23 23 dmso
D TC16 14 14 TC18 16 16 TC20 18 18 TC27 20 20 TC30 22 22 TC34 24 24 dmso
E TC39 25 25 TC43 27 27 TC50 29 29 TC54 31 31 TC56 33 33 TC58 35 35 dmso
F TC40 26 26 TC44 28 28 TC53 30 30 TC55 32 32 TC57 34 34 TC59 36 36 dmso
G TC60 37 37 TC62 39 39 TC64 41 41 TC66 43 43 TC68 45 45 TC70 47 47 dmso
H TC61 38 38 TC63 40 40 TC65 42 42 TC67 44 44 TC69 46 46 TC73 48 48 dmso
I TC76 49 49 TC78 51 51 TC82 53 53 TC84 55 55 TC86 57 57 TC88 59 59 dmso
J TC77 50 50 TC80 52 52 TC83 54 54 TC85 56 56 TC87 58 58 TC90 60 60 dmso
K TC91 61 61 TC96 63 63 TC97 65 65 TC100 67 67 TC104 69 69 TC108 71 71 dmso
L TC95 62 62 TC98 64 64 TC108SYM 66 66 TC103 68 68 TC107 70 70 TC111 72 72 dmso
M TC108re 73 73 TC116 75 75 TC126 77 77 TC131 79 79 TC140 81 81 TC142 83 83 dmso
N TC114 74 74 TC124 76 76 TC129 78 78 TC136 80 80 TC141 82 82 TC143 84 84 dmso
O TC144 85 85 TC147 87 87 TC149 89 89 TC151 91 91 RAF-265 93 93 TC155 95 95 dmso
P TC146 86 86 TC148 88 88 TC150 90 90 TC153 92 92 dmso dmso dmso TC156 96 96 dmso
[uM] 50 10 2 50 10 2 50 10 2 50 10 2 50 10 2 50 10 2
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18
A TC-165 1 1 TC-187 3 3 TC-211 5 5 TC-250 7 7 TC-267 9 9 JNJ 7706621 11 11
B TC-184 2 2 TC-197 4 4 TC-236 6 6 TC-259 8 8 TC-275 10 10 PI-103 12 12
C TC-168 13 13 TC-188 15 15 TC-212 17 17 TC-251 19 19 TC-268 21 21 NSC 693868 23 23
D TC-185 14 14 TC-199 16 16 TC-237 18 18 TC-260 20 20 TC-276 22 22 DYNACICLIB 24 24
E TC-171 25 25 TC-189 27 27 TC-213 29 29 TC-252 31 31 TC-269 33 33 II-62 35 35
F TC-159 26 26 TC-201 28 28 TC-240 30 30 TC-261 32 32 TC-277 34 34 ROSCOVITINE 36 36
G TC-172 37 37 TC-190 39 39 TC-226 41 41 TC-253 43 43 TC-270 45 45 II-65 47 47
H TC-160 38 38 TC-202 40 40 TC-243 42 42 TC-262 44 44 TC-278 46 46 PP3 48 48
I TC-173 49 49 TC-191 51 51 TC-227 53 53 TC-255 55 55 TC-271 57 57 II-66 59 59
J TC-162 50 50 TC-201F 52 52 TC-244 54 54 TC-263 56 56 TC-280 58 58 HESPERADIN 60 60
K TC-177 61 61 TC-166 63 63 TC-230 65 65 TC-256 67 67 TC-272 69 69 BIX 01294 71 71
L TC-163 62 62 TC-206 64 64 TC-247 66 66 TC-264 68 68 TC-282 70 70 SUNITINIB 72 72
M TC-179 73 73 TC194 75 75 TC-231 77 77 TC-257 79 79 TC-273 81 81 CRIZOTINIB 83 83
N TC-183 74 74 TC-207 76 76 TC-245 78 78 TC-265 80 80 TC-300 82 82 ZM 447439 84 84
O TC-181 85 85 TC-195 87 87 TC-234 89 89 TC-258 91 91 TC-274 93 93 ARQ197 95 95
P TC-186 86 86 TC-210 88 88 TC-249 90 90 TC-266 92 92 TC-301 94 94 VX680 96 96
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Dynein 1 screen, plate 1 (compounds at 10µM): 
p 0.99 0.85 1.14 1.01 1.06 0.75
column	-> 2 5 8 11 14 17
a 1.08 1.18 1.54 1.10 0.75 0.74
b 1.08 1.05 1.05 1.10 0.92 0.33
c 1.02 1.03 1.12 0.86 0.89 0.97
d 1.08 0.90 0.95 0.94 0.85 0.84
e 0.92 0.88 0.89 0.94 0.79 0.77
f 0.82 0.75 0.85 0.82 0.81 0.87
g 0.96 0.83 0.97 0.95 0.98 0.74
h 0.85 0.92 0.95 0.76 0.89 0.82
i 1.05 1.07 1.00 0.98 1.00 1.03
j 0.81 1.06 0.76 0.61 0.98 0.84
k 1.18 1.15 0.50 0.93 1.08 0.94
l 1.12 0.83 0.94 1.12 0.93 0.90
m 1.00 1.10 1.13 1.08 0.85 0.94
n 1.12 0.78 1.12 0.97 1.01 0.92
o 1.15 1.00 1.13 1.00 1.00 0.86




Dynein 1 screen, plate 2 (compounds at 20µM) 
average
column-> 2 5 8 11 14 17
a 1.16 0.94 0.92 0.81 0.63 0.39
b 0.93 0.86 0.60 0.83 0.73 0.87
c 0.80 0.57 0.21 0.74 0.61 0.71
d 1.18 0.58 0.76 0.47 0.72 0.85
e 1.08 0.78 0.99 0.83 0.81 0.64
f 0.77 0.82 0.73 0.77 1.00 0.87
g 1.10 0.60 0.95 0.83 0.81 0.61
h 0.92 0.84 0.70 0.59 0.71 0.81
i 0.87 0.86 0.96 0.66 0.80 0.74
j 0.78 0.38 0.83 0.58 0.83 0.76
k 0.87 0.81 0.93 0.74 0.71 0.49
l 0.66 0.74 0.90 0.72 0.85 0.68
m 0.86 0.83 0.94 0.71 0.70 0.87
n 0.45 0.75 0.65 0.72 0.91 0.83
o 0.76 0.91 1.00 0.91 0.86 0.78




Dynein 2 screen, plate 1 (compounds at 50µM) 
p 1.000075 0.992298 0.954636 0.933996 1.005254 0.693462
column-> 1 4 7 10 13 16
a 0.94 0.88 1.18 0.99 0.98 0.57
b 1.02 1.00 0.99 1.10 1.10 0.09
c 1.15 0.99 0.89 0.96 0.68 0.98
d 1.10 0.62 1.00 0.99 0.94 0.77
e 0.77 0.77 0.93 0.89 1.08 0.93
f 0.69 0.93 0.87 0.93 0.89 1.00
g 0.93 0.80 0.83 1.02 0.97 0.97
h 0.97 0.80 0.82 0.63 0.79 0.89
i 1.06 0.80 0.99 0.93 0.99 0.97
j 0.90 1.14 0.83 0.57 1.00 0.02
k 0.88 0.96 1.00 0.95 1.00 0.97
l 1.02 0.94 0.92 0.96 0.95 0.92
m 0.98 1.04 1.02 0.91 0.95 0.98
n 1.12 0.37 0.96 0.99 1.04 1.00
o 1.04 0.97 0.83 0.92 1.02 0.87




Compound identity: Tables presented on the following pages contain structural 
information as well as plate locations for all compounds in screening plates. 
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TC-301   80 10H
JNJ 7706621 81 11A






ARQ-197 Kapoor Lab88 11H
PI-103         (LC Labs)89 12A
Dinaciclib    (LC Labs)90 12Bpirazolo-[1,5]a pyrimidine
3,5-diamino triazol






 2-amino pyrazolyl pyrimidine      
2,4 amino- pyrido pyrimidine



































































Dinaciclib    (LC Labs)90 12B
Roscovitine (LC Labs)91 12C
PP3        (Acros)92 12D
Hesperadine Kapoor Lab93 12E
Sunitinb 94 12F
ZM-447439 Kapoor Lab95 12G





















































Compound identities, plate 1 
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Compound identities, plate 2, continued 
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Appendix 4.2 
Inhibition of AAA+ proteins by JNJ7706621 
Legend: Top, chemical structure of JNJ7706621. Bottom dose-response analysis for 
effect of JNJ 7706621 on ATPase activity of AAA+ proteins. ATPase activity was 
measured using NADH-coupled ATPase assay system at 500µM ATP. Where shown, 
error bars reflect range. Values were fit to a sigmoidal dose-response curve in prism and 
fits were constrained such that the value at saturating compound concentrations > 0. IC50 
values: spastin-2.4µM, katanin-3.7µM, fidgetin-like protein 1-18.7. Enzyme preparation 





































Appendix 4.3  
Synthesis and characterization of compounds informed by 
screen of diaminoqunazolines for inhibitors of dynein 
General synthetic methods: Reagents and solvents were used as received. Unless 
otherwise specified, precautions were not taken to exclude oxygen or moisture from 
reactions. LC/MS analysis was performed using a Waters MicroMassZQ mass 
spectrometer, with an electron spray ionization (ESI) probe. Liquid chromatographic 
separation was performed with a Symmetry® C18 column. Analysis was performed 
using MassLynx. 1H NMR data was acquired using a varian (400MHz) or Bruker 
(600MHz) device and analyzed using MestreNova® or TopSpin®. NMR data have been 
collected and analysis and assignment of spectra are ongoing. Assignments can be 
provided in an addendum to this thesis. 
3-((4-(benzylamino)thieno[3,2-d]pyrimidin-2-yl)amino)phenol, TC 405. A mixture of 
1 (25mg, 0.09mmol, synthesized by T. Cupido), 3-aminophenol (20mg, 0.18mmol), and 
concentrated hydrochloric acid (10µl) were refluxed in n-butanol (1ml) overnight. After 
cooling, hexane was added and a precipitate formed. The precipitate was collected by 
filtration and washed with water and methanol and then dried under vacuum. 9.8mg of 
TC 405 were obtained (31% yield). LC/MS: 349.82 [M+H]+. 
3-((4-(benzylamino)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2-yl)amino)phenol, TC 
406. A mixture of 2 (25mg, 0.1mmol, synthesized by T. Cupido), 3-aminophenol (20mg, 
0.18mmol), and concentrated hydrochloric acid (10µl) were refluxed in n-butanol (1ml) 

































collected by filtration and washed with water and methanol and then dried under vacuum. 
4.5mg of TC 406 were obtained (14% yield). LC/MS: 333.85 [M+H]+. 
3-((6-(benzylamino)-7-methyl-7H-purin-2-yl)amino)phenol, TC 407. A mixture of 3 
(25mg, 0.09mmol, synthesized by T. Cupido), 3-aminophenol (20mg, 0.18mmol), and 
concentrated hydrochloric acid (10µl) were refluxed in n-butanol (1ml) overnight. After 
cooling, hexane was added and a precipitate formed. The precipitate was collected by 
filtration and washed with water and methanol and then dried under vacuum. 20.7mg of 
TC 407 were obtained (66% yield). LC/MS: 347.87 [M+H]+.
3-((4-(benzylamino)-8-fluoroquinazolin-2-yl)amino)phenol, TC 408. A mixture of 4 
(25mg, 0.09mmol, synthesized by T. Cupido), 3-aminophenol (20mg, 0.18mmol), and 
concentrated hydrochloric acid (10µl) were refluxed in n-butanol (1ml) overnight. After 
cooling, hexane was added and a precipitate formed. The precipitate was collected by 
filtration and washed with water and methanol and then dried under vacuum. 11.5mg of 
TC 408 were obtained (35% yield). LC/MS: 361.81 [M+H]+.
3-((4-(benzylamino)-1H-pyrazolo[3,4-d]pyrimidin-6-yl)amino)phenol, TC 409. A 
mixture of 5 (25mg, 0.09mmol, synthesized by T. Cupido), 3-aminophenol (20mg, 
0.18mmol), and concentrated hydrochloric acid (10µl) were refluxed in n-butanol (1ml) 
overnight. After cooling, hexane was added and a precipitate formed. The precipitate was 
collected by filtration and washed with water and methanol and then dried under vacuum. 























































2-chloro-N-(2-isopropylphenyl)quinazolin-4-amine, 6. 2,4-dichloroquinazoline 
(200mg, 1mmol), 2-isopropylaniline (158mg, 1.2mmol), and diisopropylethylamine 
(258mg, 2mmol), were stirred at 70 °C in acetonitrile (4ml) for five days. Reaction was 
cooled to room temperature, then water (4ml) was added. A precipitate formed and was 
recovered by filtration. The precipitate was washed with cold acetonitrile:water, then 
with water and then dried under vacuum. 240mg of 6 were obtained (80% yield). LC/MS: 
298.71 [M+H]+. 
3-((4-((2-isopropylphenyl)amino)quinazolin-2-yl)amino)phenol, TC 410. A mixture 
of 6 (25mg, 0.09mmol), 3-aminophenol (20mg, 0.18mmol), and concentrated 
hydrochloric acid (10µl) were refluxed in n-butanol (1ml) overnight. After cooling, 
hexane was added and a precipitate formed. The precipitate was collected by filtration 
and washed with water and methanol and then dried under vacuum. 4.8mg of TC 409 
were obtained (16% yield). LC/MS: 333.85 [M+H]+. 
N2,N4-dibenzyl-8-fluoroquinazoline-2,4-diamine, TC 411. A mixture of 4 (25mg, 
0.09mmol, synthesized by T. Cupido), benzylamine (20mg, 0.18mmol), and concentrated 
hydrochloric acid (10µl) were refluxed in n-butanol (1ml) overnight. After cooling, water 
was added and a precipitate formed. The precipitate was collected by filtration and 
washed with water, 1M hydrochloric acid (aq), and hexane and then dried under vacuum. 










































N4-(1H-indazol-3-yl)-N2-(1H-indol-6-yl)quinazoline-2,4-diamine, TC 412. A mixture 
of 7 (67mg, 0.23mmol, synthesized by T. Cupido), 6-aminoindole (40mg, 0.3mmol), and 
concentrated hydrochloric acid (10µl) were refluxed in n-butanol (0.8ml) overnight. After 
cooling, a precipitate formed. The precipitate was collected by filtration and washed with 
water, 1M hydrochloric acid (aq), and hexane and then dried under vacuum. 63mg of TC 
412 were obtained (70% yield). LC/MS: 392.70 [M+H]+.  
2-chloro-N-(2-phenylpropan-2-yl)quinazolin-4-amine, 8. 2,4-dichloroquinazoline 
(200mg, 1mmol), 2-isopropylaniline (149mg, 1.1mmol), and diisopropylethylamine 
(258mg, 2mmol), were stirred at room temperature in acetonitrile (4ml) for seven days. 
The yellow precipitate was collected by filtration, washed with water, and dried under 
vacuum. 160mg of 8 were obtained (54% yield). LC/MS: 298.71 [M+H]+. 
2-chloro-N-((1S,2R)-2-methylcyclohexyl)quinazolin-4-amine, 9. 2,4-
dichloroquinazoline (200mg, 1mmol), (1S,2R)-2-methylcyclohexan-1-amine (124mg, 




































in acetonitrile (4ml) for two hours. The yellow precipitate was collected by filtration, 
washed with water, and dried under vacuum. 262mg of 9 were obtained (95% yield). 
LC/MS: 276.67 [M+H]+. 
N2-(1H-indol-6-yl)-N4-((1S,2R)-2-methylcyclohexyl)quinazoline-2,4-diamine, TC 413.  
A mixture of 9 (28mg, 0.1mmol), 6-aminoindole (20mg, 0.15mmol) was refluxed in n-
butanol (1ml) overnight. After cooling, hexane was added and a precipitate formed. The 
precipitate was collected by filtration and washed with hexane, water, and methanol and 
then dried under vacuum. 0.7mg of TC 413 were obtained (2% yield). LC/MS: 372.90 
[M+H]+. 
N-((1S,2R)-2-methylcyclohexyl)-2-((R)-3-methylpiperazin-1-yl)quinazolin-4-amine, 
TC 414. A mixture of 9 (28mg, 0.1mmol), 10 (as the HCl salt, 35mg, 0.15mmol) was 
refluxed in n-butanol (1ml) overnight. After cooling, hexane and concentrated 
hydrochloric acid were added and a precipitate formed. The precipitate was collected 
centrifugation and removal of the supernatant, and was used without further purification. 
Trifluoroacetic acid (500µl), dichloromethane (400µl), and water (100µl) were added to 
the precipitate. This mixture was stirred at room temperature for 1 hour. Solvent was 
removed under reduced pressure, the resulting slurry resuspended in diethyl ether, and the 
solvent removed again. This process was repeated two times. The resulting amorphous 
solid was dissolved in 1M sodium hydroxide (aq.) and the aqueous was extracted with 
ethyl acetate. The organic layer was washed with brine, dried over sodium sulfate, and 
the solvent was evaporated. The resulting oil was treated with ~5ul of concentrated 
hydrochloric acid (aq.), which caused precipitaton. This precipitate was collected by 
centrifugation, washed twice with acetone, and dried under vacuum. 1mg of TC 414 was 









































(R)-N-(2-isopropylphenyl)-2-(3-methylpiperazin-1-yl)quinazolin-4-amine, TC 415. A 
mixture of 6 (28mg, 0.15mmol), 10 (as the HCl salt, 53mg, 0.23mmol) was refluxed in n-
butanol (1ml) overnight. After cooling, hexane and concentrated hydrochloric acid were 
added and a precipitate formed. The precipitate was collected centrifugation and removal 
of the supernatant, and was used without further purification. Trifluoroacetic acid (500µl), 
dichloromethane (400µl), and water (100µl) were added to the precipitate. This mixture 
was stirred at room temperature for 1 hour. Solvent was removed under reduced pressure, 
the resulting slurry resuspended in diethyl ether, and the solvent removed again. This 
process was repeated two times. The resulting amorphous solid was dissolved in 1M 
sodium hydroxide (aq.) and the aqueous was extracted with ethyl acetate. The organic 
layer was washed with brine, dried over sodium sulfate, and the solvent was evaporated. 
The resulting oil was treated with ~5ul of concentrated hydrochloric acid (aq.), which 
caused precipitaton. This precipitate was collected by centrifugation, washed twice with 
acetone, and dried under vacuum. The precipitate was dissolved in 85:15 
dichloromethane:methanol and purified by preparative-scale thin-layer chromatography. 
The plate was developed using 85:15 dichloromethane:methanol. The desired band (Rf 
0.15 in 85:15 dichloromethane:methanol) was excised with a razor and the product 
removed by addition of 85:15 dichloromethane:methanol to the collected silica powder 
and removal of the powder by filtration. 3mg of TC 415 were obtained (6% yield). 




































N2-(1H-indol-6-yl)-N4-(2-phenylpropan-2-yl)quinazoline-2,4-diamine, TC 416. A 
mixture of 8 (30mg, 0.1mmol) and 6-aminoindole (20mg, 0.15mmol) was refluxed in n-
butanol (1ml) overnight. After cooling and addition of hexane, a precipitate formed. The 
precipitate was collected by filtration and washed with water and ethanol and then dried 
under vacuum. 26.6mg of TC 415 were obtained (68% yield). LC/MS: 394.79 [M+H]+.  
(R)-N-benzyl-8-fluoro-2-(3-methylpiperazin-1-yl)quinazolin-4-amine, TC 417. A 
mixture of 9 (29mg, 0.1mmol), 10 (as the HCl salt, 35mg, 0.15mmol) was refluxed in n-
butanol (1ml) overnight. After cooling, hexane and concentrated hydrochloric acid were 
added and a precipitate formed. The precipitate was collected centrifugation and removal 
of the supernatant, and was used without further purification. Trifluoroacetic acid (500µl), 
dichloromethane (400µl), and water (100µl) were added to the precipitate. This mixture 
was stirred at room temperature for 1 hour. Solvent was removed under reduced pressure, 
the resulting slurry resuspended in diethyl ether, and the solvent removed again. This 
process was repeated two times. The resulting amorphous solid was dissolved in 1M 
sodium hydroxide (aq.) and the aqueous was extracted with ethyl acetate. The organic 
layer was washed with brine, dried over sodium sulfate, and the solvent was evaporated. 
The resulting oil was treated with ~5ul of concentrated hydrochloric acid (aq.), which 
caused precipitaton. This precipitate was collected by centrifugation, washed twice with 

































(R)-2-chloro-N-(1-phenylethyl)quinazolin-4-amine, 11. 2,4-dichloroquinazoline 
(200mg, 1mmol), (R)-1-phenylethan-1-amine (133mg, 1.1mmol), and 
diisopropylethylamine (258mg, 2mmol), were stirred at room temperature in acetonitrile 
(4ml) for 24 hours. Water was added and the solution was cooled at -20°. Following 
phase separation, ethyl acetate and 0.1M hydrochloric acid (aq.) were added. The organic 
layer was collected, washed with 1M sodium hydroxide (aq.), and brine, then dried over 
sodium sulfate. The solvent was evaporated under reduced pressure. 205mg of 11 were 
obtained (72% yield).  
(S)-2-chloro-N-(1-phenylethyl)quinazolin-4-amine, 11. 2,4-dichloroquinazoline 
(200mg, 1mmol), (S)-1-phenylethan-1-amine (133mg, 1.1mmol), and 
diisopropylethylamine (258mg, 2mmol), were stirred at room temperature in acetonitrile 
(4ml) for 24 hours. Water was added and the solution was cooled at -20°. Following 
phase separation, ethyl acetate and 0.1M hydrochloric acid (aq.) were added. The organic 
layer was collected, washed with 1M sodium hydroxide (aq.), and brine, then dried over 
sodium sulfate. The solvent was evaporated under reduced pressure. 246mg of 12 were 
obtained (86% yield).  
(R)-N2-(1H-indol-6-yl)-N4-(1-phenylethyl)quinazoline-2,4-diamine, TC 418. A 
mixture of 11 (28mg, 0.1mmol) and 6-aminoindole (20mg, 0.15mmol) was refluxed in n-
butanol (1ml) overnight. After cooling and addition of hexane, a precipitate formed. The 
precipitate was collected by filtration and washed with water and then dried under 

























(S)-N2-(1H-indol-6-yl)-N4-(1-phenylethyl)quinazoline-2,4-diamine, TC 419. A mixture 
of 12 (28mg, 0.1mmol) and 6-aminoindole (20mg, 0.15mmol) was refluxed in n-butanol 
(1ml) overnight. After cooling and addition of hexane, no precipitate formed. Amorphous 
material formed in the reaction vessel. The solvent was removed under reduced pressure. 
The solid residue was dissolved in ethyl acetate and the resulting solution was washed 
with 0.1M HCl (aq.) and brine, dried over sodium sulfate, and the solvent was removed 
under reduced pressure. . The precipitate was collected by filtration and washed with 
water and then dried under vacuum. 26.9mg of TC 419 were obtained (71% yield). 
LC/MS: 380.79 [M+H]+.  
N-(2-isopropylphenyl)-2-(4-methylpiperazin-1-yl)quinazolin-4-amine, TC 420. A 
mixture of 6 (30mg, 0.1mmol) and 1-methylpiperazine (15mg, 0.15mmol) was refluxed 
in n-butanol (1ml) overnight. Solvent was removed under reduced pressure. Hexane and 
concentrated hydrochloric acid were added to the resulting oil. A precipitate formed, 
which was collected by filtered and washed with basic water (pH 10) and then neutral 
water then dried overnight under vacuum. 18.4mg of TC 420 were obtained (51% yield). 




































N-(2-isopropylphenyl)-2-(piperazin-1-yl)quinazolin-4-amine, TC 421. A mixture of 6 
(30mg, 0.1mmol) and piperazine (258mg, 3mmol) was refluxed in n-butanol (6ml) 
overnight. The solvent was removed by evaporation at reduced pressure and the resulting 
oil was dissolved in basic water (pH 10). The aqueous was extracted with ethyl acetate. 
The organic was washed with brine and dried over sodium sulfate. Solvent was removed 
under reduced pressure. The resulting oil was dissolved in 9:1 dichloromethane:methanol 
and purified by preparative-scale thin-layer chromatography. The plate was developed 
using 9:1 dichloromethane:methanol. The desired band (Rf 0.1 in 9:1 
dichloromethane:methanol) was excised with a razor and the product removed by 
addition of 9:1 dichloromethane:methanol to the collected silica powder and removal of 
the powder by filtration. 5.2mg of TC 421 were obtained (15% yield).  
2-chloro-N-(2-ethylphenyl)quinazolin-4-amine, 13. 2,4-dichloroquinazoline (200mg, 
1mmol), 2-ethylaniline (133mg, 1.1mmol), and diisopropylethylamine (258mg, 2mmol), 
were stirred at room temperature in acetonitrile (4ml) for 80 hours. Water was added and 
a precipitate formed. The precipitate was collected by filtration and washed with cold 2:1 
water:acetonitrile, then with water and then dried under vacuum. 291mg of 13 were 
obtained (>99% yield). LC/MS: 284.62 [M+H]+. 
N4-(2-ethylphenyl)-N2-(1H-indol-6-yl)quinazoline-2,4-diamine, TC 422. A mixture of 
13 (28mg, 0.1mmol) and 6-aminoindole (20mg, 0.15mmol) was refluxed in n-butanol 
(1ml) overnight. After cooling and addition of hexane, a precipitate formed. The 
precipitate was collected by filtration and washed with water and then dried under 

























(R)-N-(2-isopropylphenyl)-2-(2-methylpiperazin-1-yl)quinazolin-4-amine, TC 423. A 
mixture of 6 (29mg, 0.1mmol) and 14 (30mg, 0.15mmol) was refluxed in n-butanol (1ml) 
overnight. After cooling, hexane and concentrated hydrochloric acid but no precipitation 
occurred. Solvent was removed under reduced pressure and the residue was used without 
further purification. Trifluoroacetic acid (500µl), dichloromethane (400µl), and water 
(100µl) were added to the precipitate. This mixture was stirred at room temperature for 1 
hour. Solvent was removed under reduced pressure, the resulting slurry resuspended in 
diethyl ether, and the solvent removed again. This process was repeated two times. The 
resulting amorphous solid was dissolved in 1M sodium hydroxide (aq.) and the aqueous 
was extracted with ethyl acetate. The organic layer was washed with brine, dried over 
sodium sulfate, and the solvent was evaporated. The resulting oil was treated with ~5ul of 
concentrated hydrochloric acid (aq.), which caused precipitaton. This precipitate was 
collected by centrifugation, washed twice with acetone, and dried under vacuum. 22.6mg 
of TC 423 were obtained (62% yield). LC/MS: 362.86 [M+H]+.  
(S)-N-(2-isopropylphenyl)-2-(2-methylpiperazin-1-yl)quinazolin-4-amine, TC 424. A 
mixture of 6 (29mg, 0.1mmol) and 15 (30mg, 0.15mmol) was refluxed in n-butanol (1ml) 
overnight. After cooling, hexane and concentrated hydrochloric acid but no precipitation 
occurred. Solvent was removed under reduced pressure and the residue was used without 
further purification. Trifluoroacetic acid (500µl), dichloromethane (400µl), and water 
(100µl) were added to the precipitate. This mixture was stirred at room temperature for 1 
hour. Solvent was removed under reduced pressure, the resulting slurry resuspended in 
diethyl ether, and the solvent removed again. This process was repeated two times. The 
resulting amorphous solid was dissolved in 1M sodium hydroxide (aq.) and the aqueous 
was extracted with ethyl acetate. The organic layer was washed with brine, dried over 









































concentrated hydrochloric acid (aq.), which caused precipitaton. This precipitate was 
collected by centrifugation, washed twice with acetone, and dried under vacuum. 28.4mg 
of TC 424 were obtained (78% yield). LC/MS: 362.86 [M+H]+. 
(S)-N-(2-isopropylphenyl)-2-(3-methylpiperazin-1-yl)quinazolin-4-amine, TC 425. A 
mixture of 6 (45mg, 0.15mmol) and 16 (45mg, 0.23mmol) was refluxed in n-butanol 
(1ml) overnight. After cooling, hexane and concentrated hydrochloric acid but no 
precipitation occurred. Solvent was removed under reduced pressure and the residue was 
used without further purification. Trifluoroacetic acid (500µl), dichloromethane (400µl), 
and water (100µl) were added to the precipitate. This mixture was stirred at room 
temperature for 1 hour. Solvent was removed under reduced pressure, the resulting slurry 
resuspended in diethyl ether, and the solvent removed again. This process was repeated 
two times. The resulting amorphous solid was dissolved in 1M sodium hydroxide (aq.) 
and the aqueous was extracted with ethyl acetate. The organic layer was washed with 
brine, dried over sodium sulfate, and the solvent was evaporated. The resulting oil was 
treated with ~5ul of concentrated hydrochloric acid (aq.), which caused precipitaton. This 
precipitate was collected by centrifugation, washed twice with acetone, and dried under 
vacuum. 38.4mg of TC 425 were obtained (70% yield). LC/MS: 362.86 [M+H]+. 1H 





























(R)-2-chloro-N-(1-phenylpropyl)quinazolin-4-amine, 17. 2,4-dichloroquinazoline 
(200mg, 1mmol), (R)-1-phenylpropan-1-amine (148mg, 1.1mmol), and 
diisopropylethylamine (258mg, 2mmol), were stirred at room temperature in acetonitrile 
(4ml) for 72 hours. Hydrochloric acid (0.3M, aq) and the solution was extracted with 
ethyl acetate. The organc layer was washed with 1M sodium hydroxide (aq.) and brine, 
dried over sodium sulfate, and the solvent was removed under reduced pressure. 224mg 
of 13 were obtained (75% yield). LC/MS: 298.64 [M+H]+. 
(R)-N2-(1H-indol-6-yl)-N4-(1-phenylpropyl)quinazoline-2,4-diamine, TC 426. A 
mixture of 17 (28mg, 0.1mmol) and 6-aminoindole (20mg, 0.15mmol) was refluxed in n-
butanol (1ml) overnight. After cooling and addition of hexane, a precipitate formed. The 
precipitate was collected by filtration and washed with water and then dried under 
vacuum. 6.6mg of TC 426 were obtained (16% yield). LC/MS: 394.80 [M+H]+. 
N2-(4-chloro-3-fluorophenyl)-N4-(2-isopropylphenyl)quinazoline-2,4-diamine, TC 
427. A mixture of 17 (28mg, 0.1mmol) and 6-aminoindole (20mg, 0.15mmol) was 
refluxed in n-butanol (1ml) overnight. After cooling and addition of hexane, a precipitate 
formed. The precipitate was collected by filtration and washed with water and methanol, 
































2-chloro-4-(3,4-dihydroisoquinolin-2(1H)-yl)quinazoline, 18. 2,4-dichloroquinazoline 
(200mg, 1mmol), 1,2,3,4-tetrahydroisoquinoline (147mg, 1.1mmol), and 
diisopropylethylamine (258mg, 2mmol), were stirred at room temperature in acetonitrile 
(4ml) for 48 hours. Hydrochloric acid (0.3M, aq) and the solution was extracted with 
ethyl acetate. The organc layer was washed with 1M sodium hydroxide (aq.) and brine, 
dried over sodium sulfate, and the solvent was removed under reduced pressure. 202mg 
of 18 were obtained (68% yield). LC/MS: 292.62 [M+H]+.  
N2-(3,5-difluorophenyl)-N4-(2-isopropylphenyl)quinazoline-2,4-diamine, TC 428. A 
mixture of 6 (30mg, 0.1mmol) and 6-aminoindole (26mg, 0.2mmol) was refluxed in n-
butanol (1ml) overnight. After cooling and addition of hexane, a precipitate formed. The 
precipitate was collected by filtration and washed with water and methanol, then dried 
under vacuum. 12.6mg of TC 428 were obtained (32% yield). LC/MS: 391.73 [M+H]+. 
4-(3,4-dihydroisoquinolin-2(1H)-yl)-N-(1H-indol-6-yl)quinazolin-2-amine, TC 429. 
A mixture of 18 (30mg, 0.1mmol) and 6-aminoindole (20mg, 0.15mmol) was refluxed in 






































The precipitate was collected by filtration and washed with water and then dried under 
vacuum. 27mg of TC 429 were obtained (69% yield). LC/MS: 392.69 [M+H]+. 
N4-(2-isopropylphenyl)-N2-(3-morpholinophenyl)quinazoline-2,4-diamine, TC 430. A 
mixture of 6 (30mg, 0.1mmol) and 6-aminoindole (32mg, 0.17mmol) was refluxed in n-
butanol (1ml) overnight. After cooling and addition of hexane, a precipitate formed. The 
precipitate was collected by filtration and washed with water. The precipitate was lost 
upon washing with water, so the filtrate was acidified with hydrochloric acid and 
extracted with ethyl acetate. The organic layer was washed with brine, dried over sodium 
sulfate, and solvent removed under reduced pressure. 10mg of TC 430 were obtained 
(23% yield). LC/MS: 440.68 [M+H]+.		
N2-(3-fluoro-4-methoxyphenyl)-N4-(2-isopropylphenyl)quinazoline-2,4-diamine, TC 
431. A mixture of 6 (30mg, 0.1mmol) and 3-fluoro-4methoxyaniline (34mg, 0.25mmol) 
was refluxed in n-butanol (1ml) overnight. After cooling and addition of hexane, a 
precipitate formed. The precipitate was collected by filtration and washed with water and 
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